https://www.veristat.com/services/a-patient-centric-apprach-to-recruitment-and-retention2026-06-15https://www.veristat.com/services/regulatory-publishing-expertise2026-06-15https://www.veristat.com/solutions/neurology-fact-sheet2025-06-12https://www.veristat.com/solutions/roadmap-to-market-for-cell-and-gene-therapies2025-06-12https://www.veristat.com/library/the-importance-of-regulatory-project-management2024-07-03https://www.veristat.com/ashley_green_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2025-10-01https://www.veristat.com/solutions/fda-delays-push-biotech-companies-to-rethink-u.s.-drug-development-strategy2025-06-12https://www.veristat.com/solutions/managing-e6r2-compliance-as-it-relates-to-risk-deck2025-06-12https://www.veristat.com/library-old/real-world-considerations-when-administering-advanced-therapy-products2024-06-27https://www.veristat.com/library-old/oncology-fact-sheet2024-06-27https://www.veristat.com/services/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2026-06-15https://www.veristat.com/services/navigating-clinical-trials-with-precision-enhancing-dmc-services-through-veristats-expert-biostatistics2026-06-15https://www.veristat.com/services/fda-expedited-programs-what-you-need-to-know2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/eu-post-marketing-requirements-for-cell-and-gene-therapy-studies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/rescue-patient-recruitment-for-lagging-trial2026-06-23https://www.veristat.com/services/complex-trial-for-a-rare-pediatric-gene-therapy2026-06-15https://www.veristat.com/library/staying-ahead-of-regulatory-change-cmc-strategies-for-cell-and-gene-therapy-development2025-06-11https://www.veristat.com/sqn-clinical-joins-veristat/cardiology-fact-sheet2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/medical-writing-partnership-indtonda2026-06-23https://www.veristat.com/services/different-approaches-for-preparing-marketing-applications2026-06-15https://www.veristat.com/library/rescuing-a-global-program-for-nda-success2025-08-05https://www.veristat.com/services/sfl_is_now_veristat/addressing-drug-developer-challenges-with-decentralized-clinical-trials2026-06-23https://www.veristat.com/solutions/fdas-project-frontrunner-explained2025-06-12https://www.veristat.com/library-old/use-of-pro-in-cell-and-gene-therapy-studies2024-06-27https://www.veristat.com/library-old/similarities-and-differences-between-the-cta-and-ind2024-06-27https://www.veristat.com/library/infectious-disease-fact-sheet2024-07-03https://www.veristat.com/library/webinar-achieving-balance-in-database-design2024-07-03https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-november-20252026-01-06https://www.veristat.com/solutions/the-ctdna-clinical-trial-advantage-why-cro-work-puts-you-on-the-cutting-edge2026-01-05https://www.veristat.com/services/sfl_is_now_veristat/why-regulatory-publishing-expertise-is-essential-for-neurology-clinical-trials2026-06-23https://www.veristat.com/services/wholistic-approach-to-strategic-consulting2026-06-15https://www.veristat.com/solutions/a-creative-approach-to-achieving-an-aggressive-nda-timeline2025-10-08https://www.veristat.com/library/cmc-sd-files-for-regulatory-submissions2024-07-03https://www.veristat.com/solutions/beyond-detection-how-ctdna-could-optimize-treatment-selection2026-01-05https://www.veristat.com/library/align-new-oncology-drug-development-with-fdas-project-frontrunner-slides2024-07-03https://www.veristat.com/services/early-development-challenges-in-ind-applications2026-06-15https://www.veristat.com/instat-is-now-veristat/agile-medical-writing-support-for-an-nda2026-06-23https://www.veristat.com/services/programmed-narratives-working-smarter-not-harder2026-06-15https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-july-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-june-20232026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-april-20242026-06-15https://www.veristat.com/solutions/successful-ind-submission-paves-the-way-for-a-global-full-service-phase-i-clinical-trial-targeting-cancers2025-10-08https://www.veristat.com/library/lessons-learned-for-better-planning-of-decentralized-clinical-trials2024-07-03https://www.veristat.com/solutions/post-submission-ind-maintenance-veristat-as-u.s.-agent2025-08-05https://www.veristat.com/library/successful-preparation-strategies-for-nda-maa-marketing-applications2025-11-26https://www.veristat.com/solutions/single-arm-studies-for-use-as-a-registrational-study-in-oncology-presentation2025-06-12https://www.veristat.com/instat-is-now-veristat/flexibility-drives-progress-in-rare-disease-gene-therapy-trial2026-06-23https://www.veristat.com/library-old/respiratory-fact-sheet2024-06-27https://www.veristat.com/services/neurology-regulatory-submissions-simplified-expertise-you-can-trust2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-february-20242026-06-23https://www.veristat.com/instat-is-now-veristat/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/why-you-need-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-23https://www.veristat.com/solutions/complex-trial-for-a-rare-pediatric-gene-therapy2025-06-12https://www.veristat.com/library/comprehensive-strategic-clinical-development-consulting2024-07-03https://www.veristat.com/instat-is-now-veristat/webinar-qa-how-to-advance-new-cancer-therapies-in-alignment-with-fda-project-frontrunner2026-06-23https://www.veristat.com/instat-is-now-veristat/replay-expanding-your-clinical-trial-into-the-us2026-06-23https://www.veristat.com/library/data-analysis-excellence-the-backbone-of-successful-marketing-applications2025-04-08https://www.veristat.com/library/how-does-real-world-evidence-impact-medicinal-product-development-in-europe-blog2024-07-03https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/purpose-of-ind-ig2024-07-03https://www.veristat.com/solutions/solutions-to-accelerate-cell-and-gene-therapies2025-06-12https://www.veristat.com/solutions/planning-for-a-successful-initial-ind-and-moving-beyond2025-06-12https://www.veristat.com/solutions/the-next-leap-in-alzheimers-rd-is-coming2025-11-19https://www.veristat.com/services/sfl_is_now_veristat/guiding-an-emerging-biotechs-first-phase-i-oncology-trial2026-06-23https://www.veristat.com/library-old/leveraging-fda-expedited-programs-webinar-presentation2024-06-27https://www.veristat.com/library/resourcingfsp-model2024-07-03https://www.veristat.com/solutions/unlocking-the-promise-of-radiopharmaceuticals-safety-strategy-innovation-in-clinical-trials2025-06-12https://www.veristat.com/robin_bliss_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library-old/marketing-applications-approval-record2024-06-27https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/different-approaches-for-preparing-a-marketing-application2024-07-03https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/adaptive-design-fact-sheet2024-07-03https://www.veristat.com/instat-is-now-veristat/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2026-06-23https://www.veristat.com/services/chemistry-manufacturing-controls-cmchttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/CMC.pngCMCCMChttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Reg%20Podcast%20Oct22%20Version%20A.pngRegPodcastOct22VersionARegPodcastOct22VersionAhttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopers2025-06-12https://www.veristat.com/library-old/how-to-ensure-a-successful-fda-meeting-presentation-download2024-06-27https://www.veristat.com/solutions/accelerate-neurologypsychiatry-trial-success-with-expert-guidance2026-01-05https://www.veristat.com/instat-is-now-veristat/veristat-infographic2026-06-23https://www.veristat.com/services/solutions-to-accelerate-cell-and-gene-therapies2026-06-15https://www.veristat.com/solutions/essential-considerations-foradaptive-design-in-clinical-trials2025-06-12https://www.veristat.com/library/development-of-a-covid-19-vaccine-challenges-for-data-managers2024-07-03https://www.veristat.com/services/healthcare-compliancehttps://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Healthcare%20Compliance.pngHealthcareComplianceHealthcareCompliancehttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage132024-07-03https://www.veristat.com/services/successful-ind-submission-paves-the-way-for-a-global-full-service-phase-i-clinical-trial-targeting-cancers2026-06-15https://www.veristat.com/services/single-arm-studies-for-use-as-a-registrational-study-in-oncology-article2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/successful-full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/randomized-phase-2-study-of-cbp501-cisplatin-and-nivolumab-as-3rd-line-treatment-for-exocrine-pancreatic-cancer-patients-with-white-blood-cell-count-wbc-10000mm32026-06-23https://www.veristat.com/library-old/presentation-how-to-better-plan-a-virtual-clinical-trial2024-06-27https://www.veristat.com/library/achieving-balance-in-clinical-trial-database-design2024-07-03https://www.veristat.com/services/covid-19-success-guide2026-06-15https://www.veristat.com/instat-is-now-veristat/planning-the-way-forward-in-neurodegenerative-disease-studies2026-06-23https://www.veristat.com/solutions/biostatisticians-crucial-choreographers-behind-oncology-breakthroughs2025-10-08https://www.veristat.com/services/accelerating-patient-centric-trials2026-06-15https://www.veristat.com/solutions/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2025-06-12https://www.veristat.com/instat-is-now-veristat/fda-meeting-types-for-biosimilar-products2026-06-23https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-april-20242024-07-03https://www.veristat.com/library/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development-blog2024-07-03https://www.veristat.com/library/preparing-new-drug-application-ind2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/efficient-regulatory-publishing-for-large-scale-fda-submission2026-06-23https://www.veristat.com/library/roadmap-to-market-for-cell-and-gene-therapies2024-07-03https://www.veristat.com/solutions/fda-guidance-on-dmcs-in-clinical-trials2025-06-12https://www.veristat.com/instat-is-now-veristat/emergency-use-authorizations-blog2026-06-23https://www.veristat.com/instat-is-now-veristat/why-and-when-to-hold-a-pre-ind-meeting-with-fda2026-06-23https://www.veristat.com/instat-is-now-veristat/writing-multiple-marketing-applications-at-the-same-time2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-august-20232026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-consulting-fact-sheet2026-06-23https://www.veristat.com/services/supply-chainhttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Supply%20Chain.pngSupplyChainSupplyChainhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02a2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/real-world-considerations-when-administering-advanced-therapy-products2026-06-23https://www.veristat.com/library/regulatory-guidance-monthly-review-december-20232024-07-03https://www.veristat.com/services/preparing-data-for-maa-marketing-authorization-appliation2026-06-15https://www.veristat.com/library/cmc-pitfalls-from-benchtop-to-ind2024-07-03https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-january-20262026-06-15https://www.veristat.com/services/ensuring-regulatory-success-from-pre-ind-through-to-submission2026-06-15https://www.veristat.com/services/regulatory-guidance-monthly-review-december-20232026-06-15https://www.veristat.com/services/sfl_is_now_veristat/the-power-of-publishing-for-an-efficient-nda-submission-process2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-october-20252026-06-23https://www.veristat.com/services/regulatory-guidance-monthly-review-august-20232026-06-15https://www.veristat.com/services/bridging-science-and-regulatory-success-with-medical-writing2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/cancer-research-trends-key-asco-2024-takeaways2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/common-pitfalls-in-cell-therapy-studies2026-06-23https://www.veristat.com/instat-is-now-veristat/cross-functional-collaboration-a-cornerstone-of-successful-clinical-development2026-06-23https://www.veristat.com/library/webinar-roadmap-to-market-cell-and-gene-therapies2024-07-03https://www.veristat.com/instat-is-now-veristat/a-roundup-of-perspectives-and-predictions-on-research-misconduct-inclusivity-ai-and-more2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/supporting-global-approval-of-a-first-in-classgene-therapy-for-a-rare-genetic-disorder2026-06-23https://www.veristat.com/library-old/decentralized-clinical-trials-infographic2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/the-benefits-of-a-central-site-model2026-06-23https://www.veristat.com/solutions/understanding-the-critical-role-of-data-monitoring-committees-in-clinical-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/cmc-sd-files-for-regulatory-submissions2026-06-23https://www.veristat.com/solutions/accelerating-patient-centric-clinical-trials-through-science-based-planning-delivery-and-support2025-07-02https://www.veristat.com/library/considerations-for-natural-history-studies2024-07-03https://www.veristat.com/solutions/the-evolving-landscape-of-radiopharmaceuticals-in-oncology-research2025-06-12https://www.veristat.com/veristat-web-style-guidehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412022-02-22https://www.veristat.com/solutions/overcoming-challenges-in-orphan-drug-development2025-06-12https://www.veristat.com/solutions/successful-full-service-randomized-pancreatic-cancer-phase-ii-trial2025-10-08https://www.veristat.com/solutions/veristat-expands-global-regulatory-expertise2025-06-12https://www.veristat.com/library/accelerating-patient-centric-clinical-trials-through-science-based-planning-delivery-and-support2025-07-02https://www.veristat.com/careershttps://www.veristat.com/hubfs/Life-At-Veristat-care.jpegLifeAtVeristatcareLifeAtVeristatcarehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image3_new.jpgpeopleworkingimage3newpeopleworkingimage3newhttps://www.veristat.com/hubfs/Careers.pngCareersCareershttps://www.veristat.com/hubfs/happy_people_3women_whyV.jpeghappypeople3womenwhyVhappypeople3womenwhyVhttps://www.veristat.com/hubfs/grandfather-grandson.jpggrandfathergrandsongrandfathergrandsonhttps://www.veristat.com/hubfs/images_sizedat600px/patient-doctor_image2.jpgpatientdoctorimage2patientdoctorimage2https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffee2024-07-03https://www.veristat.com/services/veristat-and-aobiome-to-discuss-strategic-cro-partnership-at-clinical-outsourcing-group-20252026-06-15https://www.veristat.com/library/corporate-overview-fact-sheet2025-05-21https://www.veristat.com/solutions/early-detection-vs.-overdiagnosis-the-ctdna-screening-paradox2026-01-05https://www.veristat.com/instat-is-now-veristat/building-confidence-in-rwe-delivering-smarter-regulatory-strategies2026-06-23https://www.veristat.com/library/biomarker-driven-adaptive-design-for-precision-medicine2024-07-03https://www.veristat.com/solutions/recist-oncology-guidelines2025-06-12https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-september-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/understanding-the-critical-role-of-data-monitoring-committees-in-clinical-trials2026-06-23https://www.veristat.com/services/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study2026-06-15https://www.veristat.com/library/wholistic-approach-to-strategic-consulting2024-07-03https://www.veristat.com/solutions/updated-future-trends-on-european-regulations-on-medicines2025-06-12https://www.veristat.com/instat-is-now-veristat/the-science-of-simultaneous-submissions-managing-multiple-regulatory-pathways2026-06-23https://www.veristat.com/services/running-successful-clinical-programs-external-biostatistics-team2026-06-15https://www.veristat.com/services/replay-how-to-better-plan-a-virtual-clinical-trial2026-06-15https://www.veristat.com/library/programmed-narratives-working-smarter-not-harder2024-07-03https://www.veristat.com/services/strategic-consultinghttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Strategic%20Consulting.pngStrategicConsultingStrategicConsultinghttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image6.jpgpeopleworkingimage6peopleworkingimage6https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopers2026-07-10https://www.veristat.com/instat-is-now-veristat/understanding-the-impact-of-real-world-evidence-on-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/writing-multiple-marketing-applications-at-the-same-time2026-06-23https://www.veristat.com/library-old/webinar-achieving-balance-in-database-design2024-06-27https://www.veristat.com/services/medical-writing-partnership-indtonda2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/how-vaccine-clinical-trials-work2026-06-23https://www.veristat.com/services/delivering-data-that-matters-an-integrated-approach-to-biostatistics-data-management-statistical-programming-in-clinical-trials2026-06-15https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-october-20242025-06-12https://www.veristat.com/services/sfl_is_now_veristat/comprehensive-planning-for-a-first-in-human-cancer-antibody-trial2026-06-23https://www.veristat.com/library/inside-2026-the-industrys-ai-turning-point2026-01-09https://www.veristat.com/recruitment-privacy-noticehttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2025-07-02https://www.veristat.com/services/supporting-global-approval-of-a-first-in-classgene-therapy-for-a-rare-genetic-disorder2026-06-15https://www.veristat.com/instat-is-now-veristat/staying-the-course-what-fda-staffing-reductions-mean-for-drug-development-today2026-06-23https://www.veristat.com/instat-is-now-veristat/how-vaccine-clinical-trials-work2026-06-23https://www.veristat.com/services/turning-sponsor-cro-partnerships-into-success2026-06-15https://www.veristat.com/instat-is-now-veristat/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2026-06-23https://www.veristat.com/solutions/leveraging-fda-expedited-programs-webinar-replay2025-06-12https://www.veristat.com/instat-is-now-veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-article2026-06-23https://www.veristat.com/services/a-roundup-of-perspectives-and-predictions-on-research-misconduct-inclusivity-ai-and-more2026-06-15https://www.veristat.com/solutions/rescuing-site-monitoring-success2025-10-29https://www.veristat.com/rare-disease-crohttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/clinical-care.jpgclinicalcareclinicalcarehttps://www.veristat.com/hubfs/rare-disease-image.jpgrarediseaseimagerarediseaseimage2022-09-07https://www.veristat.com/library-old/rare-disease-fact-sheet2024-06-27https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-august-20252026-01-13https://www.veristat.com/instat-is-now-veristat/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2026-06-23https://www.veristat.com/services/early-detection-vs.-overdiagnosis-the-ctdna-screening-paradox2026-06-15https://www.veristat.com/content-modules-choice/writing-multiple-marketing-applications-at-the-same-time2020-07-30https://www.veristat.com/services/infectious-disease-fact-sheet2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/blog-nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-23https://www.veristat.com/solutions/data-management-fact-sheet2025-06-12https://www.veristat.com/library/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2024-07-03https://www.veristat.com/instat-is-now-veristat/7-habits-of-highly-successful-medical-writers2026-06-23https://www.veristat.com/library/marketing-application-operational-timeline-complexities2024-07-03https://www.veristat.com/library/2026-cell-and-gene-therapy-predictions2026-02-13https://www.veristat.com/solutions/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis-blog2025-08-28https://www.veristat.com/library/overcoming-complexity-in-modern-clinical-trials2025-08-21https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-july-20242025-06-12https://www.veristat.com/library/regulatory-guidance-monthly-review-october-20232024-07-03https://www.veristat.com/cookie-policyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2026-06-09https://www.veristat.com/custom-privacyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2025-05-23https://www.veristat.com/services/endocrine-and-metabolic-fact-sheet2026-06-15https://www.veristat.com/instat-is-now-veristat/executing-patient-focused-drug-development-pfdd2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-november-20242025-06-12https://www.veristat.com/library-old/medical-writing-partnership-indtonda2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/corporate-overview-fact-sheet2026-06-23https://www.veristat.com/solutions/helping-a-sponsor-overcome-a-partial-clinical-hold-and-seamlessly-steer-multiple-products-through-development2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/podcast-orphan-drug-designations-and-orphan-subsets2026-06-23https://www.veristat.com/therapeutic-expertise/vaccineshttps://www.veristat.com/hubfs/Vaccine%20Trials.pngVaccineTrialsVaccineTrialshttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image14.jpgtherapeuticimage14therapeuticimage14https://www.veristat.com/hubfs/images_sizedat600px/covid19_virusspike.jpgcovid19virusspikecovid19virusspikehttps://www.veristat.com/hubfs/HubDB_Card%20Image_CS_HIPRA%20COVID.pngHubDBCardImageCSHIPRACOVIDHubDBCardImageCSHIPRACOVIDhttps://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImage2025-06-12https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-january-20252025-06-12https://www.veristat.com/instat-is-now-veristat/the-logistics-of-a-clinical-study-scale-up2026-06-23https://www.veristat.com/library/should-an-oncology-study-expand-into-europe2025-10-22https://www.veristat.com/services/sfl_is_now_veristat/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/common-pitfalls-in-gene-therapy-studies2026-06-23https://www.veristat.com/solutions/full-service-trial-delivery-fact-sheet2025-06-12https://www.veristat.com/solutions/marketing-application-best-practices-for-publishing2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/bayesian-study-designs-in-early-phase-oncology-trials2026-06-23https://www.veristat.com/solutions/regulatory-guidance-monthly-review-september-20232025-06-12https://www.veristat.com/solutions/corporate-overview-fact-sheet2025-06-12https://www.veristat.com/services/planning-your-ind-when-and-why-to-engage-the-fda2026-06-15https://www.veristat.com/solutions/what-is-the-future-cell-gene-presentation2025-06-12https://www.veristat.com/solutions/accelerating-biologics-development-global-expertise-to-mitigate-risks2025-06-12https://www.veristat.com/medical-affairs-overviewhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Medical%20Affairs.pngMedicalAffairsMedicalAffairshttps://www.veristat.com/hubfs/data_image_personscreens_original.jpegdataimagepersonscreensoriginaldataimagepersonscreensoriginalhttps://www.veristat.com/hubfs/patient_support_image5.webppatientsupportimage5patientsupportimage5https://www.veristat.com/hubfs/layout/cards/Safety-Pharmacovigilance.jpgSafetyPharmacovigilanceSafetyPharmacovigilancehttps://www.veristat.com/hubfs/GRosu-Headshot.jpgGRosuHeadshotGRosuHeadshothttps://www.veristat.com/hubfs/patient-doctor_image2.webppatientdoctorimage2patientdoctorimage22026-07-09https://www.veristat.com/instat-is-now-veristat/making-dcts-a-successful-reality-for-complex-studies2026-06-23https://www.veristat.com/services/addressing-drug-developer-challenges-with-decentralized-clinical-trials2026-06-15https://www.veristat.com/services/planning-the-way-forward-in-neurodegenerative-disease-studies2026-06-15https://www.veristat.com/library/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-presentation2024-07-03https://www.veristat.com/services/understanding-and-operationalizing-a-complex-adaptive-design2026-06-15https://www.veristat.com/services/presentation-expanding-your-clinical-trial-into-the-us2026-06-15https://www.veristat.com/instat-is-now-veristat/targeted-indication-selection-using-simon-2-stage-design2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/similarities-and-differences-between-the-cta-and-ind2026-06-23https://www.veristat.com/library/making-dcts-a-successful-reality-for-complex-studies2024-07-03https://www.veristat.com/solutions/are-autologous-therapies-here-to-stay-are-allogeneic-therapies-the-future2025-06-12https://www.veristat.com/solutions/unleashing-flexibility-in-a-rare-disease-gene-therapy-clinical-trial2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/regulatory-consulting-fact-sheet2026-06-23https://www.veristat.com/library/a-patient-centric-apprach-to-recruitment-and-retention22024-07-03https://www.veristat.com/instat-is-now-veristat/pharmacovigilance-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-april-20252026-06-23https://www.veristat.com/solutions/laying-the-groundwork-to-measure-the-impact-of-decentralized-clinical-trials-dcts2025-06-12https://www.veristat.com/library/unleashing-flexibility-in-a-rare-disease-gene-therapy-clinical-trial2024-07-03https://www.veristat.com/library/successful-full-service-randomized-pancreatic-cancer-phase-ii-trial2025-10-08https://www.veristat.com/instat-is-now-veristat/accelerating-biologics-development-global-expertise-to-mitigate-risks2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-ctdna-clinical-trial-advantage-why-cro-work-puts-you-on-the-cutting-edge2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/virtual-hybrid-clinical-trials2026-06-23https://www.veristat.com/services/successful-preparation-strategies-for-nda-maa-marketing-applications2026-06-15https://www.veristat.com/library/regulatory-guidance-monthly-review-july-20232024-10-10https://www.veristat.com/services/sfl_is_now_veristat/ash-2025-interpreting-rapid-change-across-hematology2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/driving-multiple-global-gene-therapy-studies2026-06-23https://www.veristat.com/solutions/bold-thinking-that-delivers-results-for-rna-therapies2025-06-12https://www.veristat.com/services/regulatory-publishing2026-06-15https://www.veristat.com/services/rapid-response-to-ebola-outbreak2026-06-15https://www.veristat.com/library/the-science-of-simultaneous-submissions-managing-multiple-regulatory-pathways2026-01-15https://www.veristat.com/services/managing-e6r2-compliance-as-it-relates-to-risk-deck2026-06-15https://www.veristat.com/services/quality-assurance-and-compliancehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/social-suggested-images/www.veristat.comhs-fshubfslogologo-small-Aug-09-2024-08-57-57-5062-AM.pngwwwveristatcomhsfshubfslogologosmallAug0920240857575062AMwwwveristatcomhsfshubfslogologosmallAug0920240857575062AM2026-06-15https://www.veristat.com/solutions/rescuing-a-global-program-for-nda-success2025-08-05https://www.veristat.com/library/four-pillars-of-success-in-neurology-trials2026-02-06https://www.veristat.com/instat-is-now-veristat/use-of-pro-in-cell-and-gene-therapy-studies2026-06-23https://www.veristat.com/therapeutic-expertise/neurologyhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image18.jpghappypeopleimage18happypeopleimage18https://www.veristat.com/hubfs/images_sizedat600px/People_therapeutic_Consent_image10.jpgPeopletherapeuticConsentimage10PeopletherapeuticConsentimage10https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Heart_Failure_image3.jpgtherapeuticHeartFailureimage3therapeuticHeartFailureimage3https://www.veristat.com/hubfs/email/Biologic%20Emails/Pediatric%20Full%20Service%20239x202.pngPediatricFullService239x202PediatricFullService239x202https://www.veristat.com/hubfs/Neurology_Psychiatry-1.pngNeurologyPsychiatry1NeurologyPsychiatry1https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImage2026-07-09https://www.veristat.com/services/full-service-trial-delivery-fact-sheet2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/replay-how-to-better-plan-a-virtual-clinical-trial2026-06-23https://www.veristat.com/library/eu-pharma-package-key-takeaways-for-clinical-evidence-jca-strategy2026-01-09https://www.veristat.com/services/sfl_is_now_veristat/should-an-oncology-study-expand-into-europe2026-06-23https://www.veristat.com/solutions/medical-writing-fact-sheet2025-06-12https://www.veristat.com/library-old/veristat-infographic2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/fda-expedited-programs-what-you-need-to-know2026-06-23https://www.veristat.com/solutions/strengthening-opportunities-for-growth-in-the-european-region2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/expert-ind-publishing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/accelerating-patient-centric-trials2026-06-23https://www.veristat.com/solutions/different-approaches-for-preparing-marketing-applications2025-06-12https://www.veristat.com/services/comprehensive-strategic-clinical-development-consulting2026-06-15https://www.veristat.com/instat-is-now-veristat/a-scientific-approach-to-advance-your-novel-cancer-therapies2026-06-23https://www.veristat.com/services/the-rise-of-decentralized-clinical-trials-transforming-research-through-technology-and-patient-centricity2026-06-15https://www.veristat.com/services/marketing-application-medical-writing-strategies2026-06-15https://www.veristat.com/solutions/veristat-global-policy-insights-q1-20242025-06-12https://www.veristat.com/virtual-clinical-trial-adoptionhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Nurse-At-Home-Visit-1200px.jpegNurseAtHomeVisit1200pxNurseAtHomeVisit1200pxhttps://www.veristat.com/hubfs/HubDB_Card%20Image_Podcast_Big4Bio%20DCT.pngHubDBCardImagePodcastBig4BioDCTHubDBCardImagePodcastBig4BioDCThttps://www.veristat.com/hubfs/images_sizedat600px/virtualtrials_telemedicine.jpgvirtualtrialstelemedicinevirtualtrialstelemedicinehttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-11-20https://www.veristat.com/instat-is-now-veristat/rescuing-a-global-program-for-nda-success2026-06-23https://www.veristat.com/library/flexibility-drives-progress-in-rare-disease-gene-therapy-trial2026-02-26https://www.veristat.com/library/bayesian-study-designs-in-early-phase-oncology-trials2025-05-20https://www.veristat.com/services/sfl_is_now_veristat/how-to-ensure-a-successful-fda-meeting-presentation-download2026-06-23https://www.veristat.com/instat-is-now-veristat/dose-escalation-with-bayesian-strategies2026-06-23https://www.veristat.com/library/migration-of-data-between-edcs-blog2024-07-03https://www.veristat.com/services/biometrics/standards-implementationhttps://www.veristat.com/hubfs/Standards%20Implementation.pngStandardsImplementationStandardsImplementationhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovationhttps://www.veristat.com/hubfs/images_sizedat600px/data_image_keyboard.jpgdataimagekeyboarddataimagekeyboardhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurology2025-06-12https://www.veristat.com/library-old/how-to-ensure-successful-fda-meeting-video-replay2024-06-27https://www.veristat.com/solutions/lessons-learned-for-better-planning-of-decentralized-clinical-trials2025-06-12https://www.veristat.com/library-old/pooled-analysis-of-the-phase-3-revive-trials2024-06-27https://www.veristat.com/services/laying-the-groundwork-to-measure-the-impact-of-decentralized-clinical-trials-dcts2026-06-15https://www.veristat.com/library/regulatory-submission-infographic2024-07-03https://www.veristat.com/instat-is-now-veristat/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study-recording2026-06-23https://www.veristat.com/services/webinar-pres-roadmap-to-market-cell-and-gene-therapies2026-06-15https://www.veristat.com/services/a-scientific-approach-to-advance-your-novel-cancer-therapies2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/future-glances-more-change-more-tech-more-harmonisation2026-06-23https://www.veristat.com/services/bold-thinking-that-delivers-results-for-rna-therapies2026-06-15https://www.veristat.com/library-old/fda-expedited-pathways-explained2024-06-27https://www.veristat.com/solutions/purpose-of-ind-ig2025-06-12https://www.veristat.com/instat-is-now-veristat/bridging-science-and-regulatory-success-with-medical-writing2026-06-23https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/writing-multiple-marketing-applications-at-the-same-time2024-07-03https://www.veristat.com/instat-is-now-veristat/selecting-the-right-oncology-cro-partner2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-april-20242026-06-23https://www.veristat.com/services/regulatory-affairs/regulatory-consulting-for-program-and-trial-designhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Regulatory%20Consulting-1.pngRegulatoryConsulting1RegulatoryConsulting1https://www.veristat.com/hubfs/Veristat_icon_regulatory%20approval.pngVeristaticonregulatoryapprovalVeristaticonregulatoryapprovalhttps://www.veristat.com/hubfs/RegulatoryLifecycleChart_DarkGreenwithFade%20Background_Aug2021_ForPPT_USETHISONE-1.pngRegulatoryLifecycleChartDarkGreenwithFadeBackgroundAug2021ForPPTUSETHISONE1RegulatoryLifecycleChartDarkGreenwithFadeBackgroundAug2021ForPPTUSETHISONE12026-07-10https://www.veristat.com/instat-is-now-veristat/news-you-can-use-for-rare-disease-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/unlocking-insights-the-impact-of-new-medical-device-eu-regulation-mdr2026-06-23https://www.veristat.com/library/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis2025-08-01https://www.veristat.com/libraryhttps://www.veristat.com/hubfs/Blog%20Tackling%20the%20Complexities%20of%20Advanced%20Therapies%20for%20Neurology.pngBlogTacklingtheComplexitiesofAdvancedTherapiesforNeurologyBlogTacklingtheComplexitiesofAdvancedTherapiesforNeurologyhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialhttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Monthly%20FDA%20Guidance%20January%202026.pngMonthlyFDAGuidanceJanuary2026MonthlyFDAGuidanceJanuary2026https://www.veristat.com/hubfs/Blog%20-%20The%20Compound%20Effect%20of%20Specialized%20Knowledge.pngBlogTheCompoundEffectofSpecializedKnowledgeBlogTheCompoundEffectofSpecializedKnowledge2024-07-03https://www.veristat.com/library/fda-meeting-types2024-07-03https://www.veristat.com/solutions/development-of-a-covid-19-vaccine-challenges-for-data-managers2025-06-12https://www.veristat.com/solutions/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study2025-06-12https://www.veristat.com/solutions/advancing-your-biologic-requires-bold-scientific-strategies2025-06-12https://www.veristat.com/services/regulatory-guidance-monthly-review-july-20232026-06-15https://www.veristat.com/solutions/fda-meeting-types2025-06-12https://www.veristat.com/instat-is-now-veristat/veristats-most-downloaded-assets-of-20232026-06-23https://www.veristat.com/services/your-guide-to-mastering-cmc-regulatory-success-in-biotherapeutics-a-must-watch-webinar2026-06-15https://www.veristat.com/instat-is-now-veristat/indication-selection-using-adaptive-design2026-06-23https://www.veristat.com/instat-is-now-veristat/fspresourcing-meeting-the-moment-with-expert-resources2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-august-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/fdas-project-frontrunner-a-path-forward-for-cancer-drug-development2026-06-23https://www.veristat.com/services/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis-blog2026-06-15https://www.veristat.com/solutions/writing-multiple-marketing-applications-at-the-same-time2025-06-12https://www.veristat.com/instat-is-now-veristat/side-by-side-comparison-non-adaptive-vs.-adaptive-designs-in-clinical-trials2026-06-23https://www.veristat.com/library-old/cardiology-fact-sheet2024-06-27https://www.veristat.com/solutions/shortening-development-and-approval-timelines-for-novel-medicinal-products2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/news-you-can-use-for-rare-disease-trials2026-06-23https://www.veristat.com/services/expertise-in-rna-therapies2026-06-15https://www.veristat.com/instat-is-now-veristat/fda-guidance-series-on-patient-focused-drug-development-pfdd-to-enhance-product-development-and-regulatory-decision-making2026-06-23https://www.veristat.com/solutions/a-comprehensive-planning-approach-for-cancer-antibody2025-06-12https://www.veristat.com/content-modules-choice/cardiology-fact-sheet2020-07-30https://www.veristat.com/services/what-is-the-future-landscape-of-cell-gene-therapies-replay2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/adaptive-design-recent-advancement-in-clinical-trials2026-06-23https://www.veristat.com/solutions/use-of-pro-in-cell-and-gene-therapy-studies2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/fda-meeting-types2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-december-20242026-06-23https://www.veristat.com/instat-is-now-veristat/different-approaches-for-preparing-marketing-applications2026-06-23https://www.veristat.com/instat-is-now-veristat/veristat-achieves-ecovadis-committed-badge-a-milestone-in-our-sustainability-journey2026-06-23https://www.veristat.com/services/navigating-the-ind-submission-labyrinth-a-veristat-success-story2026-06-15https://www.veristat.com/services/medical-affairs/data-monitoring-committeeshttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Data%20Monitoring%20%20Committees.pngDataMonitoringCommitteesDataMonitoringCommitteeshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image16_virtualmeeting_600px.jpgpeopleworkingimage16virtualmeeting600pxpeopleworkingimage16virtualmeeting600pxhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovationhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image2.jpgpeopleworkingimage2peopleworkingimage2https://www.veristat.com/hubfs/images_sizedat600px/data_handsenteringdata_darkblue.jpgdatahandsenteringdatadarkbluedatahandsenteringdatadarkbluehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image9.jpgpeopleworkingimage9peopleworkingimage92025-06-12https://www.veristat.com/library/regulatory-considerations-for-biosimilars-development-in-the-us-blog2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/endocrine-and-metabolic-fact-sheet2026-06-23https://www.veristat.com/services/fdas-draft-guidance-for-data-monitoring-committees-dmcs2026-06-15https://www.veristat.com/solutions/minimizing-complexity-in-oncology-clinical-trials2025-06-12https://www.veristat.com/instat-is-now-veristat/single-arm-registrational-studies-in-oncology-research2026-06-23https://www.veristat.com/library/planning-for-a-successful-initial-ind-and-moving-beyond2024-07-03https://www.veristat.com/services/the-next-leap-in-alzheimers-rd-is-coming2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/unlocking-insights-the-impact-of-new-medical-device-eu-regulation-mdr2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/running-successful-clinical-programs-external-biostatistics-team2026-06-23https://www.veristat.com/library/understanding-data-monitoring-committees2024-09-05https://www.veristat.com/instat-is-now-veristat/advancing-dose-escalation-strategies-with-bayesian-modeling2026-06-23https://www.veristat.com/solutions/regulatory-considerations-for-biosimilars-development-in-the-us2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/autologous-vs-allogeneic-cell-and-gene-therapies2026-06-23https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/cardiology-fact-sheet2024-07-03https://www.veristat.com/services/rare-disease-fact-sheet2026-06-15https://www.veristat.com/library/how-vaccine-clinical-trials-work2024-07-03https://www.veristat.com/instat-is-now-veristat/a-playbook-for-effective-sponsorcro-partnership2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/multi-regional-clinical-trials-the-latest-guidance-from-fda2026-06-23https://www.veristat.com/services/protocol-specific-feasibility2026-06-15https://www.veristat.com/instat-is-now-veristat/strategic-clinical-development-consulting2026-06-23https://www.veristat.com/instat-is-now-veristat/recognize-rare-disease-month-with-veristat2026-06-23https://www.veristat.com/instat-is-now-veristat/marketing-application-key-planning-tips2026-06-23https://www.veristat.com/solutions/fda-introduces-new-term-nonclinical-tests-signaling-a-beginning-not-an-end2025-06-12https://www.veristat.com/library/advancing-to-your-next-milestone-global-regulatory-excellence-throughout-theentire-clinical-development-lifecycle2024-07-03https://www.veristat.com/services/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development2026-06-15https://www.veristat.com/services/a-creative-approach-to-achieving-an-aggressive-nda-timeline2026-06-15https://www.veristat.com/rfphttps://www.veristat.com/hubfs/social-suggested-images/www.veristat.comhs-fshubfslogologo-small-Aug-23-2024-08-14-21-2491-AM.pngwwwveristatcomhsfshubfslogologosmallAug2320240814212491AMwwwveristatcomhsfshubfslogologosmallAug2320240814212491AMhttps://www.veristat.com/hubfs/Veristat_logo.pngVeristatlogoVeristatlogo2024-09-26https://www.veristat.com/instat-is-now-veristat/leveraging-fda-expedited-programs-webinar-replay2026-06-23https://www.veristat.com/solutions/the-rapid-pace-of-regulatory-change2025-06-12https://www.veristat.com/library-old/regulatory-submission-infographic2024-06-27https://www.veristat.com/library/rare-disease-fact-sheet2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/are-autologous-therapies-here-to-stay-are-allogeneic-therapies-the-future2026-06-23https://www.veristat.com/library/successful-dmc-services-for-complex-hematologic-cancer-trial2024-10-10https://www.veristat.com/services/sfl_is_now_veristat/accelerating-oncology-breakthroughs2026-06-23https://www.veristat.com/instat-is-now-veristat/elevating-cns-drug-development-veristats-agile-approach-in-medical-writing-and-project-management2026-06-23https://www.veristat.com/solutions/improving-clinical-trial-efficiency-by-achieving-on-time-patient-recruitment2025-06-12https://www.veristat.com/library/measuring-what-cant-be-seen-how-ptsd-clinical-trials-prove-a-drug-works2026-05-18https://www.veristat.com/services/efficient-regulatory-publishing-for-large-scale-fda-submission2026-06-15https://www.veristat.com/services/side-by-side-comparison-non-adaptive-vs.-adaptive-designs-in-clinical-trials2026-06-15https://www.veristat.com/library-old/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2024-06-27https://www.veristat.com/services/regulatory-considerations-for-biosimilars-development-in-the-us2026-06-15https://www.veristat.com/doug_arbetter_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/instat-is-now-veristat/essential-considerations-foradaptive-design-in-clinical-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/preparing-data-for-maa-marketing-authorization-appliation2026-06-23https://www.veristat.com/services/emergency-use-authorizations2026-06-15https://www.veristat.com/services/webinar-slides-planning-for-a-successful-initial-ind-and-moving-beyond2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/webinar-slides-planning-for-a-successful-initial-ind-and-moving-beyond2026-06-23https://www.veristat.com/services/pursuing-breakthrough-therapies-for-rare-metabolic-diseases-veristats-role-in-a-landmark-clinical-study2026-06-15https://www.veristat.com/library/regulatory-guidance-monthly-review-january-20242024-07-03https://www.veristat.com/solutions/fspresourcing-meeting-the-moment-with-expert-resources2025-06-12https://www.veristat.com/instat-is-now-veristat/unlocking-potential-taking-a-statistics-driven-approach-to-clinical-trial-planning2026-06-23https://www.veristat.com/solutions/eu-post-marketing-requirements-for-cell-and-gene-therapy-studies2025-06-12https://www.veristat.com/solutions/replay-expanding-your-clinical-trial-into-the-us2025-06-12https://www.veristat.com/library/accelerate-neurologypsychiatry-trial-success-with-expert-guidance2026-01-05https://www.veristat.com/instat-is-now-veristat/turning-sponsor-cro-partnerships-into-success2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products2026-06-23https://www.veristat.com/solutions/fda-meeting-types-for-biosimilar-products2025-06-12https://www.veristat.com/pharmacovigilance/medical-information-serviceshttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Medical%20Information%20Services%20Page%20Featured%20Image.pngMedicalInformationServicesPageFeaturedImageMedicalInformationServicesPageFeaturedImagehttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_quote-216.pngVeristaticonquote216Veristaticonquote216https://www.veristat.com/hubfs/images_sizedat600px/call_center_image4.jpgcallcenterimage4callcenterimage4https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-07-03https://www.veristat.com/library-old/planning-the-way-forward-in-neurodegenerative-disease-studies2024-06-27https://www.veristat.com/solutions/is-your-trial-stuck2025-06-12https://www.veristat.com/table-top-testhttps://www.veristat.com/hubfs/layout/cards/card-placeholder.pngcardplaceholdercardplaceholderhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2020-12-07https://www.veristat.com/solutions/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2025-06-12https://www.veristat.com/services/overcoming-complexity-in-modern-clinical-trials2026-06-15https://www.veristat.com/services/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2026-06-15https://www.veristat.com/solutions/long-term-follow-up-studies-in-gene-therapy2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/ensuring-regulatory-success-from-pre-ind-through-to-submission2026-06-23https://www.veristat.com/library-old/approvals-for-an-ultra-rare-hematologic-malignancy2024-06-27https://www.veristat.com/services/marketing-application-operational-timeline-complexities2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/understanding-fdas-project-optimus2026-06-23https://www.veristat.com/services/regulatory-guidance-monthly-review-january-20232026-06-15https://www.veristat.com/services/emergency-use-authorizations-blog2026-06-15https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-february-20252025-03-13https://www.veristat.com/solutions/regulatory-publishing2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/reflections-from-asco-20252026-06-23https://www.veristat.com/services/lessons-learned-for-better-planning-of-decentralized-clinical-trials2026-06-15https://www.veristat.com/library/a-patient-centric-apprach-to-recruitment-and-retention2024-07-03https://www.veristat.com/solutions/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products2025-06-12https://www.veristat.com/services/similarities-and-differences-between-the-cta-and-ind2026-06-15https://www.veristat.com/library/a-playbook-for-effective-sponsorcro-partnership2026-01-16https://www.veristat.com/services/sfl_is_now_veristat/natural-history-study-best-practices-for-engaging-regulatory-authorities2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/indication-selection-using-adaptive-design2026-06-23https://www.veristat.com/library/common-pitfalls-in-gene-therapy-studies2024-07-03https://www.veristat.com/services/marketing-applications-data-analysis-challenges2026-06-15https://www.veristat.com/library-old/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2024-06-27https://www.veristat.com/instat-is-now-veristat/purpose-of-ind-ig2026-06-23https://www.veristat.com/services/ash-2025-interpreting-rapid-change-across-hematology2026-06-15https://www.veristat.com/content-modules-choice/achieving-an-aggressive-nda-timeline2020-07-30https://www.veristat.com/library-old/roadmap-to-market-for-cell-and-gene-therapies2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/webinar-qa-how-to-advance-new-cancer-therapies-in-alignment-with-fda-project-frontrunner2026-06-23https://www.veristat.com/instat-is-now-veristat/neurology-psychiatry-fact-sheet2026-06-23https://www.veristat.com/library/preserving-what-matters-how-institutional-knowledge-protects-value-through-ma2026-01-09https://www.veristat.com/careers/explore-benefitshttps://www.veristat.com/hubfs/LTN-photo-career.jpegLTNphotocareerLTNphotocareerhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/layout/page-images/Careers_Benefits_PlanningforFutureBox.jpgCareersBenefitsPlanningforFutureBoxCareersBenefitsPlanningforFutureBox2025-06-12https://www.veristat.com/services/purpose-of-ind-ig2026-06-15https://www.veristat.com/solutions/building-confidence-in-rwe-delivering-smarter-regulatory-strategies2025-06-12https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-july-20242026-06-15https://www.veristat.com/services/sfl_is_now_veristat/the-logistics-of-a-clinical-study-scale-up2026-06-23https://www.veristat.com/solutions/selecting-endpoints-for-an-early-phase-cell-or-gene-study2025-06-12https://www.veristat.com/library/marketing-application-key-planning-tips2024-07-03https://www.veristat.com/library/veristat-infographic2025-08-26https://www.veristat.com/library/selecting-the-right-oncology-cro-partner2025-05-21https://www.veristat.com/library/veristat-global-policy-insights-q22024-07-17https://www.veristat.com/library/fda-meeting-types-for-biosimilar-products2024-07-03https://www.veristat.com/solutions/considerations-for-developing-rare-disease-treatments2025-06-12https://www.veristat.com/services/understanding-the-impact-of-real-world-evidence-on-clinical-trials2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/managing-e6r2-compliance-as-it-relates-to-risk-deck2026-06-23https://www.veristat.com/martha_plaza_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/instat-is-now-veristat/cmc-pitfalls-from-benchtop-to-ind-blog2026-06-23https://www.veristat.com/services/regulatory-guidance-monthly-review-february-20232026-06-15https://www.veristat.com/solutions/webinar-qa-how-to-advance-new-cancer-therapies-in-alignment-with-fda-project-frontrunner2025-06-12https://www.veristat.com/services/agile-medical-writing-support-for-an-nda2026-06-15https://www.veristat.com/solutions/running-successful-clinical-programs-external-biostatistics-team2025-06-12https://www.veristat.com/library/laying-the-groundwork-to-measure-the-impact-of-decentralized-clinical-trials-dcts2024-07-03https://www.veristat.com/instat-is-now-veristat/virtual-hybrid-clinical-trials2026-06-23https://www.veristat.com/solutions/measuring-what-cant-be-seen-how-ptsd-clinical-trials-prove-a-drug-works2026-05-18https://www.veristat.com/video-replay-gene-therapy-creative-solutions-for-complex-clinical-development-pathwayshttps://info.veristat.com/hubfs/Rachel%20Smith.mp4/medium.jpgRachelSmithRachelSmithhttps://www.veristat.com/hubfs/Rachel%20Smith.mp41748nonohttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library/multi-regional-clinical-trials-the-latest-guidance-from-fda2025-01-24https://www.veristat.com/library/pooled-analysis-of-the-phase-3-revive-trials2024-07-03https://www.veristat.com/solutions/natural-history-studies-in-rare-disease-drug-development2025-08-21https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-september-20242024-10-16https://www.veristat.com/therapeutic-expertise/otherhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Respiratory_image12.jpgtherapeuticRespiratoryimage12therapeuticRespiratoryimage12https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image14.jpghappypeopleimage14happypeopleimage14https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image18.jpghappypeopleimage18happypeopleimage18https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image3.jpghappypeopleimage3happypeopleimage3https://www.veristat.com/hubfs/More%20Therapy%20Areas-1.pngMoreTherapyAreas1MoreTherapyAreas1https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/images_sizedat600px/dermatology_fungal%20Image_opt600px.jpgdermatologyfungalImageopt600pxdermatologyfungalImageopt600pxhttps://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/images_sizedat600px/happy_people_image7.jpghappypeopleimage7happypeopleimage7https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image5.jpgtherapeuticimage5therapeuticimage5https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image6.jpgtherapeuticimage6therapeuticimage6https://www.veristat.com/hubfs/images_sizedat600px/patient-doctor_image5.jpgpatientdoctorimage5patientdoctorimage52025-06-12https://www.veristat.com/services/sfl_is_now_veristat/fda-cders-accelerating-rare-disease-cures-arc-program2026-06-23https://www.veristat.com/solutions/de-risking-the-neurology-ind-lessons-from-early-fda-engagement2026-01-06https://www.veristat.com/services/project-optimus-explained-why-the-fda-is-shifting-away-from-maximum-tolerated-dose-in-oncology2026-06-15https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-january-20252025-03-13https://www.veristat.com/services/fdas-project-frontrunner-explained2026-06-15https://www.veristat.com/library/regulatory-submission-fact-sheet2024-07-03https://www.veristat.com/instat-is-now-veristat/first-gene-therapy-approved-in-europe2026-06-23https://www.veristat.com/instat-is-now-veristat/global-policy-insights-april-20242026-06-23https://www.veristat.com/meetveristat-rw2023https://www.veristat.com/hubfs/Veristat_HubDB_Single%20Arm%20Study.pngVeristatHubDBSingleArmStudyVeristatHubDBSingleArmStudyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Webinar_Accelerating%20Patient%20Centric%20Clinical%20Trials%20420X229px.pngWebinarAcceleratingPatientCentricClinicalTrials420X229pxWebinarAcceleratingPatientCentricClinicalTrials420X229px2024-11-20https://www.veristat.com/full-service-cro-biologicshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image14.jpgtherapeuticimage14therapeuticimage14https://www.veristat.com/hubfs/Biologics-2.pngBiologics2Biologics2https://www.veristat.com/hubfs/images_sizedat600px/lab-cmc_scientistinlab.jpglabcmcscientistinlablabcmcscientistinlabhttps://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/images_sizedat600px/cellandgene_splicing.jpgcellandgenesplicingcellandgenesplicinghttps://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/Reg%20Podcast%20Oct22%20Version%20A.pngRegPodcastOct22VersionARegPodcastOct22VersionA2026-07-09https://www.veristat.com/instat-is-now-veristat/clinical-trials-meet-adaptive-design2026-06-23https://www.veristat.com/solutions/news-you-can-use-for-rare-disease-trials2025-06-12https://www.veristat.com/services/considerations-for-natural-history-studies2026-06-15https://www.veristat.com/solutions/cmc-pitfalls-from-benchtop-to-ind-blog2025-06-12https://www.veristat.com/newshttps://www.veristat.com/hubfs/Veristat%20and%20AOBiome%20Therapeutics%20to%20Present%20at%20Clinical%20Outsourcing%20Group.pngVeristatandAOBiomeTherapeuticstoPresentatClinicalOutsourcingGroupVeristatandAOBiomeTherapeuticstoPresentatClinicalOutsourcingGrouphttps://www.veristat.com/hubfs/Veristat%20Achieves%20EcoVadis%20Committed%20Badge%20A%20Milestone%20in%20Our%20Sustainability%20Journey.pngVeristatAchievesEcoVadisCommittedBadgeAMilestoneinOurSustainabilityJourneyVeristatAchievesEcoVadisCommittedBadgeAMilestoneinOurSustainabilityJourneyhttps://www.veristat.com/hubfs/Growing%20Our%20Leadership%20Team.jpgGrowingOurLeadershipTeamGrowingOurLeadershipTeamhttps://www.veristat.com/hubfs/March%2010%20News.jpgMarch10NewsMarch10Newshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Kim%20Boericke%20Named%20CEO_1132025.pngKimBoerickeNamedCEO1132025KimBoerickeNamedCEO1132025https://www.veristat.com/hubfs/Cook%20MyoSite%20and%20Veristat%20Partner%20in%20Complex%20Clinical%20Study.pngCookMyoSiteandVeristatPartnerinComplexClinicalStudyCookMyoSiteandVeristatPartnerinComplexClinicalStudyhttps://www.veristat.com/hubfs/Veristat%20Congratulates%20George%20Medicines%20on%20FDA%20Approval%20of%20WIDAPLIKTM.pngVeristatCongratulatesGeorgeMedicinesonFDAApprovalofWIDAPLIKTMVeristatCongratulatesGeorgeMedicinesonFDAApprovalofWIDAPLIKTMhttps://www.veristat.com/hubfs/Veristat%20Appoints%20Gabriela%20Rosu%2c%20M.D.%2c%20to%20Lead%20Growing%20Medical%20Affairs%20Team.pngVeristatAppointsGabrielaRosuMDtoLeadGrowingMedicalAffairsTeamVeristatAppointsGabrielaRosuMDtoLeadGrowingMedicalAffairsTeamhttps://www.veristat.com/hubfs/Veristat%20Appoints%20Industry%20Veteran%20Kim%20McLean%20Boericke%20as%20its%20Chief%20Operating%20Officer.pngVeristatAppointsIndustryVeteranKimMcLeanBoerickeasitsChiefOperatingOfficerVeristatAppointsIndustryVeteranKimMcLeanBoerickeasitsChiefOperatingOfficerhttps://www.veristat.com/hubfs/Instat_invitation_launch_V1-01.jpgInstatinvitationlaunchV101InstatinvitationlaunchV1012026-06-17https://www.veristat.com/corporate-responsibilityhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image7.jpgpeopleworkingimage7peopleworkingimage7https://www.veristat.com/hubfs/images_sizedat600px/people_working_handshake.jpgpeopleworkinghandshakepeopleworkinghandshakehttps://www.veristat.com/hubfs/Veristat_Neurology%20Regulatory%20Submissions_HubDB%20Image.pngVeristatNeurologyRegulatorySubmissionsHubDBImageVeristatNeurologyRegulatorySubmissionsHubDBImagehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/images_sizedat600px/happy_people_image3.jpghappypeopleimage3happypeopleimage3https://www.veristat.com/hubfs/images_sizedat600px/people_working_image10.jpgpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/images_sizedat600px/call_center_image3.jpgcallcenterimage3callcenterimage3https://www.veristat.com/hubfs/Veristat_EcoVadis_medal2025.pngVeristatEcoVadismedal2025VeristatEcoVadismedal2025https://www.veristat.com/hubfs/images_sizedat600px/people_working_image15.jpgpeopleworkingimage15peopleworkingimage15https://www.veristat.com/hubfs/images_sizedat600px/asian_photo4.jpgasianphoto4asianphoto4https://www.veristat.com/hubfs/iStock-651671956-2.jpgiStock6516719562iStock6516719562https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2026-02-12https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-january-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-science-of-simultaneous-submissions-managing-multiple-regulatory-pathways2026-06-23https://www.veristat.com/careers/open-positions-testhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Web%20Page_Featured_open%20positions.pngWebPageFeaturedopenpositionsWebPageFeaturedopenpositions2024-07-03https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-september-20252026-01-05https://www.veristat.com/services/podcast-orphan-drug-designations-and-orphan-subsets2026-06-15https://www.veristat.com/library/may-oncology-voyager-facing-global-oncology-clinical-development-hurdles2024-07-03https://www.veristat.com/instat-is-now-veristat/interpreting-the-regulatory-perspective-on-adaptive-designs2026-06-23https://www.veristat.com/library/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2024-07-03https://www.veristat.com/solutions/marketing-application-operational-timeline-complexities2025-06-12https://www.veristat.com/library/veristat-expands-global-regulatory-expertise2025-04-01https://www.veristat.com/services/improving-clinical-trial-efficiency-by-achieving-on-time-patient-recruitment2026-06-15https://www.veristat.com/instat-is-now-veristat/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2026-06-23https://www.veristat.com/instat-is-now-veristat/how-does-real-world-evidence-impact-medicinal-product-development-in-europe2026-06-23https://www.veristat.com/library/common-pitfalls-in-cell-therapy-studies2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/leveraging-fda-expedited-programs-webinar-presentation2026-06-23https://www.veristat.com/services/7-habits-of-highly-successful-medical-writers2026-06-15https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-august-20242026-06-15https://www.veristat.com/services/single-arm-studies-a-strategic-path-to-oncology-drug-approval2026-06-15https://www.veristat.com/library/veristat-achieves-ecovadis-committed-badge-a-milestone-in-our-sustainability-journey2025-09-10https://www.veristat.com/services/global-policy-insights-april-20242026-06-15https://www.veristat.com/instat-is-now-veristat/dedicated-regulatory-project-management2026-06-23https://www.veristat.com/instat-is-now-veristat/webinar-achieving-balance-in-database-design2026-06-23https://www.veristat.com/therapeutic-expertise/infectious-diseasehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/images_sizedat600px/dermatology_fungal%20Image_opt600px.jpgdermatologyfungalImageopt600pxdermatologyfungalImageopt600pxhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/lab_cmc_nurseppehandstop.jpglabcmcnurseppehandstoplabcmcnurseppehandstophttps://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/images_sizedat600px/covid19_virusspike.jpgcovid19virusspikecovid19virusspikehttps://www.veristat.com/hubfs/images_sizedat600px/covid19_nurseinppe.jpgcovid19nurseinppecovid19nurseinppehttps://www.veristat.com/hubfs/HubDB_Card%20Image_CS_HIPRA%20COVID.pngHubDBCardImageCSHIPRACOVIDHubDBCardImageCSHIPRACOVIDhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Respiratory_image12.jpgtherapeuticRespiratoryimage12therapeuticRespiratoryimage12https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/Infectious%20Disease-2.pngInfectiousDisease2InfectiousDisease22026-07-10https://www.veristat.com/services/demystifying-ectd-4.0-what-you-need-to-know2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/webinar-slides-single-arm-registrational-studies-in-oncology-research2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/multi-regional-clinical-trials-key-recommendations-for-a-global-clinical-development-program2026-06-23https://www.veristat.com/library-old/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2024-06-27https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-july-20252025-08-26https://www.veristat.com/services/sfl_is_now_veristat/how-does-real-world-evidence-impact-medicinal-product-development-in-europe2026-06-23https://www.veristat.com/library/helping-a-sponsor-overcome-a-partial-clinical-hold-and-seamlessly-steer-multiple-products-through-development2024-07-03https://www.veristat.com/solutions/demystifying-ectd-4.0-what-you-need-to-know2025-07-01https://www.veristat.com/services/decentralized-solutions-for-complex-clinical-trails2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/staying-the-course-what-fda-staffing-reductions-mean-for-drug-development-today2026-06-23https://www.veristat.com/services/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis2026-06-15https://www.veristat.com/library-old/the-benefits-of-a-central-site-model2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-july-20232026-06-23https://www.veristat.com/services/sfl_is_now_veristat/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2026-06-23https://www.veristat.com/careers/open-positions-test-2https://www.veristat.com/hubfs/Web%20Page_Featured_open%20positions.pngWebPageFeaturedopenpositionsWebPageFeaturedopenpositionshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412023-03-20https://www.veristat.com/solutions/ind-planning-webinar-presentation2025-06-12https://www.veristat.com/solutions/decentralized-clinical-trials-infographic2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-november-20232026-06-23https://www.veristat.com/services/sfl_is_now_veristat/marketing-applications-data-analysis-challenges2026-06-23https://www.veristat.com/services/data-collection-efficiency-for-a-novel-anti-infective-therapy2026-06-15https://www.veristat.com/services/de-risking-the-neurology-ind-lessons-from-early-fda-engagement2026-06-15https://www.veristat.com/solutions/meeting-the-challenges-of-the-moment2025-06-12https://www.veristat.com/library/single-arm-studies-for-use-as-a-registrational-study-in-oncology-presentation2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/webinar-pres-roadmap-to-market-cell-and-gene-therapies2026-06-23https://www.veristat.com/services/rescue-patient-recruitment-for-lagging-trial2026-06-15https://www.veristat.com/services/eu-post-marketing-requirements-for-cell-and-gene-therapy-studies2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/future-trends-on-european-regulations-on-medicines2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/rescuing-site-monitoring-success2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-october-20242026-06-23https://www.veristat.com/solutions/marketing-applications-data-analysis-challenges2025-06-12https://www.veristat.com/instat-is-now-veristat/full-service-trial-delivery-fact-sheet2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/four-pillars-of-success-in-neurology-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/fda-meeting-types2026-06-23https://www.veristat.com/solutions/fda-guidance-series-on-patient-focused-drug-development-pfdd-to-enhance-product-development-and-regulatory-decision-making2025-06-12https://www.veristat.com/instat-is-now-veristat/neurology-regulatory-submissions-simplified-expertise-you-can-trust2026-06-23https://www.veristat.com/library/weighing-the-suitability-of-a-functional-service-provider-fsp-model-for-clinical-trials2024-07-03https://www.veristat.com/library/regulatory-guidance-monthly-review-march-20232024-07-03https://www.veristat.com/services/sfl_is_now_veristat/biostatisticians-ensuring-the-validity-reliability-and-interpretability-of-clinical-trial-data2026-06-23https://www.veristat.com/library/endocrine-and-metabolic-fact-sheet2024-07-03https://www.veristat.com/services/quality-assurancehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Quality%20Assurance.pngQualityAssuranceQualityAssurancehttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffee2024-07-03https://www.veristat.com/solutions/regulatory-guidance-monthly-review-january-20232025-06-12https://www.veristat.com/services/resourcingfsp-model2026-06-15https://www.veristat.com/library-old/managing-e6r2-compliance-as-it-relates-to-risk-deck2024-06-27https://www.veristat.com/services/study-collaboration-for-successful-covid-19-vaccine-program2026-06-15https://www.veristat.com/services/understanding-the-critical-role-of-data-monitoring-committees-in-clinical-trials2026-06-15https://www.veristat.com/solutions/how-does-real-world-evidence-impact-medicinal-product-development-in-europe2025-06-12https://www.veristat.com/library/nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2025-08-01https://www.veristat.com/instat-is-now-veristat/fdas-draft-guidance-for-data-monitoring-committees-dmcs2026-06-23https://www.veristat.com/instat-is-now-veristat/webinar-slides-planning-for-a-successful-initial-ind-and-moving-beyond2026-06-23https://www.veristat.com/library-old/a-patient-centric-apprach-to-recruitment-and-retention2024-06-27https://www.veristat.com/solutions/regulatory-consulting-fact-sheet2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/what-is-the-future-landscape-of-cell-gene-therapies-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/how-does-real-world-evidence-impact-medicinal-product-development-in-europe-blog2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/ind-planning-webinar-presentation2026-06-23https://www.veristat.com/services/collaborating-together-for-rare-disease2026-06-15https://www.veristat.com/library/integrated-dct-solutions-for-complex-studies2024-07-03https://www.veristat.com/services/understanding-fdas-project-optimus2026-06-15https://www.veristat.com/solutions/four-pillars-of-success-in-neurology-trials2026-02-06https://www.veristat.com/instat-is-now-veristat/multi-regional-clinical-trials-key-recommendations-for-a-global-clinical-development-program2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-article2026-06-23https://www.veristat.com/instat-is-now-veristat/conducting-clinical-trials-in-a-virtual-world2026-06-23https://www.veristat.com/services/veristat-works-well-with-growing-firms2026-06-15https://www.veristat.com/library/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-replay2024-07-03https://www.veristat.com/services/the-benefits-of-a-central-site-model2026-06-15https://www.veristat.com/library/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-presentation2024-07-03https://www.veristat.com/services/understanding-data-monitoring-committees2026-06-15https://www.veristat.com/library/successful-eu-maa-submission-enabled-by-u.s.-eu-regulatory-collaboration2026-01-16https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-january-20232026-06-23https://www.veristat.com/adaptive-designshttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Heart_Failure_image3.jpgtherapeuticHeartFailureimage3therapeuticHeartFailureimage3https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovationhttps://www.veristat.com/hubfs/images_sizedat600px/dna_molecules_yellowblue.jpgdnamoleculesyellowbluednamoleculesyellowbluehttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_cancer_image12.jpgtherapeuticcancerimage12therapeuticcancerimage12https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image9.jpgtherapeuticimage9therapeuticimage9https://www.veristat.com/hubfs/Adaptive%20Design.pngAdaptiveDesignAdaptiveDesignhttps://www.veristat.com/hubfs/images_sizedat600px/dna_molecules_blueonly.jpgdnamoleculesblueonlydnamoleculesblueonlyhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image7.jpgpeopleworkingimage7peopleworkingimage7https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-january-20262026-06-23https://www.veristat.com/solutions/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-presentation2025-06-12https://www.veristat.com/services/regulatory-affairs/regulatory-publishinghttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Blog%20-%20The%20Compound%20Effect%20of%20Specialized%20Knowledge.pngBlogTheCompoundEffectofSpecializedKnowledgeBlogTheCompoundEffectofSpecializedKnowledgehttps://www.veristat.com/hubfs/HubDB_Card%20Image_Podcast_S3E4.pngHubDBCardImagePodcastS3E4HubDBCardImagePodcastS3E4https://www.veristat.com/hubfs/Regulatory%20Publishing-2.pngRegulatoryPublishing2RegulatoryPublishing2https://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2025-06-12https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-october-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/global-policy-insights-april-20242026-06-23https://www.veristat.com/library/bold-thinking-that-delivers-results-for-rna-therapies2024-07-03https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-april-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/veristat-works-well-with-growing-firms2026-06-23https://www.veristat.com/solutions/global-policy-insights-april-20242025-06-12https://www.veristat.com/pharmacovigilance/gvp-audits-and-inspectionshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_regulatory-approval-216.pngVeristaticonregulatoryapproval216Veristaticonregulatoryapproval216https://www.veristat.com/hubfs/images_sizedat600px/GVP%20Audits%20and%20Inspections%20Page%20Featured%20Image.pngGVPAuditsandInspectionsPageFeaturedImageGVPAuditsandInspectionsPageFeaturedImagehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image10.jpgpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurology2024-07-03https://www.veristat.com/library/rescuing-site-monitoring-success2025-10-29https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-august-20242024-10-10https://www.veristat.com/library/randomized-phase-2-study-of-cbp501-cisplatin-and-nivolumab-as-3rd-line-treatment-for-exocrine-pancreatic-cancer-patients-with-white-blood-cell-count-wbc-10000mm32024-07-03https://www.veristat.com/services/sfl_is_now_veristat/on-demand-webinar-single-arm-studies-for-use-as-a-registrational-study-in-oncology2026-06-23https://www.veristat.com/library/side-by-side-comparison-non-adaptive-vs.-adaptive-designs-in-clinical-trials2025-10-23https://www.veristat.com/solutions/different-approaches-for-preparing-a-marketing-application2025-06-12https://www.veristat.com/services/webinar-roadmap-to-market-cell-and-gene-therapies2026-06-15https://www.veristat.com/library-old/turning-sponsor-cro-partnerships-into-success2024-06-27https://www.veristat.com/solutions/making-dcts-a-successful-reality-for-complex-studies2025-06-12https://www.veristat.com/library/strategic-clinical-development-consulting2024-07-03https://www.veristat.com/solutions/biostats-programming-fact-sheet2025-06-12https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-august-20252026-01-13https://www.veristat.com/library/ind-planning-webinar-presentation2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/biosimilar-fda-meeting-types2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products-blog2026-06-23https://www.veristat.com/sqn-clinical-joins-veristat/regulatory-submission-infographic2024-07-03https://www.veristat.com/library/the-human-factor-why-team-integration-makes-or-breaks-marketing-applications2025-03-25https://www.veristat.com/instat-is-now-veristat/accelerating-oncology-breakthroughs2026-06-23https://www.veristat.com/solutions/migration-of-data-between-edcs2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/decentralized-trial-solutions-for-complex-clinical-trials-slides2026-06-23https://www.veristat.com/library/accelerating-biologics-development-global-expertise-to-mitigate-risks2024-09-05https://www.veristat.com/services/sfl_is_now_veristat/accelerating-biologics-development-global-expertise-to-mitigate-risks2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-october-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/veristat-and-aobiome-to-discuss-strategic-cro-partnership-at-clinical-outsourcing-group-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/fda-guidance-on-dmcs-in-clinical-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-november-20252026-06-23https://www.veristat.com/instat-is-now-veristat/decentralized-trial-solutions-for-complex-clinical-trials-slides2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/multiple-arms-design-incorporating-efficacy-and-safety2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-june-20242025-06-12https://www.veristat.com/library-old/regulatory-consulting-fact-sheet2024-06-27https://www.veristat.com/solutions/from-strategy-to-submission-end-to-end-clinical-biometrics-and-regulatory-support-in-neurology2025-12-04https://www.veristat.com/solutions/on-demand-webinar-single-arm-studies-for-use-as-a-registrational-study-in-oncology2025-06-12https://www.veristat.com/services/medical-affairs/medical-monitoring-for-clinical-trialshttps://www.veristat.com/hubfs/Medical%20Monitoring.pngMedicalMonitoringMedicalMonitoringhttps://www.veristat.com/hubfs/review-of-successful-NDA-prep.jpgreviewofsuccessfulNDAprepreviewofsuccessfulNDAprephttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/FactSheet_Veristat.pngFactSheetVeristatFactSheetVeristathttps://www.veristat.com/hubfs/content-resource-thumbs-2020/regulatory-submission-expertise.jpgregulatorysubmissionexpertiseregulatorysubmissionexpertisehttps://www.veristat.com/hubfs/images_sizedat600px/patient-doctor_image6.jpgpatientdoctorimage6patientdoctorimage62025-06-12https://www.veristat.com/pharmacovigilance/risk-managementhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Risk%20Management_People%20Working_600x400.pngRiskManagementPeopleWorking600x400RiskManagementPeopleWorking600x400https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Rick%20Management%20Page%20Featured%20Image.pngRickManagementPageFeaturedImageRickManagementPageFeaturedImagehttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_quote-216.pngVeristaticonquote216Veristaticonquote2162024-07-03https://www.veristat.com/instat-is-now-veristat/navigating-the-ind-submission-labyrinth-a-veristat-success-story2026-06-23https://www.veristat.com/instat-is-now-veristat/guiding-an-emerging-biotechs-first-phase-i-oncology-trial2026-06-23https://www.veristat.com/decentralizedclinicaltrialshttps://info.veristat.com/hubfs/DCT%20Solutions%20at%20Veristat_Video.mp4/medium.jpgDCTSolutionsatVeristatVideoDCTSolutionsatVeristatVideohttps://www.veristat.com/hubfs/DCT%20Solutions%20at%20Veristat_Video.mp4110nonohttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/images_sizedat600px/DCT%20Solutions%20PinWheel.pngDCTSolutionsPinWheelDCTSolutionsPinWheelhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_quote.pngVeristaticonquoteVeristaticonquotehttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB_Card%20Image_Podcast_Big4Bio%20DCT.pngHubDBCardImagePodcastBig4BioDCTHubDBCardImagePodcastBig4BioDCThttps://www.veristat.com/hubfs/images_sizedat600px/virtualtrials_homevisit1.jpgvirtualtrialshomevisit1virtualtrialshomevisit1https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/DCT-2.pngDCT2DCT22026-07-10https://www.veristat.com/instat-is-now-veristat/an-introduction-to-natural-history-studies2026-06-23https://www.veristat.com/solutions/ensuring-regulatory-success-from-pre-ind-through-to-submission2025-06-12https://www.veristat.com/solutions/stem-cell-therapy-for-stroke-patients2025-06-12https://www.veristat.com/solutions/elevating-cns-drug-development-veristats-agile-approach-in-medical-writing-and-project-management2025-06-12https://www.veristat.com/gillian_birnie_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-07-27https://www.veristat.com/resources/brochures-and-service-sheetshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-12-21https://www.veristat.com/library-old/complex-trial-for-a-rare-pediatric-gene-therapy2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/neurology-psychiatry-fact-sheet2026-06-23https://www.veristat.com/library/presentation-how-to-better-plan-a-virtual-clinical-trial2024-07-03https://www.veristat.com/services/unlocking-potential-taking-a-statistics-driven-approach-to-clinical-trial-planning2026-06-15https://www.veristat.com/library/medical-writing-partnership-indtonda2024-07-03https://www.veristat.com/services/oncology-webinar-video-replay2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/improving-clinical-trial-efficiency-by-achieving-on-time-patient-recruitment2026-06-23https://www.veristat.com/library-old/stem-cell-therapy-for-stroke-patients2024-06-27https://www.veristat.com/instat-is-now-veristat/selecting-endpoints-for-an-early-phase-cell-or-gene-study2026-06-23https://www.veristat.com/solutions/should-an-oncology-study-expand-into-europe2025-10-22https://www.veristat.com/solutions/unlocking-insights-the-impact-of-new-medical-device-eu-regulation-mdr2025-06-12https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/writing-multiple-marketing-applications-at-the-same-time2024-07-03https://www.veristat.com/library-old/achieving-an-aggressive-nda-timeline2024-06-27https://www.veristat.com/solutions/planning-your-ind-when-and-why-to-engage-the-fda2025-06-19https://www.veristat.com/services/sfl_is_now_veristat/agile-medical-writing-support-for-an-nda2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/executing-patient-focused-drug-development-pfdd2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-january-20252026-06-15https://www.veristat.com/library/planning-the-way-forward-in-neurodegenerative-disease-studies2024-07-03https://www.veristat.com/eventshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2023-10-04https://www.veristat.com/solutions/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/regulatory-submission-fact-sheet2026-06-23https://www.veristat.com/services/unleashing-flexibility-in-a-rare-disease-gene-therapy-clinical-trial2026-06-15https://www.veristat.com/services/leveraging-fda-expedited-programs-webinar-replay2026-06-15https://www.veristat.com/library-old/pharmacovigilance-fact-sheet2024-06-27https://www.veristat.com/instat-is-now-veristat/laying-the-groundwork-to-measure-the-impact-of-decentralized-clinical-trials-dcts2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-february-20252025-06-12https://www.veristat.com/meetveristat-li2023https://www.veristat.com/hubfs/Veristat_HubDB_Single%20Arm%20Study.pngVeristatHubDBSingleArmStudyVeristatHubDBSingleArmStudyhttps://www.veristat.com/hubfs/Webinar_Accelerating%20Patient%20Centric%20Clinical%20Trials%20420X229px.pngWebinarAcceleratingPatientCentricClinicalTrials420X229pxWebinarAcceleratingPatientCentricClinicalTrials420X229pxhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-11-20https://www.veristat.com/services/sfl_is_now_veristat/european-medicines-and-medical-devices-future-trends2026-06-23https://www.veristat.com/library/neurology-regulatory-submissions-simplified-expertise-you-can-trust2025-10-23https://www.veristat.com/services/future-glances-more-change-more-tech-more-harmonisation2026-06-15https://www.veristat.com/solutions/podcast-orphan-drug-designations-and-orphan-subsets2025-06-12https://www.veristat.com/clinical-trial-conducthttps://www.veristat.com/hubfs/review-of-successful-NDA-prep.jpgreviewofsuccessfulNDAprepreviewofsuccessfulNDAprephttps://www.veristat.com/hubfs/content-resource-thumbs-2020/regulatory-submission-expertise.jpgregulatorysubmissionexpertiseregulatorysubmissionexpertisehttps://www.veristat.com/hubfs/Clinical%20Trial%20Conduct.pngClinicalTrialConductClinicalTrialConducthttps://www.veristat.com/hubfs/FactSheet_Veristat.pngFactSheetVeristatFactSheetVeristathttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-07-10https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-december-20242026-06-23https://www.veristat.com/library/an-introduction-to-natural-history-studies2024-07-03https://www.veristat.com/library/the-benefits-of-a-central-site-model2024-07-03https://www.veristat.com/library-old/accelerating-clinical-trial-design-and-operations2024-06-27https://www.veristat.com/library-old/virtual-hybrid-clinical-trials2024-06-27https://www.veristat.com/sqn-clinical-joins-veristat/achieving-an-aggressive-nda-timeline2024-07-03https://www.veristat.com/solutions/the-importance-of-regulatory-project-management2025-06-12https://www.veristat.com/library-old/opportunities-for-virtual-and-central-site-models-in-cell-and-gene-therapy-trials2024-06-27https://www.veristat.com/solutions/keeping-up-with-an-over-performing-site-case-study2026-02-04https://www.veristat.com/services/pursuing-breakthrough-therapies-for-rare-metabolic-diseases2026-06-15https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/veristat-fact-sheet2024-07-03https://www.veristat.com/library/podcast-orphan-drug-designations-and-orphan-subsets2024-07-03https://www.veristat.com/solutions/biosimilar-fda-meeting-types2025-06-12https://www.veristat.com/services/virtual-hybrid-clinical-trials2026-06-15https://www.veristat.com/library/new-tumor-evaluation-modality2024-07-03https://www.veristat.com/solutions/neurology-psychiatry-fact-sheet2025-06-12https://www.veristat.com/instat-is-now-veristat/the-power-of-strategic-partnerships-how-veristat-and-ao-biome-redefined-cro-sponsor-collaboration2026-06-23https://www.veristat.com/services/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/a-patient-centric-apprach-to-recruitment-and-retention2026-06-23https://www.veristat.com/library-old/marketing-application-medical-writing-strategies2024-06-27https://www.veristat.com/services/the-rapid-pace-of-regulatory-change2026-06-15https://www.veristat.com/solutions/ind-planning-webinar-video-replay2025-06-12https://www.veristat.com/solutions/how-vaccine-clinical-trials-work2025-06-12https://www.veristat.com/library/from-strategy-to-submission-end-to-end-clinical-biometrics-and-regulatory-support-in-neurology2025-12-04https://www.veristat.com/library/multiple-arms-design-incorporating-efficacy-and-safety2024-07-03https://www.veristat.com/services/overcoming-challenges-in-orphan-drug-development2026-06-15https://www.veristat.com/services/accelerating-biologics-development-global-expertise-to-mitigate-risks2026-06-15https://www.veristat.com/library/marketing-applications-approval-record2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/turning-sponsor-cro-partnerships-into-success2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/marketing-applications-approval-record2026-06-23https://www.veristat.com/library/preparing-data-for-maa-marketing-authorization-appliation2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-operational-timeline-complexities2026-06-23https://www.veristat.com/library/early-detection-vs.-overdiagnosis-the-ctdna-screening-paradox2026-01-05https://www.veristat.com/library/complex-trial-for-a-rare-pediatric-gene-therapy2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/regulatory-submission-infographic2026-06-23https://www.veristat.com/library/replay-expanding-your-clinical-trial-into-the-us2024-07-03https://www.veristat.com/library/a-wearable-moment2025-09-24https://www.veristat.com/services/sfl_is_now_veristat/accelerating-patient-centric-clinical-trials-through-science-based-planning-delivery-and-support2026-06-23https://www.veristat.com/library/cancer-research-trends-key-asco-2024-takeaways2025-01-23https://www.veristat.com/library/pursuing-breakthrough-therapies-for-rare-metabolic-diseases-veristats-role-in-a-landmark-clinical-study2024-07-03https://www.veristat.com/services/minimizing-complexity-in-oncology-clinical-trials2026-06-15https://www.veristat.com/services/regulatory-affairs/medical-writinghttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat%20HubDB%20Card%20Image_Successful%20IND%20Submission.pngVeristatHubDBCardImageSuccessfulINDSubmissionVeristatHubDBCardImageSuccessfulINDSubmissionhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Medical%20Writing.pngMedicalWritingMedicalWriting2026-07-09https://www.veristat.com/solutions/exploring-future-trends-on-european-regulations-a-webinar-by-veristat-and-topra2025-06-12https://www.veristat.com/contact-ushttps://www.veristat.com/hubfs/people_working_image10.jpegpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-10-30https://www.veristat.com/instat-is-now-veristat/bold-thinking-that-delivers-results-for-rna-therapies2026-06-23https://www.veristat.com/solutions/the-power-of-strategic-partnerships-how-veristat-and-ao-biome-redefined-cro-sponsor-collaboration2025-12-16https://www.veristat.com/services/reflections-from-asco-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/supporting-a-sponsor-from-spa-rejection-to-bla-submission2026-06-23https://www.veristat.com/solutions/cmc-pitfalls-from-benchtop-to-ind2025-06-12https://www.veristat.com/webinarshttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_advanced%20cell%20&%20gene%20therapies.pngVeristaticonadvancedcellgenetherapiesVeristaticonadvancedcellgenetherapieshttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_database.pngVeristaticondatabaseVeristaticondatabasehttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_oncology.pngVeristaticononcologyVeristaticononcologyhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_team.pngVeristaticonteamVeristaticonteamhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_north%20america.pngVeristaticonnorthamericaVeristaticonnorthamericahttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_enrollment.pngVeristaticonenrollmentVeristaticonenrollmenthttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_strategic-consulting-216.pngVeristaticonstrategicconsulting216Veristaticonstrategicconsulting216https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_implementation.pngVeristaticonimplementationVeristaticonimplementationhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_regulatory%20affairs.pngVeristaticonregulatoryaffairsVeristaticonregulatoryaffairshttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_telemedicine-216.pngVeristaticontelemedicine216Veristaticontelemedicine216https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_devices.pngVeristaticondevicesVeristaticondeviceshttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_protocol.pngVeristaticonprotocolVeristaticonprotocolhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_medical%20writing.pngVeristaticonmedicalwritingVeristaticonmedicalwritinghttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study-recording2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-publishing2026-06-23https://www.veristat.com/services/fda-guidance-series-on-patient-focused-drug-development-pfdd-to-enhance-product-development-and-regulatory-decision-making2026-06-15https://www.veristat.com/services/regulatory-affairs-expertshttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_image1.jpgpeopleworkingimage1peopleworkingimage1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image6.jpgpeopleworkingimage6peopleworkingimage6https://www.veristat.com/hubfs/images_sizedat600px/people_working_image12.jpgpeopleworkingimage12peopleworkingimage122024-11-20https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-july-20242026-06-23https://www.veristat.com/services/sfl_is_now_veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/clinical-trials-meet-adaptive-design2026-06-23https://www.veristat.com/services/the-science-of-simultaneous-submissions-managing-multiple-regulatory-pathways2026-06-15https://www.veristat.com/solutions/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2025-06-12https://www.veristat.com/library/navigating-clinical-trials-with-precision-enhancing-dmc-services-through-veristats-expert-biostatistics2025-10-22https://www.veristat.com/instat-is-now-veristat/what-is-the-future-landscape-of-cell-gene-therapies-replay2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-june-20252026-06-23https://www.veristat.com/services/2026-cell-and-gene-therapy-predictions2026-06-15https://www.veristat.com/sqn-clinical-joins-veristat/writing-multiple-marketing-applications-at-the-same-time2024-07-03https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/regulatory-submission-infographic2024-07-03https://www.veristat.com/instat-is-now-veristat/randomized-phase-2-study-of-cbp501-cisplatin-and-nivolumab-as-3rd-line-treatment-for-exocrine-pancreatic-cancer-patients-with-white-blood-cell-count-wbc-10000mm32026-06-23https://www.veristat.com/services/staying-the-course-what-fda-staffing-reductions-mean-for-drug-development-today2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/unlocking-potential-taking-a-statistics-driven-approach-to-clinical-trial-planning2026-06-23https://www.veristat.com/instat-is-now-veristat/eu-pharma-package-key-takeaways-for-clinical-evidence-jca-strategy2026-06-23https://www.veristat.com/services/regulatory-considerations-for-biosimilars-development-in-the-us-blog2026-06-15https://www.veristat.com/solutions/integrated-dct-solutions-for-complex-studies2025-06-12https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-june-20242024-07-17https://www.veristat.com/library-old/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/webinar-gene-therapy-complex-clinical-development-pathways2026-06-23https://www.veristat.com/instat-is-now-veristat/emergency-use-authorizations2026-06-23https://www.veristat.com/services/biometrics/statistical-programminghttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/images_sizedat600px/data_image_personscreens_original.jpgdataimagepersonscreensoriginaldataimagepersonscreensoriginalhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/data%20image_programming_600px_web-1.webpdataimageprogramming600pxweb1dataimageprogramming600pxweb1https://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovationhttps://www.veristat.com/hubfs/Statistical%20Programming.pngStatisticalProgrammingStatisticalProgramminghttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurology2026-07-10https://www.veristat.com/library/staying-the-course-what-fda-staffing-reductions-mean-for-drug-development-today2025-05-13https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-april-20252026-06-23https://www.veristat.com/library/driving-multiple-global-gene-therapy-studies2025-01-22https://www.veristat.com/library-old/multiple-arms-design-incorporating-efficacy-and-safety2024-06-27https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-december-20232026-06-23https://www.veristat.com/library/replay-how-to-better-plan-a-virtual-clinical-trial2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/is-your-trial-stuck2026-06-23https://www.veristat.com/solutions/biomarker-driven-adaptive-design-for-precision-medicine2025-06-12https://www.veristat.com/library/decentralized-trial-solutions-for-complex-clinical-trials-slides2024-07-03https://www.veristat.com/solutions/clinical-trials-meet-adaptive-design2025-10-22https://www.veristat.com/library/european-medicines-and-medical-devices-future-trends2024-07-03https://www.veristat.com/homepage-1https://info.veristat.com/hubfs/video-files/Veristat_2023_CorpVideo_RealBottomLine_Patrick.mp4/medium.jpgVeristat2023CorpVideoRealBottomLinePatrickVeristat2023CorpVideoRealBottomLinePatrickhttps://www.veristat.com/hubfs/video-files/Veristat_2023_CorpVideo_RealBottomLine_Patrick.mp457nonohttps://www.veristat.com/hubfs/image-png-2.pngimagepng2imagepng2https://www.veristat.com/hubfs/image-png-4.pngimagepng4imagepng4https://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH-2.pngSuccessStoriesPhaseIIIafterNH2SuccessStoriesPhaseIIIafterNH2https://www.veristat.com/hubfs/Veristat_icon_oncology-216.pngVeristaticononcology216Veristaticononcology216https://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH.pngSuccessStoriesPhaseIIIafterNHSuccessStoriesPhaseIIIafterNHhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_CaseStudy_HomePage_Marketing.pngVeristatCaseStudyHomePageMarketingVeristatCaseStudyHomePageMarketinghttps://www.veristat.com/hubfs/veristat-phases-november-v2.svgveristatphasesnovemberv2veristatphasesnovemberv2https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_molecular%20entities-216.pngVeristaticonmolecularentities216Veristaticonmolecularentities216https://www.veristat.com/hubfs/Veristat_icon_diverse%20backgrounds-1.pngVeristaticondiversebackgrounds1Veristaticondiversebackgrounds1https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_telemedicine-216.pngVeristaticontelemedicine216Veristaticontelemedicine216https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_strategic-consulting-216.pngVeristaticonstrategicconsulting216Veristaticonstrategicconsulting216https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_rare-disease-216.pngVeristaticonraredisease216Veristaticonraredisease216https://www.veristat.com/hubfs/homepage/homepage-2024/specialty-expertise-bkgd-2024.jpgspecialtyexpertisebkgd2024specialtyexpertisebkgd2024https://www.veristat.com/hubfs/images_sizedat600px/people_working_image10.jpgpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/Home_ARMPR_Apr2024.pngHomeARMPRApr2024HomeARMPRApr2024https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_regulatory-affairs-216.pngVeristaticonregulatoryaffairs216Veristaticonregulatoryaffairs216https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_enrollment.pngVeristaticonenrollmentVeristaticonenrollmenthttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_biologic.pngVeristaticonbiologicVeristaticonbiologichttps://www.veristat.com/hubfs/Voyager_RareDisease_Feb2024.pngVoyagerRareDiseaseFeb2024VoyagerRareDiseaseFeb2024https://www.veristat.com/hubfs/image-png-3.pngimagepng3imagepng3https://www.veristat.com/hubfs/homepage/homepage-2024/blue-lights-bkgd-w-diamonds-2024.jpgbluelightsbkgdwdiamonds2024bluelightsbkgdwdiamonds20242026-06-23https://www.veristat.com/instat-is-now-veristat/full-service-support-for-a-gene-therapy-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/ash-2025-interpreting-rapid-change-across-hematology2026-06-23https://www.veristat.com/library-old/hematology-fact-sheet2024-06-27https://www.veristat.com/library/improving-clinical-trial-efficiency-by-achieving-patient-recruitment-on-time2024-11-21https://www.veristat.com/services/sfl_is_now_veristat/how-to-ensure-successful-fda-meeting-video-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/decentralized-solutions-for-complex-clinical-trails2026-06-23https://www.veristat.com/instat-is-now-veristat/autologous-vs-allogeneic-cell-and-gene-therapies2026-06-23https://www.veristat.com/services/overcoming-nda-refusal-to-file2026-06-15https://www.veristat.com/instat-is-now-veristat/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development-blog2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2026-06-23https://www.veristat.com/library/interpreting-the-regulatory-perspective-on-adaptive-designs2024-07-03https://www.veristat.com/instat-is-now-veristat/accelerating-patient-centric-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/complex-trial-for-a-rare-pediatric-gene-therapy2026-06-23https://www.veristat.com/solutions/why-you-need-a-cro-that-excels-in-oncology-regulatory-publishing2026-02-06https://www.veristat.com/bloghttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/May%20FDA%20Guidance.pngMayFDAGuidanceMayFDAGuidancehttps://www.veristat.com/hubfs/Blog%20Clear%20Inclusive%20Human.jpgBlogClearInclusiveHumanBlogClearInclusiveHumanhttps://www.veristat.com/hubfs/ASCO%202026_%20Next-Generation%20Immunotherapies.jpgASCO2026NextGenerationImmunotherapiesASCO2026NextGenerationImmunotherapieshttps://www.veristat.com/hubfs/Cover_Why%20Medical%20Regulatory%20Writing.jpgCoverWhyMedicalRegulatoryWritingCoverWhyMedicalRegulatoryWritinghttps://www.veristat.com/hubfs/ASCO%202026_%20ADCs%20Are%20Redefining%20What%20Targeted%20Therapy%20Can%20Do%20By%20Gabriela%20Rosu.jpgASCO2026ADCsAreRedefiningWhatTargetedTherapyCanDoByGabrielaRosuASCO2026ADCsAreRedefiningWhatTargetedTherapyCanDoByGabrielaRosuhttps://www.veristat.com/hubfs/FDA%20Prior%20Knowledge%20Guidance_%20A%20New%20Framework%20for%20Natural%20History%20Evidence.jpgFDAPriorKnowledgeGuidanceANewFrameworkforNaturalHistoryEvidenceFDAPriorKnowledgeGuidanceANewFrameworkforNaturalHistoryEvidencehttps://www.veristat.com/hubfs/blog.jpgblogbloghttps://www.veristat.com/hubfs/June%20FDA%20Guidance.pngJuneFDAGuidanceJuneFDAGuidancehttps://www.veristat.com/hubfs/ras%20is%20no%20longer%20blog.jpgrasisnolongerblograsisnolongerblog2023-01-07https://www.veristat.com/library/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2024-07-03https://www.veristat.com/library/fdas-project-frontrunner-explained2025-05-20https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-january-20262026-02-19https://www.veristat.com/services/sfl_is_now_veristat/oncology-webinar-video-replay2026-06-23https://www.veristat.com/library/webinar-pres-roadmap-to-market-cell-and-gene-therapies2024-07-03https://www.veristat.com/solutions/the-compound-effect-of-specialized-knowledge2026-02-26https://www.veristat.com/solutions/side-by-side-comparison-non-adaptive-vs.-adaptive-designs-in-clinical-trials2025-10-23https://www.veristat.com/services/sfl_is_now_veristat/overcoming-challenges-in-orphan-drug-development2026-06-23https://www.veristat.com/library/align-new-oncology-drug-development-with-fdas-project-frontrunner2024-07-03https://www.veristat.com/instat-is-now-veristat/shortening-development-and-approval-timelines-for-novel-medicinal-products2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/veristat-fact-sheet2026-06-23https://www.veristat.com/library/biostatisticians-crucial-choreographers-behind-oncology-breakthroughs2025-10-08https://www.veristat.com/library/indication-selection-using-adaptive-design2025-06-25https://www.veristat.com/services/sfl_is_now_veristat/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2026-06-23https://www.veristat.com/library/strengthening-opportunities-for-growth-in-the-european-region2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/ensuring-patient-safety-and-data-integrity-with-veristats-dmc-expertise2026-06-23https://www.veristat.com/instat-is-now-veristat/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development2026-06-23https://www.veristat.com/solutions/webinar-gene-therapy-complex-clinical-development-pathways2025-06-12https://www.veristat.com/library/biostatisticians-ensuring-the-validity-reliability-and-interpretability-of-clinical-trial-data2025-01-22https://www.veristat.com/services/sfl_is_now_veristat/recist-oncology-guidelines2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/emergency-use-authorizations-blog2026-06-23https://www.veristat.com/library/supporting-a-sponsor-from-spa-rejection-to-bla-submission2024-07-03https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/adaptive-design-fact-sheet2024-07-03https://www.veristat.com/instat-is-now-veristat/why-regulatory-publishing-expertise-is-essential-for-neurology-clinical-trials2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-march-20252026-06-15https://www.veristat.com/instat-is-now-veristat/from-clinical-strategy-to-patient-impact-5-lessons-from-cindy-henderson2026-06-23https://www.veristat.com/library-old/what-is-the-future-cell-gene-presentation2024-06-27https://www.veristat.com/solutions/safety-tolerability-and-pharmacokinetics-of-a-single-orally-inhaled-dose-of-pur3100-a-dry-powder-formulation-of-dihydroergotamine-versus-intravenous-dihydroergotamine-a-phase-1-randomized-double-blind-study-in-healthy-adults2025-06-12https://www.veristat.com/services/database-design-considerations-ig2026-06-15https://www.veristat.com/solutions/common-pitfalls-in-gene-therapy-studies2025-06-12https://www.veristat.com/library/single-arm-studies-a-strategic-path-to-oncology-drug-approval2026-01-13https://www.veristat.com/services/sfl_is_now_veristat/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2026-06-23https://www.veristat.com/services/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2026-06-15https://www.veristat.com/library-old/a-patient-centric-apprach-to-recruitment-and-retention22024-06-27https://www.veristat.com/instat-is-now-veristat/future-trends-on-european-regulations-on-medicines-replay2026-06-23https://www.veristat.com/library/the-power-of-publishing-for-an-efficient-nda-submission-process2024-07-03https://www.veristat.com/instat-is-now-veristat/the-power-of-publishing-for-an-efficient-nda-submission-process2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/timeline-mastery-the-strategic-backbone-of-marketing-application-success2026-06-23https://www.veristat.com/library-old/oncology-webinar-video-replay2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/veristat-global-policy-insights-q22026-06-23https://www.veristat.com/instat-is-now-veristat/veristat-and-aobiome-to-discuss-strategic-cro-partnership-at-clinical-outsourcing-group-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-september-20242026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-october-20252026-01-05https://www.veristat.com/instat-is-now-veristat/the-compound-effect-of-specialized-knowledge2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/veristat-global-policy-insights-q1-20242026-06-23https://www.veristat.com/services/clinical-trials-meet-adaptive-design2026-06-15https://www.veristat.com/services/essential-considerations-foradaptive-design-in-clinical-trials2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/strengthening-opportunities-for-growth-in-the-european-region2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/long-term-follow-up-studies-in-gene-therapy2026-06-23https://www.veristat.com/instat-is-now-veristat/data-management-fact-sheet2026-06-23https://www.veristat.com/library/protocol-specific-feasibility2026-06-09https://www.veristat.com/library/understanding-the-critical-role-of-data-monitoring-committees-in-clinical-trials2024-10-10https://www.veristat.com/solutions/nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2025-08-01https://www.veristat.com/instat-is-now-veristat/inside-2026-the-industrys-ai-turning-point2026-06-23https://www.veristat.com/services/sfl_is_now_veristathttps://www.veristat.com/hubfs/images_sizedat600px/puzzlepiece_supplychain_600pxwide.jpgpuzzlepiecesupplychain600pxwidepuzzlepiecesupplychain600pxwidehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/puzzlepieces_regulatoryaffairs_600px.jpgpuzzlepiecesregulatoryaffairs600pxpuzzlepiecesregulatoryaffairs600pxhttps://www.veristat.com/hubfs/puzzlepieces_healthcarecompliance_600px.jpgpuzzlepieceshealthcarecompliance600pxpuzzlepieceshealthcarecompliance600pxhttps://www.veristat.com/hubfs/puzzlepieces_marketaccess_600px.jpgpuzzlepiecesmarketaccess600pxpuzzlepiecesmarketaccess600pxhttps://www.veristat.com/hubfs/puzzlepieces_pharmacovigilance_600px.jpgpuzzlepiecespharmacovigilance600pxpuzzlepiecespharmacovigilance600pxhttps://www.veristat.com/hubfs/puzzplepieces_qualityandcompliance_600px.jpgpuzzplepiecesqualityandcompliance600pxpuzzplepiecesqualityandcompliance600pxhttps://www.veristat.com/hubfs/SFL-Veristat_Logo-Lockup_RGB.pngSFLVeristatLogoLockupRGBSFLVeristatLogoLockupRGBhttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/SFL%20is%20Now%20Veristat%20-%20LP.pngSFLisNowVeristatLPSFLisNowVeristatLP2026-06-23https://www.veristat.com/instat-is-now-veristat/long-term-follow-up-studies-in-gene-therapy2026-06-23https://www.veristat.com/instat-is-now-veristat/replay-how-to-better-plan-a-virtual-clinical-trial2026-06-23https://www.veristat.com/solutions/pooled-analysis-of-the-phase-3-revive-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/new-tumor-evaluation-modality2026-06-23https://www.veristat.com/resources/case-studieshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-07-27https://www.veristat.com/library/recist-oncology-guidelines2024-07-03https://www.veristat.com/services/clinical-development-support-for-multiple-alzheimers-and-parkinsons-studies2026-06-15https://www.veristat.com/library/first-gene-therapy-approved-in-europe2024-07-03https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-december-20252026-01-29https://www.veristat.com/services/early-data-strategy-building-todays-trial-for-tomorrows-scalable-success2026-06-15https://www.veristat.com/instat-is-now-veristat/advancing-oncology-innovation2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/covid-19-success-guide2026-06-23https://www.veristat.com/services/indication-selection-using-adaptive-design2026-06-15https://www.veristat.com/library/advancing-dose-escalation-strategies-with-bayesian-modeling2026-01-13https://www.veristat.com/services/sfl_is_now_veristat/unlocking-the-promise-of-radiopharmaceuticals-safety-strategy-innovation-in-clinical-trials2026-06-23https://www.veristat.com/services/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2026-06-15https://www.veristat.com/instat-is-now-veristat/navigating-clinical-trials-with-precision-enhancing-dmc-services-through-veristats-expert-biostatistics2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/biostats-programming-fact-sheet2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/safety-tolerability-and-pharmacokinetics-of-a-single-orally-inhaled-dose-of-pur3100-a-dry-powder-formulation-of-dihydroergotamine-versus-intravenous-dihydroergotamine-a-phase-1-randomized-double-blind-study-in-healthy-adults2026-06-23https://www.veristat.com/solutions/global-pediatric-full-service-phase-iii-clinical-trial-begins-on-heels-of-successful-natural-history-study2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/a-comprehensive-planning-approach-for-cancer-antibody2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/updated-future-trends-on-european-regulations-on-medicines2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-publishing2026-06-23https://www.veristat.com/solutions/navigating-clinical-trials-with-precision-enhancing-dmc-services-through-veristats-expert-biostatistics2025-10-22https://www.veristat.com/instat-is-now-veristat/regulatory-submission-infographic2026-06-23https://www.veristat.com/instat-is-now-veristat/the-importance-of-regulatory-project-management2026-06-23https://www.veristat.com/resources/infographicshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-10-25https://www.veristat.com/services/new-tumor-evaluation-modality2026-06-15https://www.veristat.com/instat-is-now-veristat/understanding-and-operationalizing-a-complex-adaptive-design2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/orphan-drug-designations-and-orphan-subsets2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-rise-of-decentralized-clinical-trials-transforming-research-through-technology-and-patient-centricity2026-06-23https://www.veristat.com/services/leveraging-fda-expedited-programs-webinar-presentation2026-06-15https://www.veristat.com/instat-is-now-veristat/improving-clinical-trial-efficiency-by-achieving-patient-recruitment-on-time2026-06-23https://www.veristat.com/instat-is-now-veristat/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products-blog2026-06-23https://www.veristat.com/solutions/fda-expedited-programs-what-you-need-to-know2025-11-07https://www.veristat.com/services/sfl_is_now_veristat/what-is-the-future-cell-gene-presentation2026-06-23https://www.veristat.com/services/preserving-what-matters-how-institutional-knowledge-protects-value-through-ma2026-06-15https://www.veristat.com/services/fda-introduces-new-term-nonclinical-tests-signaling-a-beginning-not-an-end2026-06-15https://www.veristat.com/library/early-data-strategy-building-todays-trial-for-tomorrows-scalable-success2026-01-28https://www.veristat.com/library/a-practical-guide-for-managing-multiple-global-regulatory-pathways2026-01-16https://www.veristat.com/solutions/inside-2026-the-industrys-ai-turning-point2026-01-09https://www.veristat.com/library-old/the-rapid-pace-of-regulatory-change2024-06-27https://www.veristat.com/instat-is-now-veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-presentation2026-06-23https://www.veristat.com/library/ensuring-patient-safety-and-data-integrity-with-veristats-dmc-expertise2025-06-03https://www.veristat.com/services/full-service-solutionshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Kim%20Boericke%20Named%20CEO_1132025.pngKimBoerickeNamedCEO1132025KimBoerickeNamedCEO1132025https://www.veristat.com/hubfs/layout/page-images/full_service%20solutions_across_development_lifecycle_webgraphic.jpgfullservicesolutionsacrossdevelopmentlifecyclewebgraphicfullservicesolutionsacrossdevelopmentlifecyclewebgraphichttps://www.veristat.com/hubfs/Full-Service-2.pngFullService2FullService22026-07-09https://www.veristat.com/instat-is-now-veristat/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis2026-06-23https://www.veristat.com/solutions/first-gene-therapy-approved-in-europe2025-06-12https://www.veristat.com/instat-is-now-veristat/veristat-names-industry-veteran-kim-mclean-boericke-as-new-chief-executive-officer2026-06-23https://www.veristat.com/services/veristat-achieves-ecovadis-committed-badge-a-milestone-in-our-sustainability-journey2026-06-15https://www.veristat.com/services/advancing-your-biologic-requires-bold-scientific-strategies2026-06-15https://www.veristat.com/library/marketing-applications-data-analysis-challenges2024-07-03https://www.veristat.com/library-old/programmed-narratives-working-smarter-not-harder2024-06-27https://www.veristat.com/instat-is-now-veristat/veristat-global-policy-insights-q22026-06-23https://www.veristat.com/solutions/comprehensive-strategic-clinical-development-consulting2025-06-12https://www.veristat.com/solutions/regulatory-guidance-monthly-review-january-20242025-06-12https://www.veristat.com/library/vaccines-fact-sheet2024-07-03https://www.veristat.com/services/marketing-application-fact-sheet2026-06-15https://www.veristat.com/instat-is-now-veristat/fda-delays-push-biotech-companies-to-rethink-u.s.-drug-development-strategy2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-september-20252026-06-23https://www.veristat.com/services/regulatory-guidance-monthly-review-january-20242026-06-15https://www.veristat.com/library/understanding-fdas-project-optimus2024-07-03https://www.veristat.com/instat-is-now-veristat/presentation-expanding-your-clinical-trial-into-the-us2026-06-23https://www.veristat.com/services/accelerating-clinical-trial-design-and-operations2026-06-15https://www.veristat.com/library-old/conducting-clinical-trials-in-a-virtual-world2024-06-27https://www.veristat.com/solutions/align-new-oncology-drug-development-with-fdas-project-frontrunner2025-06-12https://www.veristat.com/solutions/ash-2025-interpreting-rapid-change-across-hematology2026-01-06https://www.veristat.com/instat-is-now-veristat/comprehensive-planning-for-a-first-in-human-cancer-antibody-trial2026-06-23https://www.veristat.com/services/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2026-06-15https://www.veristat.com/instat-is-now-veristat/collaborating-together-for-rare-disease2026-06-23https://www.veristat.com/library/medical-writing-fact-sheet2024-07-03https://www.veristat.com/services/rare-disease-development-navigating-small-populations-and-complex-protocols2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/the-human-factor-why-team-integration-makes-or-breaks-marketing-applications2026-06-23https://www.veristat.com/services/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-presentation2026-06-15https://www.veristat.com/solutions/wholistic-approach-to-strategic-consulting2025-06-12https://www.veristat.com/library/data-collection-efficiency-for-a-novel-anti-infective-therapy2024-07-03https://www.veristat.com/services/writing-multiple-marketing-applications-at-the-same-time2026-06-15https://www.veristat.com/solutions/accelerating-patient-centric-clinical-trials-three-key-takeaways-for-smarter-design-and-execution2026-01-13https://www.veristat.com/services/sfl_is_now_veristat/full-service-trial-delivery-fact-sheet2026-06-23https://www.veristat.com/solutions/successful-eu-maa-submission-enabled-by-u.s.-eu-regulatory-collaboration2026-01-16https://www.veristat.com/services/trends-in-oncology-regulation-fda-draft-guidance-on-os-and-radiopharmaceuticals2026-06-15https://www.veristat.com/library-old/writing-multiple-marketing-applications-at-the-same-time2024-06-27https://www.veristat.com/library/purpose-of-ind-ig2024-07-03https://www.veristat.com/services/should-an-oncology-study-expand-into-europe2026-06-15https://www.veristat.com/library/rescue-patient-recruitment-for-lagging-trial2024-07-03https://www.veristat.com/services/a-playbook-for-effective-sponsorcro-partnership2026-06-15https://www.veristat.com/solutions/veristat-names-industry-veteran-kim-mclean-boericke-as-new-chief-executive-officer2026-01-15https://www.veristat.com/services/sfl_is_now_veristat/preparing-data-for-maa-marketing-authorization-appliation2026-06-23https://www.veristat.com/instat-is-now-veristat/post-submission-ind-maintenance-veristat-as-u.s.-agent2026-06-23https://www.veristat.com/instat-is-now-veristat/improving-clinical-trial-efficiency-by-achieving-on-time-patient-recruitment2026-06-23https://www.veristat.com/instat-is-now-veristat/early-detection-vs.-overdiagnosis-the-ctdna-screening-paradox2026-06-23https://www.veristat.com/library-old/webinar-gene-therapy-complex-clinical-development-pathways2024-06-27https://www.veristat.com/library/marketing-application-best-practices-for-publishing2024-07-03https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-february-20252026-06-15https://www.veristat.com/instat-is-now-veristat/presentation-how-to-better-plan-a-virtual-clinical-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/natural-history-study-best-practices-for-engaging-regulatory-authorities2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-january-20252026-06-23https://www.veristat.com/solutions/targeted-indication-selection-using-simon-2-stage-design2026-01-06https://www.veristat.com/services/sfl_is_now_veristat/helping-a-sponsor-overcome-a-partial-clinical-hold-and-seamlessly-steer-multiple-products-through-development2026-06-23https://www.veristat.com/solutions/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study-recording2025-06-12https://www.veristat.com/services/webinar-achieving-balance-in-database-design2026-06-15https://www.veristat.com/library-old/overcoming-nda-refusal-to-file2024-06-27https://www.veristat.com/services/decentralized-clinical-trials-infographic2026-06-15https://www.veristat.com/services/selecting-endpoints-for-an-early-phase-cell-or-gene-study2026-06-15https://www.veristat.com/library-old/rapid-response-to-ebola-outbreak2024-06-27https://www.veristat.com/library-old/medical-writing-fact-sheet2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/the-next-leap-in-alzheimers-rd-is-coming2026-06-23https://www.veristat.com/library-old/first-gene-therapy-approved-in-europe2024-06-27https://www.veristat.com/library/managing-e6r2-compliance-as-it-relates-to-risk-video2024-07-03https://www.veristat.com/library/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2024-07-03https://www.veristat.com/solutions/efficient-regulatory-publishing-for-large-scale-fda-submission2026-02-06https://www.veristat.com/library/early-development-challenges-in-ind-applications2024-07-03https://www.veristat.com/instat-is-now-veristat/mastering-a-global-approach-to-medical-writing2026-06-23https://www.veristat.com/solutions/regulatory-guidance-monthly-review-february-20242025-06-12https://www.veristat.com/services/why-you-need-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-15https://www.veristat.com/library/the-ctdna-clinical-trial-advantage-why-cro-work-puts-you-on-the-cutting-edge2026-01-05https://www.veristat.com/solutions/decentralized-trial-solutions-for-complex-clinical-trials2025-06-12https://www.veristat.com/services/roadmap-to-market-for-cell-and-gene-therapies2026-06-15https://www.veristat.com/services/on-track-and-in-sync-how-veristat-continues-to-support-efficient-fda-interactions2026-06-15https://www.veristat.com/instat-is-now-veristat/accelerating-patient-centric-clinical-trials-three-key-takeaways-for-smarter-design-and-execution2026-06-23https://www.veristat.com/services/eu-pharma-package-key-takeaways-for-clinical-evidence-jca-strategy2026-06-15https://www.veristat.com/services/veristats-most-downloaded-assets-of-20232026-06-15https://www.veristat.com/instat-is-now-veristat/align-new-oncology-drug-development-with-fdas-project-frontrunner2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-march-20252025-06-12https://www.veristat.com/instat-is-now-veristat/fda-expedited-programs-what-you-need-to-know2026-06-23https://www.veristat.com/library/beyond-detection-how-ctdna-could-optimize-treatment-selection2026-01-05https://www.veristat.com/library-old/marketing-applications-data-analysis-challenges2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/pharmacovigilance-fact-sheet2026-06-23https://www.veristat.com/services/unlocking-the-promise-of-radiopharmaceuticals-safety-strategy-innovation-in-clinical-trials2026-06-15https://www.veristat.com/services/the-evolving-landscape-of-radiopharmaceuticals-in-oncology-research2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/overcoming-nda-refusal-to-file2026-06-23https://www.veristat.com/solutions/webinar-achieving-balance-in-database-design2025-06-12https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-june-20242026-06-23https://www.veristat.com/services/post-submission-ind-maintenance-veristat-as-u.s.-agent2026-06-15https://www.veristat.com/library/accelerating-clinical-trial-design-and-operations2024-07-03https://www.veristat.com/services/medical-and-regulatory-affairshttps://www.veristat.com/hubfs/layout/cards/data_image_personscreens_opt1024px.jpgdataimagepersonscreensopt1024pxdataimagepersonscreensopt1024pxhttps://www.veristat.com/hubfs/layout/cards/high_science_image3_opt1024.jpghighscienceimage3opt1024highscienceimage3opt1024https://www.veristat.com/hubfs/layout/cards/formula_image_bluedna_opt1024px.jpgformulaimagebluednaopt1024pxformulaimagebluednaopt1024pxhttps://www.veristat.com/hubfs/layout/cards/data_image_keyboard_opt1024px.jpgdataimagekeyboardopt1024pxdataimagekeyboardopt1024pxhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-10-03https://www.veristat.com/library-old/webinar-roadmap-to-market-cell-and-gene-therapies2024-06-27https://www.veristat.com/solutions/data-collection-efficiency-for-a-novel-anti-infective-therapy2025-06-12https://www.veristat.com/library/keeping-up-with-an-over-performing-site-case-study2026-02-04https://www.veristat.com/services/regulatory-guidance-monthly-review-february-20242026-06-15https://www.veristat.com/solutions/multi-regional-clinical-trials-key-recommendations-for-a-global-clinical-development-program2025-06-12https://www.veristat.com/library-old/full-service-support-for-a-gene-therapy-trial2024-06-27https://www.veristat.com/library/advancing-oncology-innovation-with-adaptive-trial-designs2026-01-13https://www.veristat.com/solutions/regulatory-considerations-for-biosimilars-development-in-the-us-blog2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/inside-2026-the-industrys-ai-turning-point2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-august-20242025-06-12https://www.veristat.com/instat-is-now-veristat/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study2026-06-23https://www.veristat.com/services/real-world-considerations-when-administering-advanced-therapy-products2026-06-15https://www.veristat.com/library-old/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2024-06-27https://www.veristat.com/solutions/veristat-and-aobiome-to-discuss-strategic-cro-partnership-at-clinical-outsourcing-group-20252025-10-08https://www.veristat.com/library/fdas-project-frontrunner-a-path-forward-for-cancer-drug-development2025-07-17https://www.veristat.com/instat-is-now-veristat/how-to-ensure-successful-fda-meeting-video-replay2026-06-23https://www.veristat.com/library/the-power-of-strategic-partnerships-how-veristat-and-ao-biome-redefined-cro-sponsor-collaboration2025-12-16https://www.veristat.com/instat-is-now-veristat/leveraging-fda-expedited-programs-webinar-presentation2026-06-23https://www.veristat.com/instat-is-now-veristat/from-strategy-to-submission-end-to-end-clinical-biometrics-and-regulatory-support-in-neurology2026-06-23https://www.veristat.com/instat-is-now-veristat/understanding-data-monitoring-committees2026-06-23https://www.veristat.com/library/natural-history-study-best-practices-for-engaging-regulatory-authorities2024-07-03https://www.veristat.com/library/considerations-for-developing-rare-disease-treatments2024-07-03https://www.veristat.com/solutions/bridging-science-and-regulatory-success-with-medical-writing2025-06-12https://www.veristat.com/pharmacovigilance/icsr-aggregate-and-individual-reportshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_virtual-trials-216.pngVeristaticonvirtualtrials216Veristaticonvirtualtrials216https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/images_sizedat600px/Case%20Reporting%20Page%20Featured%20Image.pngCaseReportingPageFeaturedImageCaseReportingPageFeaturedImage2024-07-03https://www.veristat.com/services/future-trends-on-european-regulations-on-medicines2026-06-15https://www.veristat.com/instat-is-now-veristat/oncology-webinar-video-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-march-20232026-06-23https://www.veristat.com/library-old/webinar-pres-roadmap-to-market-cell-and-gene-therapies2024-06-27https://www.veristat.com/library/agile-solutions-to-maintain-trial-momentum2024-07-03https://www.veristat.com/solutions/fdas-draft-guidance-for-data-monitoring-committees-dmcs2025-06-12https://www.veristat.com/library/regulatory-consulting-fact-sheet2024-07-03https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-april-20252025-05-19https://www.veristat.com/library/full-service-support-for-a-gene-therapy-trial2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/medical-writing-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/recognize-rare-disease-month-with-veristat2026-06-23https://www.veristat.com/services/building-confidence-in-rwe-delivering-smarter-regulatory-strategies2026-06-15https://www.veristat.com/library/navigating-regulatory-challenges-in-biologics-a-case-study-in-overcoming-clinical-holds2024-07-03https://www.veristat.com/therapeutic-expertise/rare-diseaseshttps://info.veristat.com/hubfs/video-files/veristat%E2%80%93rare_disease_video%20(720p).mp4/medium.jpgveristatrarediseasevideo720pveristatrarediseasevideo720phttps://www.veristat.com/hubfs/video-files/veristat%E2%80%93rare_disease_video%20(720p).mp4169nonohttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialhttps://www.veristat.com/hubfs/images_sizedat600px/call_center_image1.jpgcallcenterimage1callcenterimage1https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Rare%20Diseases-2.pngRareDiseases2RareDiseases2https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/call_center_image6.jpgcallcenterimage6callcenterimage6https://www.veristat.com/hubfs/images_sizedat600px/covid19_nurseinppe.jpgcovid19nurseinppecovid19nurseinppehttps://www.veristat.com/hubfs/Veristat_Card%20Image_S3E7.pngVeristatCardImageS3E7VeristatCardImageS3E7https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image6.jpgtherapeuticimage6therapeuticimage6https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Heart_Failure_image3.jpgtherapeuticHeartFailureimage3therapeuticHeartFailureimage3https://www.veristat.com/hubfs/images_sizedat600px/People_therapeutic_Consent_image10.jpgPeopletherapeuticConsentimage10PeopletherapeuticConsentimage10https://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorder2026-07-09https://www.veristat.com/instat-is-now-veristat/agile-solutions-to-maintain-trial-momentum2026-06-23https://www.veristat.com/library-old/ind-planning-webinar-video-replay2024-06-27https://www.veristat.com/library/study-collaboration-for-successful-covid-19-vaccine-program2024-07-03https://www.veristat.com/library/neurology-fact-sheet2024-07-03https://www.veristat.com/library/oncology-webinar-video-replay2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/purpose-of-ind-ig2026-06-23https://www.veristat.com/instat-is-now-veristat/early-data-strategy-building-todays-trial-for-tomorrows-scalable-success2026-06-23https://www.veristat.com/services/development-of-a-covid-19-vaccine-challenges-for-data-managers2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-december-20252026-06-23https://www.veristat.com/library/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products-blog2024-07-03https://www.veristat.com/instat-is-now-veristat/marketing-applications-data-analysis-challenges2026-06-23https://www.veristat.com/services/expert-ind-publishing2026-06-15https://www.veristat.com/library/mastering-a-global-approach-to-solving-the-complexities-of-successful-medical-writing2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/fda-delays-push-biotech-companies-to-rethink-u.s.-drug-development-strategy2026-06-23https://www.veristat.com/solutions/how-to-ensure-a-successful-fda-meeting-presentation-download2025-06-12https://www.veristat.com/services/supporting-a-sponsor-from-spa-rejection-to-bla-submission2026-06-15https://www.veristat.com/library/pursuing-breakthrough-therapies-for-rare-metabolic-diseases2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/project-optimus-explained-why-the-fda-is-shifting-away-from-maximum-tolerated-dose-in-oncology2026-06-23https://www.veristat.com/solutions/may-oncology-voyager-facing-global-oncology-clinical-development-hurdles2025-06-12https://www.veristat.com/solutions/approvals-for-an-ultra-rare-hematologic-malignancy2025-06-12https://www.veristat.com/services/veristat-fact-sheet2026-06-15https://www.veristat.com/content-modules-choice/veristat-fact-sheet2020-07-30https://www.veristat.com/services/natural-history-study-best-practices-for-engaging-regulatory-authorities2026-06-15https://www.veristat.com/clinical-trial-rescue-programshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_implementation.pngVeristaticonimplementationVeristaticonimplementationhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_regulatory%20approval.pngVeristaticonregulatoryapprovalVeristaticonregulatoryapprovalhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_rare%20disease.pngVeristaticonrarediseaseVeristaticonrarediseasehttps://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_start-up-1.pngVeristaticonstartup1Veristaticonstartup1https://www.veristat.com/hubfs/Rescue%20Trials-1.pngRescueTrials1RescueTrials12026-07-10https://www.veristat.com/instat-is-now-veristat/unlocking-the-promise-of-radiopharmaceuticals-safety-strategy-innovation-in-clinical-trials2026-06-23https://www.veristat.com/services/long-term-follow-up-studies-in-gene-therapy2026-06-15https://www.veristat.com/services/a-comprehensive-planning-approach-for-cancer-antibody2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/why-and-when-to-hold-a-pre-ind-meeting-with-fda2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/fda-introduces-new-term-nonclinical-tests-signaling-a-beginning-not-an-end2026-06-23https://www.veristat.com/instat-is-now-veristat/webinar-slides-single-arm-registrational-studies-in-oncology-research2026-06-23https://www.veristat.com/solutions/how-does-real-world-evidence-impact-medicinal-product-development-in-europe-blog2025-06-12https://www.veristat.com/services/webinar-qa-how-to-advance-new-cancer-therapies-in-alignment-with-fda-project-frontrunner2026-06-15https://www.veristat.com/solutions/a-scientific-approach-to-advance-your-novel-cancer-therapies2025-06-12https://www.veristat.com/library/conducting-clinical-trials-in-a-virtual-world2024-07-03https://www.veristat.com/library-old/regulatory-publishing2024-06-27https://www.veristat.com/solutions/project-optimus-explained-why-the-fda-is-shifting-away-from-maximum-tolerated-dose-in-oncology2025-06-17https://www.veristat.com/solutions/considerations-for-natural-history-studies2025-06-12https://www.veristat.com/instat-is-now-veristat/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2026-06-23https://www.veristat.com/library/rare-disease-development-navigating-small-populations-and-complex-protocols2026-02-12https://www.veristat.com/services/accelerate-neurologypsychiatry-trial-success-with-expert-guidance2026-06-15https://www.veristat.com/library/ind-planning-webinar-video-replay2024-07-03https://www.veristat.com/solutions/a-practical-guide-for-managing-multiple-global-regulatory-pathways2026-01-16https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safetyhttps://www.veristat.com/hubfs/blog_images/Certus%20PV%20Acquisition/PVG%20Side%20Image.pngPVGSideImagePVGSideImagehttps://www.veristat.com/hubfs/homepage/homepage-2019/homepage%20hero%20images/safety_image_certuspvlike_homehero_mobile.jpgsafetyimagecertuspvlikehomeheromobilesafetyimagecertuspvlikehomeheromobilehttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_regulatory%20affairs.pngVeristaticonregulatoryaffairsVeristaticonregulatoryaffairshttps://www.veristat.com/hubfs/blog_images/Certus%20PV%20Acquisition/safety_image_certuspvlike_600%20px.jpgsafetyimagecertuspvlike600pxsafetyimagecertuspvlike600pxhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_team.pngVeristaticonteamVeristaticonteamhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library/guiding-an-emerging-biotechs-first-phase-i-oncology-trial2025-10-08https://www.veristat.com/library/from-clinical-strategy-to-patient-impact-5-lessons-from-cindy-henderson2025-07-31https://www.veristat.com/services/data-management-fact-sheet2026-06-15https://www.veristat.com/company/leadership-team-03https://www.veristat.com/hubfs/team_member_headshots/leadership_team_page/Agnes%20Headshot_Website2021.jpgAgnesHeadshotWebsite2021AgnesHeadshotWebsite2021https://www.veristat.com/hubfs/team_member_headshots/leadership_team_page/Lianne_Riley_veristat_website.jpgLianneRileyveristatwebsiteLianneRileyveristatwebsitehttps://www.veristat.com/hubfs/team_member_headshots/_Mark%20Annan%20photo%20for%20website%20768x512.jpgMarkAnnanphotoforwebsite768x512MarkAnnanphotoforwebsite768x512https://www.veristat.com/hubfs/thumbnail.jpegthumbnailthumbnailhttps://www.veristat.com/hubfs/team_member_headshots/Montse_Leadership%20Team%20Page%20Photo.jpgMontseLeadershipTeamPagePhotoMontseLeadershipTeamPagePhotohttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2023-01-05https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-september-20232026-06-23https://www.veristat.com/instat-is-now-veristat/achieving-balance-in-clinical-trial-database-design2026-06-23https://www.veristat.com/services/advancing-oncology-innovation-with-adaptive-trial-designs2026-06-15https://www.veristat.com/instat-is-now-veristat/staying-ahead-of-regulatory-change-cmc-strategies-for-cell-and-gene-therapy-development2026-06-23https://www.veristat.com/instat-is-now-veristat/how-does-real-world-evidence-impact-medicinal-product-development-in-europe-blog2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/understanding-and-operationalizing-a-complex-adaptive-design2026-06-23https://www.veristat.com/solutions/rare-disease-development-navigating-small-populations-and-complex-protocols2026-02-12https://www.veristat.com/solutions/how-to-ensure-successful-fda-meeting-video-replay2025-06-12https://www.veristat.com/instat-is-now-veristat/multi-regional-clinical-trials-the-latest-guidance-from-fda2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/staying-ahead-of-regulatory-change-cmc-strategies-for-cell-and-gene-therapy-development2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/interpreting-the-regulatory-perspective-on-adaptive-designs2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-july-20232026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-medical-device-ivd-fact-sheet2026-06-23https://www.veristat.com/library-old/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2024-06-27https://www.veristat.com/services/supporting-multiple-global-gene-therapy-studies-for-rare-diseases2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-april-20242026-06-23https://www.veristat.com/services/different-approaches-for-preparing-a-marketing-application2026-06-15https://www.veristat.com/instat-is-now-veristat/the-evolving-landscape-of-radiopharmaceuticals-in-oncology-research2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-publishing-best-practices2026-06-23https://www.veristat.com/library/leveraging-fda-expedited-programs-webinar-replay2024-07-03https://www.veristat.com/services/news-you-can-use-for-rare-disease-trials2026-06-15https://www.veristat.com/services/pooled-analysis-of-the-phase-3-revive-trials2026-06-15https://www.veristat.com/services/regulatory-affairs/regulatory-approvalshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Marketing%20Applications.pngMarketingApplicationsMarketingApplicationshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2026-07-10https://www.veristat.com/services/medicalcommunicationshttps://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Medical%20Communications.pngMedicalCommunicationsMedicalCommunicationshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card%20Image_Successful%20IND%20Submission.pngVeristatHubDBCardImageSuccessfulINDSubmissionVeristatHubDBCardImageSuccessfulINDSubmission2024-07-03https://www.veristat.com/library/mastering-a-global-approach-to-medical-writing2025-06-26https://www.veristat.com/instat-is-now-veristat/development-of-a-covid-19-vaccine-challenges-for-data-managers2026-06-23https://www.veristat.com/services/a-patient-centric-apprach-to-recruitment-and-retention22026-06-15https://www.veristat.com/library/collaborating-together-for-rare-disease2024-07-03https://www.veristat.com/solutions/eu-pharma-package-key-takeaways-for-clinical-evidence-jca-strategy2026-01-09https://www.veristat.com/library/agile-medical-writing-support-for-an-nda2024-07-03https://www.veristat.com/solutions/flexibility-drives-progress-during-a-rare-disease-gene-therapy-clinical-trial2025-06-12https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-april-20252025-06-12https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-october-20232026-06-23https://www.veristat.com/library-old/running-successful-clinical-programs-external-biostatistics-team2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/cmc-pitfalls-from-benchtop-to-ind-blog2026-06-23https://www.veristat.com/instat-is-now-veristat/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis-blog2026-06-23https://www.veristat.com/solutions/accelerating-oncology-breakthroughs2025-06-12https://www.veristat.com/solutions/early-development-challenges-in-ind-applications2025-06-12https://www.veristat.com/instat-is-now-veristat/cancer-research-trends-key-asco-2024-takeaways2026-06-23https://www.veristat.com/solutions/study-collaboration-for-successful-covid-19-vaccine-program2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/on-track-and-in-sync-how-veristat-continues-to-support-efficient-fda-interactions2026-06-23https://www.veristat.com/instat-is-now-veristat/planning-your-ind-when-and-why-to-engage-the-fda2026-06-23https://www.veristat.com/content-modules-choice/purpose-of-ind-ig2020-07-30https://www.veristat.com/services/orphan-drug-designations-and-orphan-subsets2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/decentralized-clinical-trials-infographic2026-06-23https://www.veristat.com/instat-is-now-veristat/veristat-fact-sheet2026-06-23https://www.veristat.com/rare-disease-cro/purpose-of-ind-ig2022-09-07https://www.veristat.com/instat-is-now-veristat/measuring-what-cant-be-seen-how-ptsd-clinical-trials-prove-a-drug-works2026-06-23https://www.veristat.com/services/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development-blog2026-06-15https://www.veristat.com/services/pharmacovigilance-fact-sheet2026-06-15https://www.veristat.com/instat-is-now-veristat/new-tumor-evaluation-modality2026-06-23https://www.veristat.com/instat-is-now-veristat/preparing-global-marketing-authorizations-10-keys-to-success2026-06-23https://www.veristat.com/instat-is-now-veristat/migration-of-data-between-edcs2026-06-23https://www.veristat.com/services/use-of-pro-in-cell-and-gene-therapy-studies2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/targeted-indication-selection-using-simon-2-stage-design2026-06-23https://www.veristat.com/services/cross-functional-collaboration-a-cornerstone-of-successful-clinical-development2026-06-15https://www.veristat.com/services/biometrics/data-managementhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/database-design-considerations-IG-1.jpgdatabasedesignconsiderationsIG1databasedesignconsiderationsIG1https://www.veristat.com/hubfs/people_working_image1_cropped.jpgpeopleworkingimage1croppedpeopleworkingimage1croppedhttps://www.veristat.com/hubfs/Data%20Management.pngDataManagementDataManagementhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card%20Image_Guiding%20an%20Emerging%20Biotech.pngVeristatHubDBCardImageGuidinganEmergingBiotechVeristatHubDBCardImageGuidinganEmergingBiotechhttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-07-10https://www.veristat.com/services/sfl_is_now_veristat/advancing-your-biologic-requires-bold-scientific-strategies2026-06-23https://www.veristat.com/library-old/interpreting-the-regulatory-perspective-on-adaptive-designs2024-06-27https://www.veristat.com/services/biometrics/biostatisticshttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Biostatistics.pngBiostatisticsBiostatisticshttps://www.veristat.com/hubfs/images_sizedat600px/data%20image_programming_600px_web-1.webpdataimageprogramming600pxweb1dataimageprogramming600pxweb1https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovation2026-07-09https://www.veristat.com/instat-is-now-veristat/exceeding-expectations-for-patient-enrollment-case-study2026-06-23https://www.veristat.com/services/integrated-dct-solutions-for-complex-studies2026-06-15https://www.veristat.com/instat-is-now-veristat/real-world-considerations-when-administering-advanced-therapy-products2026-06-23https://www.veristat.com/instat-is-now-veristat/is-your-trial-stuck2026-06-23https://www.veristat.com/instat-is-now-veristat/flexibility-drives-progress-during-a-rare-disease-gene-therapy-clinical-trial2026-06-23https://www.veristat.com/services/is-your-trial-stuck2026-06-15https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-november-20242026-06-23https://www.veristat.com/services/advancing-oncology-innovation2026-06-15https://www.veristat.com/solutions/veristat-works-well-with-growing-firms2025-06-12https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-may-20252026-06-23https://www.veristat.com/instat-is-now-veristat/unlock-the-secrets-of-effective-sd-file-preparation-for-fda-submissions2026-06-23https://www.veristat.com/services/single-arm-studies-for-use-as-a-registrational-study-in-oncology-replay2026-06-15https://www.veristat.com/barbara_balser_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/achieving-balance-in-clinical-trial-database-design2026-06-23https://www.veristat.com/solutions/unlocking-potential-taking-a-statistics-driven-approach-to-clinical-trial-planning2025-06-12https://www.veristat.com/sqn-clinical-joins-veristathttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotmhttps://www.veristat.com/hubfs/homepage/homepage-2021/Homepage-Event-Image_SQN_final.jpgHomepageEventImageSQNfinalHomepageEventImageSQNfinal2024-07-03https://www.veristat.com/solutions/staying-ahead-of-regulatory-change-cmc-strategies-for-cell-and-gene-therapy-development2025-06-12https://www.veristat.com/library/regulatory-guidance-monthly-review-february-20232024-07-03https://www.veristat.com/library/fdas-draft-guidance-for-data-monitoring-committees-dmcs2025-01-23https://www.veristat.com/solutions/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2025-06-12https://www.veristat.com/services/dedicated-regulatory-project-management2026-06-15https://www.veristat.com/company/strengthening-our-impacthttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderhttps://www.veristat.com/hubfs/HubDB-Efficient%20Regulatory%20Publishing%20for%20Large-Scale%20FDA%20Submission.pngHubDBEfficientRegulatoryPublishingforLargeScaleFDASubmissionHubDBEfficientRegulatoryPublishingforLargeScaleFDASubmissionhttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrial2024-11-20https://www.veristat.com/rare-disease-cro/veristat-fact-sheet2022-09-07https://www.veristat.com/library/the-logistics-of-a-clinical-study-scale-up2024-07-03https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-october-20242025-03-13https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-may-20232026-06-23https://www.veristat.com/library/targeted-indication-selection-using-simon-2-stage-design2026-01-06https://www.veristat.com/instat-is-now-veristat/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2026-06-23https://www.veristat.com/instat-is-now-veristat/migration-of-data-between-edcs-blog2026-06-23https://www.veristat.com/services/common-pitfalls-in-gene-therapy-studies2026-06-15https://www.veristat.com/instat-is-now-veristat/medical-writing-partnership-indtonda2026-06-23https://www.veristat.com/library/unlocking-insights-the-impact-of-new-medical-device-eu-regulation-mdr2024-07-03https://www.veristat.com/company/leadership-team-testhttps://www.veristat.com/hubfs/John-P-Balser-1.jpegJohnPBalser1JohnPBalser1https://www.veristat.com/hubfs/Barbara-Balser-1.jpegBarbaraBalser1BarbaraBalser1https://www.veristat.com/hubfs/Patrick-Flanagan_2019_WebHeadshot-1.jpegPatrickFlanagan2019WebHeadshot1PatrickFlanagan2019WebHeadshot1https://www.veristat.com/hubfs/leadership-nav-bar.pngleadershipnavbarleadershipnavbarhttps://www.veristat.com/hubfs/Colleen-Pelton.jpgColleenPeltonColleenPeltonhttps://www.veristat.com/hubfs/Cindy-Henderson.jpgCindyHendersonCindyHendersonhttps://www.veristat.com/hubfs/Shaheen-Limbada_2019.jpgShaheenLimbada2019ShaheenLimbada2019https://www.veristat.com/hubfs/Alecia-Barbee.jpgAleciaBarbeeAleciaBarbeehttps://www.veristat.com/hubfs/SQN-Veristat-logo-lockup-white.pngSQNVeristatlogolockupwhiteSQNVeristatlogolockupwhitehttps://www.veristat.com/hubfs/SQN-Veristat-logo-lockup-white-2.pngSQNVeristatlogolockupwhite2SQNVeristatlogolockupwhite22024-02-02https://www.veristat.com/instat-is-now-veristat/on-demand-webinar-decentralized-trial-solutions-for-complex-clinical-trials2026-06-23https://www.veristat.com/client-testimonialshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/natural-history-studies-in-rare-disease-drug-development2026-06-23https://www.veristat.com/services/global-pediatric-full-service-phase-iii-clinical-trial-begins-on-heels-of-successful-natural-history-study2026-06-15https://www.veristat.com/solutions/full-service-support-for-a-gene-therapy-trial2025-06-12https://www.veristat.com/services/natural-history-studies-in-rare-disease-drug-development2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/an-introduction-to-natural-history-studies2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-publishing-expertise2026-06-23https://www.veristat.com/instat-is-now-veristat/on-demand-webinar-single-arm-studies-for-use-as-a-registrational-study-in-oncology2026-06-23https://www.veristat.com/library/different-approaches-for-preparing-a-marketing-application2024-07-03https://www.veristat.com/library/autologous-vs-allogeneic-cell-and-gene-therapies2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/fda-guidance-series-on-patient-focused-drug-development-pfdd-to-enhance-product-development-and-regulatory-decision-making2026-06-23https://www.veristat.com/instat-is-now-veristat/nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-23https://www.veristat.com/library/cell-and-gene-therapies-fact-sheet2024-07-03https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experiencehttps://www.veristat.com/hubfs/Hematology_Right-Column-Image-copy.jpgHematologyRightColumnImagecopyHematologyRightColumnImagecopyhttps://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/ASH%202025%20Interpreting%20Rapid%20Change.pngASH2025InterpretingRapidChangeASH2025InterpretingRapidChangehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/success-quotes.pngsuccessquotessuccessquoteshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library/veristat-works-well-with-growing-firms2024-07-03https://www.veristat.com/solutions/agile-medical-writing-support-for-an-nda2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/on-demand-webinar-decentralized-trial-solutions-for-complex-clinical-trials2026-06-23https://www.veristat.com/services/ensuring-patient-safety-and-data-integrity-with-veristats-dmc-expertise2026-06-15https://www.veristat.com/library/single-arm-studies-for-use-as-a-registrational-study-in-oncology-replay2024-07-03https://www.veristat.com/services/the-importance-of-regulatory-project-management2026-06-15https://www.veristat.com/services/mastering-a-global-approach-to-solving-the-complexities-of-successful-medical-writing2026-06-15https://www.veristat.com/solutions/pursuing-breakthrough-therapies-for-rare-metabolic-diseases2025-06-12https://www.veristat.com/solutions/advancing-dose-escalation-strategies-with-bayesian-modeling2026-01-13https://www.veristat.com/services/sfl_is_now_veristat/improving-clinical-trial-efficiency-by-achieving-patient-recruitment-on-time2026-06-23https://www.veristat.com/solutions/unlock-the-secrets-of-effective-sd-file-preparation-for-fda-submissions2025-06-12https://www.veristat.com/solutions/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/advancing-oncology-innovation2026-06-23https://www.veristat.com/library-old/ind-planning-webinar-presentation2024-06-27https://www.veristat.com/instat-is-now-veristat/a-creative-approach-to-achieving-an-aggressive-nda-timeline2026-06-23https://www.veristat.com/solutions/a-patient-centric-apprach-to-recruitment-and-retention2025-06-12https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/regulatory-submission-infographic2024-07-03https://www.veristat.com/services/targeted-indication-selection-using-simon-2-stage-design2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/data-collection-efficiency-for-a-novel-anti-infective-therapy2026-06-23https://www.veristat.com/services/advancing-to-your-next-milestone-global-regulatory-excellence-throughout-theentire-clinical-development-lifecycle2026-06-15https://www.veristat.com/therapeutic-expertisehttps://www.veristat.com/hubfs/thera-endocrine-800.webptheraendocrine800theraendocrine800https://www.veristat.com/hubfs/thera-covid-19-800.webptheracovid19800theracovid19800https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_cancer_image12.jpgtherapeuticcancerimage12therapeuticcancerimage12https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image14.jpgtherapeuticimage14therapeuticimage14https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Endocrine_image4.jpgtherapeuticEndocrineimage4therapeuticEndocrineimage4https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image9.jpghappypeopleimage9happypeopleimage9https://www.veristat.com/hubfs/images_sizedat600px/happy_people_image19.jpghappypeopleimage19happypeopleimage19https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image15.jpgtherapeuticimage15therapeuticimage15https://www.veristat.com/hubfs/images_sizedat600px/cellandgene_splicing.jpgcellandgenesplicingcellandgenesplicinghttps://www.veristat.com/hubfs/images_sizedat600px/dna_limeandblue.jpgdnalimeandbluednalimeandblue2025-09-24https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/different-approaches-for-preparing-a-marketing-application2024-07-03https://www.veristat.com/library/demystifying-ectd-4.0-what-you-need-to-know2025-07-01https://www.veristat.com/library/neurology-psychiatry-fact-sheet2025-05-21https://www.veristat.com/library/regulatory-guidance-monthly-review-february-20242024-07-03https://www.veristat.com/library/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study-recording2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/resourcingfsp-model2026-06-23https://www.veristat.com/privacy-policyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2026-06-17https://www.veristat.com/library-old/meeting-the-challenges-of-the-moment2024-06-27https://www.veristat.com/services/preparing-global-marketing-authorizations-10-keys-to-success2026-06-15https://www.veristat.com/library/fda-cders-accelerating-rare-disease-cures-arc-program2024-07-03https://www.veristat.com/instat-is-now-veristat/align-new-oncology-drug-development-with-fdas-project-frontrunner-slides2026-06-23https://www.veristat.com/services/why-and-when-to-hold-a-pre-ind-meeting-with-fda2026-06-15https://www.veristat.com/solutions/advancing-to-your-next-milestone-global-regulatory-excellence-throughout-theentire-clinical-development-lifecycle2025-06-12https://www.veristat.com/library-old/exceeding-expectations-for-patient-enrollment-case-study2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/the-power-of-strategic-partnerships-how-veristat-and-ao-biome-redefined-cro-sponsor-collaboration2026-06-23https://www.veristat.com/library/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2024-07-03https://www.veristat.com/content-modules-choice/different-approaches-for-preparing-a-marketing-application2020-07-30https://www.veristat.com/services/why-regulatory-publishing-expertise-is-essential-for-neurology-clinical-trials2026-06-15https://www.veristat.com/solutions/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2025-06-12https://www.veristat.com/library/managing-e6r2-compliance-as-it-relates-to-risk-deck2024-07-03https://www.veristat.com/library/webinar-slides-single-arm-registrational-studies-in-oncology-research2025-10-08https://www.veristat.com/veristat-events-04https://info.veristat.com/hubfs/library_all-assets/2020June23_Xtalks%20Webinar_Methods%20for%20Minimizing%20the%20Disruption%20of%20Oncology%20Trials.mp4/medium.jpg2020June23XtalksWebinarMethodsforMinimizingtheDisruptionofOncologyTrials2020June23XtalksWebinarMethodsforMinimizingtheDisruptionofOncologyTrialshttps://www.veristat.com/hubfs/library_all-assets/2020June23_Xtalks%20Webinar_Methods%20for%20Minimizing%20the%20Disruption%20of%20Oncology%20Trials.mp43491nonohttps://info.veristat.com/hubfs/video-files/5-20%20Veristat%20SWC%20_RAPS%20WEBINAR%20RECORDING%20VIDEO.mp4/medium.jpg520VeristatSWCRAPSWEBINARRECORDINGVIDEO520VeristatSWCRAPSWEBINARRECORDINGVIDEOhttps://www.veristat.com/hubfs/video-files/5-20%20Veristat%20SWC%20_RAPS%20WEBINAR%20RECORDING%20VIDEO.mp43599nonohttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2020-10-09https://www.veristat.com/services/veristat-expands-global-regulatory-expertise2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/advancing-oncology-innovation-with-adaptive-trial-designs2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/making-dcts-a-successful-reality-for-complex-studies2026-06-23https://www.veristat.com/instat-is-now-veristat/eu-post-marketing-requirements-for-cell-and-gene-therapy-studies2026-06-23https://www.veristat.com/library/regulatory-guidance-monthly-review-august-20232024-07-03https://www.veristat.com/instat-is-now-veristat/the-human-factor-why-team-integration-makes-or-breaks-marketing-applications2026-06-23https://www.veristat.com/instat-is-now-veristat/clinical-development-support-for-multiple-alzheimers-and-parkinsons-studies2026-06-23https://www.veristat.com/instat-is-now-veristat/fda-guidance-on-dmcs-in-clinical-trials2026-06-23https://www.veristat.com/custom-privacy/privacyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/side-by-side-comparison-non-adaptive-vs.-adaptive-designs-in-clinical-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/why-you-need-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-considerations-for-biosimilars-development-in-the-us2026-06-23https://www.veristat.com/instat-is-now-veristat/multiple-arms-design-incorporating-efficacy-and-safety2026-06-23https://www.veristat.com/instat-is-now-veristat/project-optimus-explained-why-the-fda-is-shifting-away-from-maximum-tolerated-dose-in-oncology2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-september-20232026-06-23https://www.veristat.com/library-old/cell-and-gene-therapies-fact-sheet2024-06-27https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-december-20252026-01-29https://www.veristat.com/instat-is-now-veristat/marketing-application-operational-timeline-complexities2026-06-23https://www.veristat.com/library/future-glances-more-change-more-tech-more-harmonisation2025-12-16https://www.veristat.com/services/regulatory-submission-infographic2026-06-15https://www.veristat.com/solutions/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-replay2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/rapid-covid-19-phasei-vaccine-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/strengthening-opportunities-for-growth-in-the-european-region2026-06-23https://www.veristat.com/library/preparing-global-marketing-authorizations-10-keys-to-success2025-10-16https://www.veristat.com/library-old/infectious-disease-fact-sheet2024-06-27https://www.veristat.com/solutions/regulatory-submission-fact-sheet2025-06-12https://www.veristat.com/solutions/webinar-slides-planning-for-a-successful-initial-ind-and-moving-beyond2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/veristat-names-industry-veteran-kim-mclean-boericke-as-new-chief-executive-officer2026-06-23https://www.veristat.com/services/rapid-covid-19-phasei-vaccine-trial2026-06-15https://www.veristat.com/library/full-service-randomized-pancreatic-cancer-phase-ii-trial2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/align-new-oncology-drug-development-with-fdas-project-frontrunner-slides2026-06-23https://www.veristat.com/solutions/preparing-global-marketing-authorizations-10-keys-to-success2025-10-16https://www.veristat.com/library/fda-delays-push-biotech-companies-to-rethink-u.s.-drug-development-strategy2025-05-22https://www.veristat.com/services/sfl_is_now_veristat/clinical-development-support-for-multiple-alzheimers-and-parkinsons-studies2026-06-23https://www.veristat.com/library/long-term-follow-up-studies-in-gene-therapy2024-07-03https://www.veristat.com/library/are-autologous-therapies-here-to-stay-are-allogeneic-therapies-the-future2024-07-03https://www.veristat.com/library-old/veristat-works-well-with-growing-firms2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-may-20242026-06-23https://www.veristat.com/instat-is-now-veristat/roadmap-to-market-for-cell-and-gene-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/successful-swissmedic-marketing-authorization-application-for-an-oncology-therapy2026-06-23https://www.veristat.com/services/pharmacovigilance-customer-vignettes2026-06-15https://www.veristat.com/library/minimizing-complexity-in-oncology-clinical-trials2024-07-03https://www.veristat.com/because-we-carehttps://www.veristat.com/hubfs/CFSIntructor-careers.jpegCFSIntructorcareersCFSIntructorcareershttps://www.veristat.com/hubfs/LTN-photo-career.jpegLTNphotocareerLTNphotocareerhttps://www.veristat.com/hubfs/CristoRey2018.jpegCristoRey2018CristoRey2018https://www.veristat.com/hubfs/veristat_photo_redcrossblood-drive.pngveristatphotoredcrossblooddriveveristatphotoredcrossblooddrivehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412025-09-12https://www.veristat.com/instat-is-now-veristat/biostatisticians-crucial-choreographers-behind-oncology-breakthroughs2026-06-23https://www.veristat.com/instat-is-now-veristat/resourcingfsp-model2026-06-23https://www.veristat.com/services/fda-meeting-types-for-biosimilar-products2026-06-15https://www.veristat.com/solutions/replay-how-to-better-plan-a-virtual-clinical-trial2025-06-12https://www.veristat.com/instat-is-now-veristat/updated-future-trends-on-european-regulations-on-medicines2026-06-23https://www.veristat.com/solutions/marketing-applications-approval-record2025-06-12https://www.veristat.com/library/exploring-future-trends-on-european-regulations-a-webinar-by-veristat-and-topra2024-07-03https://www.veristat.com/solutions/achieving-balance-in-clinical-trial-database-design2025-06-12https://www.veristat.com/library/on-demand-webinar-single-arm-studies-for-use-as-a-registrational-study-in-oncology2024-07-03https://www.veristat.com/instat-is-now-veristat/marketing-application-medical-writing-strategies2026-06-23https://www.veristat.com/library-old/covid-19-success-guide2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/veristat-expands-global-regulatory-expertise2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-november-20242026-06-15https://www.veristat.com/instat-is-now-veristat/understanding-the-critical-role-of-data-monitoring-committees-in-clinical-trials2026-06-23https://www.veristat.com/solutions/future-trends-on-european-regulations-on-medicines-replay2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/global-pediatric-full-service-phase-iii-clinical-trial-begins-on-heels-of-successful-natural-history-study2026-06-23https://www.veristat.com/library/emergency-use-authorizations-blog2024-07-03https://www.veristat.com/services/ind-planning-webinar-video-replay2026-06-15https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-december-20242025-03-13https://www.veristat.com/kimberly_newton_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-december-20232026-06-23https://www.veristat.com/library/unlocking-the-promise-of-radiopharmaceuticals-safety-strategy-innovation-in-clinical-trials2025-05-06https://www.veristat.com/solutions/pursuing-breakthrough-therapies-for-rare-metabolic-diseases-veristats-role-in-a-landmark-clinical-study2025-06-12https://www.veristat.com/defining-decentralized-clinical-trials-audio-infographichttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_team.pngVeristaticonteamVeristaticonteamhttps://www.veristat.com/hubfs/full-experience-graphic.jpgfullexperiencegraphicfullexperiencegraphichttps://www.veristat.com/hubfs/trad-trials-graphic-01-1.pngtradtrialsgraphic011tradtrialsgraphic011https://www.veristat.com/hubfs/decentral-toolkit-40.pngdecentraltoolkit40decentraltoolkit40https://www.veristat.com/hubfs/social-channel_post-images/LinkedIn%20Image_DCT%20Audio%20IG.pngLinkedInImageDCTAudioIGLinkedInImageDCTAudioIGhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotmhttps://www.veristat.com/hubfs/full-decentral-graphic-03.pngfulldecentralgraphic03fulldecentralgraphic03https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_Time-216.pngVeristaticonTime216VeristaticonTime216https://www.veristat.com/hubfs/image-png.pngimagepngimagepnghttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_flexibility.pngVeristaticonflexibilityVeristaticonflexibilityhttps://www.veristat.com/hubfs/hybrid-trials-graphic-02.pnghybridtrialsgraphic02hybridtrialsgraphic02https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_global%20reach.pngVeristaticonglobalreachVeristaticonglobalreach2024-07-03https://www.veristat.com/library/rapid-response-to-ebola-outbreak2024-07-03https://www.veristat.com/instat-is-now-veristat/complex-trial-for-a-rare-pediatric-gene-therapy2026-06-23https://www.veristat.com/instat-is-now-veristat/cmc-pitfalls-from-benchtop-to-ind2026-06-23https://www.veristat.com/library-old/agile-solutions-to-maintain-trial-momentum2024-06-27https://www.veristat.com/services/the-human-factor-why-team-integration-makes-or-breaks-marketing-applications2026-06-15https://www.veristat.com/instat-is-now-veristat/a-patient-centric-apprach-to-recruitment-and-retention2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-may-20232026-06-23https://www.veristat.com/library-old/site-monitoring-success-with-teamwork2024-06-27https://www.veristat.com/instat-is-now-veristat/lessons-learned-for-better-planning-of-decentralized-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study2026-06-23https://www.veristat.com/instat-is-now-veristat/four-pillars-of-success-in-neurology-trials2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-july-20252025-08-26https://www.veristat.com/services/corporate-overview-fact-sheet2026-06-15https://www.veristat.com/services/how-vaccine-clinical-trials-work2026-06-15https://www.veristat.com/instat-is-now-veristat/solutions-to-accelerate-cell-and-gene-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/endocrine-and-metabolic-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/veristat-global-policy-insights-q1-20242026-06-23https://www.veristat.com/services/full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-presentation2026-06-23https://www.veristat.com/instat-is-now-veristat/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products2026-06-23https://www.veristat.com/instat-is-now-veristat/neurology-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/managing-e6r2-compliance-as-it-relates-to-risk-deck2026-06-23https://www.veristat.com/services/fdas-project-frontrunner-a-path-forward-for-cancer-drug-development2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/database-design-considerations-ig2026-06-23https://www.veristat.com/instat-is-now-veristat/rescue-patient-recruitment-for-lagging-trial2026-06-23https://www.veristat.com/solutions/webinar-pres-roadmap-to-market-cell-and-gene-therapies2025-06-12https://www.veristat.com/library/veristat-and-aobiome-to-discuss-strategic-cro-partnership-at-clinical-outsourcing-group-20252025-10-08https://www.veristat.com/library/similarities-and-differences-between-the-cta-and-ind2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/rescuing-a-global-program-for-nda-success2026-06-23https://www.veristat.com/services/decentralized-trial-solutions-for-complex-clinical-trials2026-06-15https://www.veristat.com/library/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2024-07-03https://www.veristat.com/library/the-rapid-pace-of-regulatory-change2024-07-03https://www.veristat.com/services/regulatory-affairs-overviewhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image6.jpgpeopleworkingimage6peopleworkingimage6https://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/Regulatory%20Affairs.pngRegulatoryAffairsRegulatoryAffairshttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/images_sizedat600px/lab_cmc_mouseescapebeaker.jpglabcmcmouseescapebeakerlabcmcmouseescapebeakerhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image12.jpgpeopleworkingimage12peopleworkingimage12https://www.veristat.com/hubfs/images_sizedat600px/people_working_image1.jpgpeopleworkingimage1peopleworkingimage1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image9.jpgpeopleworkingimage9peopleworkingimage9https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-07-09https://www.veristat.com/solutions/planning-the-way-forward-in-neurodegenerative-disease-studies2025-06-12https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-december-20252026-06-23https://www.veristat.com/solutions/overcoming-nda-refusal-to-file2025-06-12https://www.veristat.com/services/interpreting-the-regulatory-perspective-on-adaptive-designs2026-06-15https://www.veristat.com/library/fda-guidance-series-on-patient-focused-drug-development-pfdd-to-enhance-product-development-and-regulatory-decision-making2024-07-03https://www.veristat.com/therapeutic-expertise/cardiologyhttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Cardiovascular-1.pngCardiovascular1Cardiovascular1https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Heart_Failure_image3.jpgtherapeuticHeartFailureimage3therapeuticHeartFailureimage3https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Hypertension_image2.jpgtherapeuticHypertensionimage2therapeuticHypertensionimage2https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImage2026-07-10https://www.veristat.com/library-oldhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-06-27https://www.veristat.com/services/a-practical-guide-for-managing-multiple-global-regulatory-pathways2026-06-15https://www.veristat.com/instat-is-now-veristat/biosimilar-fda-meeting-types2026-06-23https://www.veristat.com/library/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2024-07-03https://www.veristat.com/solutions/rescue-patient-recruitment-for-lagging-trial2025-06-12https://www.veristat.com/library/emergency-use-authorizations2024-07-03https://www.veristat.com/services/regulatory-guidance-monthly-review-may-20232026-06-15https://www.veristat.com/services/sfl_is_now_veristat/use-of-pro-in-cell-and-gene-therapy-studies2026-06-23https://www.veristat.com/services/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2026-06-15https://www.veristat.com/services/keeping-up-with-an-over-performing-site-case-study2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/from-clinical-strategy-to-patient-impact-5-lessons-from-cindy-henderson2026-06-23https://www.veristat.com/quality-assurance-and-compliancehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/social-suggested-images/www.veristat.comhs-fshubfslogologo-small-Aug-09-2024-08-57-57-5062-AM.pngwwwveristatcomhsfshubfslogologosmallAug0920240857575062AMwwwveristatcomhsfshubfslogologosmallAug0920240857575062AM2026-06-16https://www.veristat.com/instat-is-now-veristat/fda-introduces-new-term-nonclinical-tests-signaling-a-beginning-not-an-end2026-06-23https://www.veristat.com/solutions/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-replay2025-06-12https://www.veristat.com/instat-is-now-veristat/exploring-future-trends-on-european-regulations-a-webinar-by-veristat-and-topra2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/stem-cell-therapy-for-stroke-patients2026-06-23https://www.veristat.com/instat-is-now-veristat/a-practical-guide-for-managing-multiple-global-regulatory-pathways2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2026-06-23https://www.veristat.com/company/abouthttps://info.veristat.com/hubfs/End%20of%202025%20Stats%20FINAL.mp4/medium.jpgEndof2025StatsFINALEndof2025StatsFINALhttps://www.veristat.com/hubfs/End%20of%202025%20Stats%20FINAL.mp48nonohttps://www.veristat.com/hubfs/HubDB-Efficient%20Regulatory%20Publishing%20for%20Large-Scale%20FDA%20Submission.pngHubDBEfficientRegulatoryPublishingforLargeScaleFDASubmissionHubDBEfficientRegulatoryPublishingforLargeScaleFDASubmissionhttps://www.veristat.com/hubfs/About%20Us.pngAboutUsAboutUshttps://www.veristat.com/hubfs/nurse-patient-home-1200.webpnursepatienthome1200nursepatienthome1200https://www.veristat.com/hubfs/iStock-651671956-2.jpgiStock6516719562iStock6516719562https://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderhttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-06-23https://www.veristat.com/instat-is-now-veristat/should-an-oncology-study-expand-into-europe2026-06-23https://www.veristat.com/instat-is-now-veristat/fdas-project-frontrunner-a-path-forward-for-cancer-drug-development2026-06-23https://www.veristat.com/solutions/rare-disease-fact-sheet2025-06-12https://www.veristat.com/services/evaluating-adaptive-trials-do-they-align-with-your-studys-goals-and-requirements2026-06-15https://www.veristat.com/regulatory-medical-device-ivdhttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Veristat_Regulatory_Publishing.pngVeristatRegulatoryPublishingVeristatRegulatoryPublishinghttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_image12.jpgpeopleworkingimage12peopleworkingimage12https://www.veristat.com/hubfs/Medical%20Devices.pngMedicalDevicesMedicalDevices2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/align-new-oncology-drug-development-with-fdas-project-frontrunner2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/data-management-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/natural-history-studies-in-rare-disease-drug-development2026-06-23https://www.veristat.com/services/first-gene-therapy-approved-in-europe2026-06-15https://www.veristat.com/services/four-pillars-of-success-in-neurology-trials2026-06-15https://www.veristat.com/services/successful-eu-maa-submission-enabled-by-u.s.-eu-regulatory-collaboration2026-06-15https://www.veristat.com/services/strengthening-opportunities-for-growth-in-the-european-region2026-06-15https://www.veristat.com/library/eu-post-marketing-requirements-for-cell-and-gene-therapy-studies2024-07-03https://www.veristat.com/solutions/adaptive-design-recent-advancement-in-clinical-trials2025-06-12https://www.veristat.com/john_balser_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-08-01https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-august-20232026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-april-20232026-06-23https://www.veristat.com/library/addressing-drug-developer-challenges-with-decentralized-clinical-trials2024-07-03https://www.veristat.com/services/staying-ahead-of-regulatory-change-cmc-strategies-for-cell-and-gene-therapy-development2026-06-15https://www.veristat.com/services/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2026-06-15https://www.veristat.com/instat-is-now-veristat/delivering-data-that-matters-an-integrated-approach-to-biostatistics-data-management-statistical-programming-in-clinical-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/database-design-considerations-ig2026-06-23https://www.veristat.com/services/achieving-balance-in-clinical-trial-database-design2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/considerations-for-developing-rare-disease-treatments2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/single-arm-studies-a-strategic-path-to-oncology-drug-approval2026-06-23https://www.veristat.com/instat-is-now-veristat/ind-planning-webinar-video-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-23https://www.veristat.com/solutions/the-human-factor-why-team-integration-makes-or-breaks-marketing-applications2025-06-12https://www.veristat.com/solutions/successful-preparation-strategies-for-nda-maa-marketing-applications2025-11-26https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-february-20232026-06-23https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/purpose-of-ind-ig2024-07-03https://www.veristat.com/sqn-clinical-joins-veristat/adaptive-design-fact-sheet2024-07-03https://www.veristat.com/library/turning-sponsor-cro-partnerships-into-success2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/fda-meeting-types-for-biosimilar-products2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/dedicated-regulatory-project-management2026-06-23https://www.veristat.com/solutions/your-guide-to-mastering-cmc-regulatory-success-in-biotherapeutics-a-must-watch-webinar2025-06-12https://www.veristat.com/solutions/regulatory-publishing-expertise2025-06-12https://www.veristat.com/solutions/driving-multiple-global-gene-therapy-studies2025-06-12https://www.veristat.com/services/accelerating-patient-centric-clinical-trials-through-science-based-planning-delivery-and-support2026-06-15https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-may-20242024-07-03https://www.veristat.com/services/sfl_is_now_veristat/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-replay2026-06-23https://www.veristat.com/solutions/align-new-oncology-drug-development-with-fdas-project-frontrunner-slides2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/planning-for-a-successful-initial-ind-and-moving-beyond2026-06-23https://www.veristat.com/solutions/reflections-from-asco-20252025-06-18https://www.veristat.com/solutions/fdas-project-frontrunner-a-path-forward-for-cancer-drug-development2025-07-17https://www.veristat.com/services/sfl_is_now_veristat/essential-considerations-foradaptive-design-in-clinical-trials2026-06-23https://www.veristat.com/library/project-optimus-explained-why-the-fda-is-shifting-away-from-maximum-tolerated-dose-in-oncology2025-06-17https://www.veristat.com/services/beyond-detection-how-ctdna-could-optimize-treatment-selection2026-06-15https://www.veristat.com/library-old/different-approaches-for-preparing-marketing-applications2024-06-27https://www.veristat.com/solutions/migration-of-data-between-edcs-blog2025-06-12https://www.veristat.com/therapeutic-expertise/oncologyhttps://www.veristat.com/hubfs/layout/page-images/Hematology%20Image.pngHematologyImageHematologyImagehttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image9.jpgtherapeuticimage9therapeuticimage9https://www.veristat.com/hubfs/ASH%202025%20Interpreting%20Rapid%20Change.pngASH2025InterpretingRapidChangeASH2025InterpretingRapidChangehttps://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/Oncology_Hematology-1.pngOncologyHematology1OncologyHematology1https://www.veristat.com/hubfs/Randomized%20Pancreatic%20Cancer%20Phase%20II_Full.pngRandomizedPancreaticCancerPhaseIIFullRandomizedPancreaticCancerPhaseIIFullhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_cancer_image12.jpgtherapeuticcancerimage12therapeuticcancerimage12https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB-Why%20You%20Need%20a%20CRO%20That%20Excels%20in%20Oncology%20Regulatory%20Publishing.pngHubDBWhyYouNeedaCROThatExcelsinOncologyRegulatoryPublishingHubDBWhyYouNeedaCROThatExcelsinOncologyRegulatoryPublishing2026-07-09https://www.veristat.com/instat-is-now-veristat/biomarker-driven-adaptive-design-for-precision-medicine2026-06-23https://www.veristat.com/therapeutic-expertise/immunology-and-inflammationhttps://www.veristat.com/hubfs/Inflammation_Immunology-1.pngInflammationImmunology1InflammationImmunology1https://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Endocrine_image4.jpgtherapeuticEndocrineimage4therapeuticEndocrineimage4https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image5.jpgtherapeuticimage5therapeuticimage5https://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2026-07-10https://www.veristat.com/library/accelerating-patient-centric-clinical-trials-three-key-takeaways-for-smarter-design-and-execution2026-01-13https://www.veristat.com/library/decentralized-clinical-trials-infographic2024-07-03https://www.veristat.com/solutions/turning-sponsor-cro-partnerships-into-success2025-06-12https://www.veristat.com/solutions/multiple-arms-design-incorporating-efficacy-and-safety2025-06-12https://www.veristat.com/solutions/conducting-clinical-trials-in-a-virtual-world2025-06-12https://www.veristat.com/library/global-policy-insights-april-20242024-07-03https://www.veristat.com/solutions/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-presentation2025-06-12https://www.veristat.com/library/single-arm-studies-for-use-as-a-registrational-study-in-oncology-article2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/navigating-regulatory-challenges-in-biologics-a-case-study-in-overcoming-clinical-holds2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/cell-and-gene-therapies-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/understanding-fdas-project-optimus2026-06-23https://www.veristat.com/instat-is-now-veristat/webinar-pres-roadmap-to-market-cell-and-gene-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/future-glances-more-change-more-tech-more-harmonisation2026-06-23https://www.veristat.com/solutions/a-playbook-for-effective-sponsorcro-partnership2026-01-16https://www.veristat.com/solutions/regulatory-guidance-monthly-review-june-20232025-06-12https://www.veristat.com/services/sfl_is_now_veristat/infectious-disease-fact-sheet2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/agile-solutions-to-maintain-trial-momentum2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/preserving-what-matters-how-institutional-knowledge-protects-value-through-ma2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/collaborating-together-for-rare-disease2026-06-23https://www.veristat.com/solutions/infectious-disease-fact-sheet2025-06-12https://www.veristat.com/veristat-culture-our-core-valueshttps://www.veristat.com/hubfs/CristoRey2018.jpegCristoRey2018CristoRey2018https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/social-channel_post-images/OD%20Booth%20ok.jpgODBoothokODBoothok2025-06-12https://www.veristat.com/services/helping-a-sponsor-overcome-a-partial-clinical-hold-and-seamlessly-steer-multiple-products-through-development2026-06-15https://www.veristat.com/library-old/leveraging-fda-expedited-programs-webinar-replay2024-06-27https://www.veristat.com/solutions/interpreting-the-regulatory-perspective-on-adaptive-designs2025-06-12https://www.veristat.com/services/strategic-clinical-development-consulting2026-06-15https://www.veristat.com/solutions/collaborating-together-for-rare-disease2025-06-12https://www.veristat.com/solutions/an-introduction-to-natural-history-studies2025-06-12https://www.veristat.com/solutions/european-medicines-and-medical-devices-future-trends2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/protocol-specific-feasibility2026-06-23https://www.veristat.com/library-old/neurology-fact-sheet2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/conducting-clinical-trials-in-a-virtual-world2026-06-23https://www.veristat.com/instat-is-now-veristat/successful-ind-submission-paves-the-way-for-a-global-full-service-phase-i-clinical-trial-targeting-cancers2026-06-23https://www.veristat.com/solutions/full-service-randomized-pancreatic-cancer-phase-ii-trial2025-06-12https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-may-20242026-06-15https://www.veristat.com/careers/life-at-veristathttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/image_spotlight_jenniferharmon.pngimagespotlightjenniferharmonimagespotlightjenniferharmonhttps://www.veristat.com/hubfs/life-at-veristat-testimonial-grouped.pnglifeatveristattestimonialgroupedlifeatveristattestimonialgroupedhttps://www.veristat.com/hubfs/life-at-veristat-testimonial-2.pnglifeatveristattestimonial2lifeatveristattestimonial22025-06-12https://www.veristat.com/library-old/what-is-the-future-landscape-of-cell-gene-therapies-replay2024-06-27https://www.veristat.com/services/data-analysis-excellence-the-backbone-of-successful-marketing-applications2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/regulatory-publishing-expertise2026-06-23https://www.veristat.com/solutions/a-wearable-moment2025-09-24https://www.veristat.com/library-old/rapid-covid-19-phasei-vaccine-trial2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/keeping-up-with-an-over-performing-site-case-study2026-06-23https://www.veristat.com/library/marketing-application-publishing-best-practices2025-06-11https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-september-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/demystifying-ectd-4.0-what-you-need-to-know2026-06-23https://www.veristat.com/solutions/advancing-oncology-innovation2025-11-07https://www.veristat.com/solutions/comprehensive-planning-for-a-first-in-human-cancer-antibody-trial2025-10-08https://www.veristat.com/solutions/why-regulatory-publishing-expertise-is-essential-for-neurology-clinical-trials2025-10-02https://www.veristat.com/veristat-press-coveragehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_Inc5000_Inc%202-2.pngVeristatInc5000Inc22VeristatInc5000Inc22https://www.veristat.com/hubfs/social-suggested-images/www.veristat.comhs-fshubfslogologo-small-Aug-09-2024-08-57-57-5062-AM.pngwwwveristatcomhsfshubfslogologosmallAug0920240857575062AMwwwveristatcomhsfshubfslogologosmallAug0920240857575062AM2026-07-10https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-june-20232026-06-23https://www.veristat.com/solutions/flexibility-drives-progress-in-rare-disease-gene-therapy-trial2026-02-26https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-september-20242025-06-12https://www.veristat.com/library/successful-ind-submission-paves-the-way-for-a-global-full-service-phase-i-clinical-trial-targeting-cancers2025-10-08https://www.veristat.com/instat-is-now-veristat/pursuing-breakthrough-therapies-for-rare-metabolic-diseases-veristats-role-in-a-landmark-clinical-study2026-06-23https://www.veristat.com/services/fda-cders-accelerating-rare-disease-cures-arc-program2026-06-15https://www.veristat.com/solutions/autologous-vs-allogeneic-cell-and-gene-therapies2025-06-12https://www.veristat.com/solutions/the-science-of-simultaneous-submissions-managing-multiple-regulatory-pathways2026-01-15https://www.veristat.com/services/flexibility-drives-progress-during-a-rare-disease-gene-therapy-clinical-trial2026-06-15https://www.veristat.com/solutions/single-arm-registrational-studies-in-oncology-research2025-10-29https://www.veristat.com/services/adaptive-design-recent-advancement-in-clinical-trials2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-august-20242026-06-23https://www.veristat.com/instat-is-now-veristat/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2026-06-23https://www.veristat.com/services/flexibility-drives-progress-in-rare-disease-gene-therapy-trial2026-06-15https://www.veristat.com/instat-is-now-veristat/successful-dmc-services-for-complex-hematologic-cancer-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/a-patient-centric-apprach-to-recruitment-and-retention22026-06-23https://www.veristat.com/solutions/database-design-considerations-ig2025-06-12https://www.veristat.com/services/fda-guidance-on-dmcs-in-clinical-trials2026-06-15https://www.veristat.com/library/blog-nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2025-08-19https://www.veristat.com/rare-disease-cro/different-approaches-for-preparing-a-marketing-application2022-09-07https://www.veristat.com/solutions/leveraging-fda-expedited-programs-webinar-presentation2025-06-12https://www.veristat.com/content-modules-choice/adaptive-design-fact-sheet2020-07-30https://www.veristat.com/library-old/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2024-06-27https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-march-20252025-04-17https://www.veristat.com/solutions/bayesian-study-designs-in-early-phase-oncology-trials2025-06-12https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-november-20232026-06-23https://www.veristat.com/services/sfl_is_now_veristat/planning-the-way-forward-in-neurodegenerative-disease-studies2026-06-23https://www.veristat.com/library/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2024-07-03https://www.veristat.com/solutions/improving-clinical-trial-efficiency-by-achieving-patient-recruitment-on-time2025-06-12https://www.veristat.com/solutions/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development2025-06-12https://www.veristat.com/services/regulatory-guidance-monthly-review-april-20232026-06-15https://www.veristat.com/library/stem-cell-therapy-for-stroke-patients2024-07-03https://www.veristat.com/instat-is-now-veristat/a-wearable-moment2026-06-23https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/cardiology-fact-sheet2024-07-03https://www.veristat.com/solutions/regulatory-guidance-monthly-review-february-20232025-06-12https://www.veristat.com/solutions/pharmacovigilance-fact-sheet2025-06-12https://www.veristat.com/services/the-power-of-publishing-for-an-efficient-nda-submission-process2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/strategic-clinical-development-consulting2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/presentation-expanding-your-clinical-trial-into-the-us2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-june-20242026-06-23https://www.veristat.com/instat-is-now-veristat/early-development-challenges-in-ind-applications2026-06-23https://www.veristat.com/services/regulatory-medical-device-ivd-fact-sheet2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/emergency-use-authorizations2026-06-23https://www.veristat.com/solutions/the-rise-of-decentralized-clinical-trials-transforming-research-through-technology-and-patient-centricity2025-06-12https://www.veristat.com/solutions/dedicated-regulatory-project-management2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2026-06-23https://www.veristat.com/instat-is-now-veristat/corporate-overview-fact-sheet2026-06-23https://www.veristat.com/library/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products2024-07-03https://www.veristat.com/library/shortening-development-and-approval-timelines-for-novel-medicinal-products2024-07-03https://www.veristat.com/library/expert-ind-publishing2024-07-03https://www.veristat.com/solutions/accelerating-patient-centric-trials2025-08-18https://www.veristat.com/instat-is-now-veristat/biostats-programming-fact-sheet2026-06-23https://www.veristat.com/library-old/considerations-for-natural-history-studies2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/fspresourcing-meeting-the-moment-with-expert-resources2026-06-23https://www.veristat.com/library-old/essential-considerations-foradaptive-design-in-clinical-trials2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/vaccine-clinical-trial-showcase-phase-2b-hipra-study-against-covid-19-presented-by-veristat2026-06-23https://www.veristat.com/services/from-clinical-strategy-to-patient-impact-5-lessons-from-cindy-henderson2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/bold-thinking-that-delivers-results-for-rna-therapies2026-06-23https://www.veristat.com/sqn-clinical-joins-veristat/veristat-fact-sheet2024-07-03https://www.veristat.com/solutions/on-track-and-in-sync-how-veristat-continues-to-support-efficient-fda-interactions2025-12-11https://www.veristat.com/sqn-clinical-joins-veristat/different-approaches-for-preparing-a-marketing-application2024-07-03https://www.veristat.com/cro-cell-genehttps://info.veristat.com/hubfs/video-files/Veristat_Advanced%20Therapies%20Defined.mp4.mp4/medium.jpgVeristatAdvancedTherapiesDefinedmp4VeristatAdvancedTherapiesDefinedmp4https://www.veristat.com/hubfs/video-files/Veristat_Advanced%20Therapies%20Defined.mp4.mp491nonohttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Cell%20and%20Gene%20Therapies.pngCellandGeneTherapiesCellandGeneTherapieshttps://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrial2026-07-09https://www.veristat.com/instat-is-now-veristat/advancing-your-biologic-requires-bold-scientific-strategies2026-06-23https://www.veristat.com/services/unlocking-insights-the-impact-of-new-medical-device-eu-regulation-mdr2026-06-15https://www.veristat.com/instat-is-now-veristat/a-comprehensive-planning-approach-for-cancer-antibody2026-06-23https://www.veristat.com/instat-is-now-veristat/successful-eu-maa-submission-enabled-by-u.s.-eu-regulatory-collaboration2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/migration-of-data-between-edcs2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/cmc-pitfalls-from-benchtop-to-ind2026-06-23https://www.veristat.com/solutions/navigating-the-ind-submission-labyrinth-a-veristat-success-story2025-06-12https://www.veristat.com/instat-is-now-veristat/data-analysis-excellence-the-backbone-of-successful-marketing-applications2026-06-23https://www.veristat.com/resourceshttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-07-26https://www.veristat.com/instat-is-now-veristat/orphan-drug-designations-and-orphan-subsets2026-06-23https://www.veristat.com/instat-is-now-veristat/pooled-analysis-of-the-phase-3-revive-trials2026-06-23https://www.veristat.com/global-reach-locationshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Location.pngLocationLocationhttps://www.veristat.com/hubfs/world-bkgd.pngworldbkgdworldbkgd2025-12-03https://www.veristat.com/services/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/selecting-the-right-oncology-cro-partner2026-06-23https://www.veristat.com/services/future-trends-on-european-regulations-on-medicines-replay2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development2026-06-23https://www.veristat.com/solutions/data-analysis-excellence-the-backbone-of-successful-marketing-applications2025-06-12https://www.veristat.com/solutions/successful-dmc-services-for-complex-hematologic-cancer-trial2025-06-12https://www.veristat.com/library/selecting-endpoints-for-an-early-phase-cell-or-gene-study2024-07-03https://www.veristat.com/instat-is-now-veristat/full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-23https://www.veristat.com/solutions/successful-swissmedic-marketing-authorization-application-for-an-oncology-therapy2025-11-28https://www.veristat.com/pharmacovigilance/system-setup-and-inspection-readinesshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/people_working_image7.jpgpeopleworkingimage7peopleworkingimage7https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/PV%20Systems%20Set%20Up%20Page%20Featured%20Image.pngPVSystemsSetUpPageFeaturedImagePVSystemsSetUpPageFeaturedImagehttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_quote-216.pngVeristaticonquote216Veristaticonquote216https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-07-03https://www.veristat.com/instat-is-now-veristat/webinar-gene-therapy-complex-clinical-development-pathways2026-06-23https://www.veristat.com/solutions/oncology-webinar-video-replay2025-06-12https://www.veristat.com/solutions/managing-e6r2-compliance-as-it-relates-to-risk-video2025-06-12https://www.veristat.com/services/cmc-pitfalls-from-benchtop-to-ind2026-06-15https://www.veristat.com/instat-is-now-veristat/comprehensive-strategic-clinical-development-consulting2026-06-23https://www.veristat.com/instat-is-now-veristat/running-successful-clinical-programs-external-biostatistics-team2026-06-23https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-june-20252025-08-18https://www.veristat.com/rare-disease-cro/regulatory-submission-infographic2022-09-07https://www.veristat.com/services/regulatory-intelligencehttps://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Regulatory%20Intelligence.pngRegulatoryIntelligenceRegulatoryIntelligencehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach12024-07-03https://www.veristat.com/library/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/exploring-future-trends-on-european-regulations-a-webinar-by-veristat-and-topra2026-06-23https://www.veristat.com/library/accelerating-patient-centric-trials2025-08-18https://www.veristat.com/solutions/marketing-application-key-planning-tips2025-06-12https://www.veristat.com/library/advancing-your-biologic-requires-bold-scientific-strategies2024-07-03https://www.veristat.com/library/approvals-for-an-ultra-rare-hematologic-malignancy2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-november-20252026-06-23https://www.veristat.com/instat-is-now-veristat/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2026-06-23https://www.veristat.com/solutions/systematic-comparison-of-the-statistical-operating-characteristics-of-various-phase-i-oncology-designs2025-06-12https://www.veristat.com/services/navigating-the-patient-experience-when-pivoting-to-a-virtual-model-mid-study-recording2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/data-driven-strategies-to-advance-development-and-approval-of-rareultra-rare-disease-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/decentralized-solutions-for-complex-clinical-trails2026-06-23https://www.veristat.com/services/weighing-the-suitability-of-a-functional-service-provider-fsp-model-for-clinical-trials2026-06-15https://www.veristat.com/solutions/webinar-slides-single-arm-registrational-studies-in-oncology-research2025-10-08https://www.veristat.com/instat-is-now-veristat/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-replay2026-06-23https://www.veristat.com/library/improving-clinical-trial-efficiency-by-achieving-on-time-patient-recruitment2025-01-22https://www.veristat.com/library-old/vaccines-fact-sheet2024-06-27https://www.veristat.com/services/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2026-06-15https://www.veristat.com/services/cmc-sd-files-for-regulatory-submissions2026-06-15https://www.veristat.com/library/unlocking-potential-taking-a-statistics-driven-approach-to-clinical-trial-planning2025-02-28https://www.veristat.com/podcast-listing-page-03https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-07-03https://www.veristat.com/services/sfl_is_now_veristat/vaccines-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/driving-multiple-global-gene-therapy-studies2026-06-23https://www.veristat.com/services/cell-and-gene-therapies-fact-sheet2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/preparing-global-marketing-authorizations-10-keys-to-success2026-06-23https://www.veristat.com/services/mastering-a-global-approach-to-medical-writing2026-06-15https://www.veristat.com/library/regulatory-publishing2024-07-03https://www.veristat.com/services/from-strategy-to-submission-end-to-end-clinical-biometrics-and-regulatory-support-in-neurology2026-06-15https://www.veristat.com/services/stem-cell-therapy-for-stroke-patients2026-06-15https://www.veristat.com/library/dedicated-regulatory-project-management2024-07-03https://www.veristat.com/instat-is-now-veristat/how-to-ensure-a-successful-fda-meeting-presentation-download2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-compound-effect-of-specialized-knowledge2026-06-23https://www.veristat.com/services/fspresourcing-meeting-the-moment-with-expert-resources2026-06-15https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/achieving-an-aggressive-nda-timeline2024-07-03https://www.veristat.com/tanya_larsenbollenbach_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/instat-is-now-veristat/overcoming-nda-refusal-to-file2026-06-23https://www.veristat.com/solutions/recognize-rare-disease-month-with-veristat2025-06-12https://www.veristat.com/library-old/adaptive-design-fact-sheet2024-06-27https://www.veristat.com/instat-is-now-veristat/integrated-dct-solutions-for-complex-studies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/successful-eu-maa-submission-enabled-by-u.s.-eu-regulatory-collaboration2026-06-23https://www.veristat.com/instat-is-now-veristat/programmed-narratives-working-smarter-not-harder2026-06-23https://www.veristat.com/library-old/purpose-of-ind-ig2024-06-27https://www.veristat.com/library/decentralized-solutions-for-complex-clinical-trails2024-07-03https://www.veristat.com/solutions/protocol-specific-feasibility2026-06-09https://www.veristat.com/instat-is-now-veristat/the-rapid-pace-of-regulatory-change2026-06-23https://www.veristat.com/services/replay-expanding-your-clinical-trial-into-the-us2026-06-15https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-june-20252025-08-18https://www.veristat.com/library-old/preparing-new-drug-application-ind2024-06-27https://www.veristat.com/solutions/dose-escalation-with-bayesian-strategies2025-06-25https://www.veristat.com/library/regulatory-guidance-monthly-review-june-20232024-07-03https://www.veristat.com/services/sfl_is_now_veristat/neurology-regulatory-submissions-simplified-expertise-you-can-trust2026-06-23https://www.veristat.com/library/flexibility-drives-progress-during-a-rare-disease-gene-therapy-clinical-trial2024-07-03https://www.veristat.com/solutions/timeline-mastery-the-strategic-backbone-of-marketing-application-success2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/approvals-for-an-ultra-rare-hematologic-malignancy2026-06-23https://www.veristat.com/solutions/veristat-infographic2025-08-26https://www.veristat.com/solutions/medical-writing-partnership-indtonda2025-06-12https://www.veristat.com/instat-is-now-veristat/decentralized-trial-solutions-for-complex-clinical-trials2026-06-23https://www.veristat.com/solutions/cell-and-gene-therapies-fact-sheet2025-06-12https://www.veristat.comhttps://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH-2.pngSuccessStoriesPhaseIIIafterNH2SuccessStoriesPhaseIIIafterNH2https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_medical%20affairs-216.pngVeristaticonmedicalaffairs216Veristaticonmedicalaffairs216https://www.veristat.com/hubfs/HomePage_MarchUpdate_RegulatorySuccess.pngHomePageMarchUpdateRegulatorySuccessHomePageMarchUpdateRegulatorySuccesshttps://www.veristat.com/hubfs/HomePage_MarchUpdate_ClinicalTrial.pngHomePageMarchUpdateClinicalTrialHomePageMarchUpdateClinicalTrialhttps://www.veristat.com/hubfs/Veristat_icon_diverse%20backgrounds-1.pngVeristaticondiversebackgrounds1Veristaticondiversebackgrounds1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image10.jpgpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_enrollment.pngVeristaticonenrollmentVeristaticonenrollmenthttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_biologic.pngVeristaticonbiologicVeristaticonbiologichttps://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH.pngSuccessStoriesPhaseIIIafterNHSuccessStoriesPhaseIIIafterNHhttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_neurology-216.pngVeristaticonneurology216Veristaticonneurology216https://www.veristat.com/hubfs/HomePage_MarchUpdate_ConsultingSolutions%20(1).pngHomePageMarchUpdateConsultingSolutions1HomePageMarchUpdateConsultingSolutions1https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_oncology-216.pngVeristaticononcology216Veristaticononcology2162026-07-08https://www.veristat.com/website-terms-of-usehttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2025-04-17https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-may-20252025-06-12https://www.veristat.com/services/sfl_is_now_veristat/regulatory-considerations-for-biosimilars-development-in-the-us-blog2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-may-20242025-06-12https://www.veristat.com/services/what-is-the-future-cell-gene-presentation2026-06-15https://www.veristat.com/instat-is-now-veristat/podcast-orphan-drug-designations-and-orphan-subsets2026-06-23https://www.veristat.com/solutions/overcoming-complexity-in-modern-clinical-trials2025-08-21https://www.veristat.com/services/sfl_is_now_veristat/a-patient-centric-apprach-to-recruitment-and-retention22026-06-23https://www.veristat.com/services/sfl_is_now_veristat/pursuing-breakthrough-therapies-for-rare-metabolic-diseases2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2026-06-23https://www.veristat.com/solutions/single-arm-studies-a-strategic-path-to-oncology-drug-approval2026-01-13https://www.veristat.com/services/multi-regional-clinical-trials-the-latest-guidance-from-fda2026-06-15https://www.veristat.com/services/veristat-names-industry-veteran-kim-mclean-boericke-as-new-chief-executive-officer2026-06-15https://www.veristat.com/therapeutic-expertise/pediatric-clinical-trialshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB_Card%20Image_Flobal%20Pediatric%20FSCS.pngHubDBCardImageFlobalPediatricFSCSHubDBCardImageFlobalPediatricFSCShttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image9.jpgtherapeuticimage9therapeuticimage9https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/images_sizedat600px/cellandgene_splicing.jpgcellandgenesplicingcellandgenesplicinghttps://www.veristat.com/hubfs/images_sizedat600px/happy_people_image11.jpghappypeopleimage11happypeopleimage11https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedProgramshttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Pediatric_image8.jpgtherapeuticPediatricimage8therapeuticPediatricimage82026-07-10https://www.veristat.com/services/sfl_is_now_veristat/beyond-detection-how-ctdna-could-optimize-treatment-selection2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-june-20242026-06-15https://www.veristat.com/services/sfl_is_now_veristat/a-creative-approach-to-achieving-an-aggressive-nda-timeline2026-06-23https://www.veristat.com/services/regulatory-consulting-fact-sheet2026-06-15https://www.veristat.com/library/biostats-programming-fact-sheet2025-05-21https://www.veristat.com/solutions/regulatory-guidance-monthly-review-august-20232025-06-12https://www.veristat.com/library/natural-history-studies-in-rare-disease-drug-development2025-08-21https://www.veristat.com/services/align-new-oncology-drug-development-with-fdas-project-frontrunner-slides2026-06-15https://www.veristat.com/library/pharmacovigilance-customer-vignettes2024-07-03https://www.veristat.com/library/building-confidence-in-rwe-delivering-smarter-regulatory-strategies2025-04-29https://www.veristat.com/library/news-you-can-use-for-rare-disease-trials2024-07-03https://www.veristat.com/services/single-arm-registrational-studies-in-oncology-research2026-06-15https://www.veristat.com/library/successful-swissmedic-marketing-authorization-application-for-an-oncology-therapy2025-11-28https://www.veristat.com/services/making-dcts-a-successful-reality-for-complex-studies2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/pharmacovigilance-customer-vignettes2026-06-23https://www.veristat.com/solutions/veristat-fact-sheet2025-06-12https://www.veristat.com/searchhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2026-07-08https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-february-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/flexibility-drives-progress-in-rare-disease-gene-therapy-trial2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-medical-writing-strategies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/comprehensive-strategic-clinical-development-consulting2026-06-23https://www.veristat.com/instat-is-now-veristat/on-track-and-in-sync-how-veristat-continues-to-support-efficient-fda-interactions2026-06-23https://www.veristat.com/library/adaptive-design-recent-advancement-in-clinical-trials2024-07-03https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-september-20252026-01-05https://www.veristat.com/library/why-regulatory-publishing-expertise-is-essential-for-neurology-clinical-trials2025-10-02https://www.veristat.com/instat-is-now-veristat/overcoming-complexity-in-modern-clinical-trials2026-06-23https://www.veristat.com/instat-is-now-veristat/advancing-oncology-innovation-with-adaptive-trial-designs2026-06-23https://www.veristat.com/zoom-info-test-pagehttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotmhttps://www.veristat.com/hubfs/layout/cards/card-placeholder.pngcardplaceholdercardplaceholder2020-05-28https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-january-20262026-02-19https://www.veristat.com/services/sfl_is_now_veristat/fdas-draft-guidance-for-data-monitoring-committees-dmcs2026-06-23https://www.veristat.com/solutions/veristat-global-policy-insights-q22025-06-12https://www.veristat.com/solutions/neurology-regulatory-submissions-simplified-expertise-you-can-trust2025-10-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-may-20242026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-january-20242026-06-23https://www.veristat.com/library-old/preparing-data-for-maa-marketing-authorization-appliation2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/programmed-narratives-working-smarter-not-harder2026-06-23https://www.veristat.com/instat-is-now-veristat/common-pitfalls-in-gene-therapy-studies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/neurology-fact-sheet2026-06-23https://www.veristat.com/solutions/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products-blog2025-06-12https://www.veristat.com/library/migration-of-data-between-edcs2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/7-habits-of-highly-successful-medical-writers2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/first-gene-therapy-approved-in-europe2026-06-23https://www.veristat.com/services/full-service-support-for-a-gene-therapy-trial2026-06-15https://www.veristat.com/instat-is-now-veristat/supporting-a-sponsor-from-spa-rejection-to-bla-submission2026-06-23https://www.veristat.com/services/recist-oncology-guidelines2026-06-15https://www.veristat.com/library/comprehensive-planning-for-a-first-in-human-cancer-antibody-trial2025-10-08https://www.veristat.com/library/what-is-the-future-cell-gene-presentation2024-07-03https://www.veristat.com/search-test-5-21https://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotmhttps://www.veristat.com/hubfs/layout/cards/card-placeholder.pngcardplaceholdercardplaceholder2020-05-22https://www.veristat.com/services/sfl_is_now_veristat/study-collaboration-for-successful-covid-19-vaccine-program2026-06-23https://www.veristat.com/instat-is-now-veristat/approvals-for-an-ultra-rare-hematologic-malignancy2026-06-23https://www.veristat.com/library-old/keeping-up-with-an-over-performing-site-case-study2024-06-27https://www.veristat.com/services/the-logistics-of-a-clinical-study-scale-up2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/de-risking-the-neurology-ind-lessons-from-early-fda-engagement2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/full-service-support-for-a-gene-therapy-trial2026-06-23https://www.veristat.com/library/veristat-names-industry-veteran-kim-mclean-boericke-as-new-chief-executive-officer2026-01-15https://www.veristat.com/content-modules-choice/regulatory-submission-infographic2020-07-30https://www.veristat.com/services/webinar-slides-single-arm-registrational-studies-in-oncology-research2026-06-15https://www.veristat.com/solutions/vaccine-clinical-trial-showcase-phase-2b-hipra-study-against-covid-19-presented-by-veristat2025-06-12https://www.veristat.com/library-old/managing-e6r2-compliance-as-it-relates-to-risk-video2024-06-27https://www.veristat.com/library/recognize-rare-disease-month-with-veristat2024-07-03https://www.veristat.com/pre-approval-and-post-marketing-pharmacovigilance-safety/veristat-fact-sheet2024-07-03https://www.veristat.com/instat-is-now-veristat/ensuring-regulatory-success-from-pre-ind-through-to-submission2026-06-23https://www.veristat.com/instat-is-now-veristat/de-risking-the-neurology-ind-lessons-from-early-fda-engagement2026-06-23https://www.veristat.com/library/de-risking-the-neurology-ind-lessons-from-early-fda-engagement2026-01-06https://www.veristat.com/services/ind-planning-webinar-presentation2026-06-15https://www.veristat.com/instat-is-now-veristat/expertise-in-rna-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/efficient-regulatory-publishing-for-large-scale-fda-submission2026-06-23https://www.veristat.com/library-old/overcoming-challenges-in-orphan-drug-development2024-06-27https://www.veristat.com/solutions/vaccines-fact-sheet2025-06-12https://www.veristat.com/library/future-trends-on-european-regulations-on-medicines2024-07-03https://www.veristat.com/patient-recruitment-for-clinical-trialshttps://www.veristat.com/hubfs/HubDB_Card%20Image_Podcast_Big4Bio%20DCT.pngHubDBCardImagePodcastBig4BioDCTHubDBCardImagePodcastBig4BioDCThttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Patient%20Recruitment.pngPatientRecruitmentPatientRecruitmenthttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2026-07-10https://www.veristat.com/mobile-trigger-testhttps://www.veristat.com/hubfs/layout/cards/card-placeholder.pngcardplaceholdercardplaceholderhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2020-11-21https://www.veristat.com/content-modules-choicehttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/infectious_disease_stats.pnginfectiousdiseasestatsinfectiousdiseasestatshttps://www.veristat.com/hubfs/HubDB-Supporting%20Global%20Approval%20of%20a%20First-in-ClassGene%20Therapy%20for%20a%20Rare%20Genetic%20Disorder.pngHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderHubDBSupportingGlobalApprovalofaFirstinClassGeneTherapyforaRareGeneticDisorderhttps://www.veristat.com/hubfs/infectious_disease_experience_table.pnginfectiousdiseaseexperiencetableinfectiousdiseaseexperiencetablehttps://www.veristat.com/hubfs/HubDB-Case%20Study_Flexibility%20Drives%20Progress%20During%20a%20Rare%20Disease%20Clinical%20Trial.pngHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialHubDBCaseStudyFlexibilityDrivesProgressDuringaRareDiseaseClinicalTrialhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2020-07-30https://www.veristat.com/services/rescuing-a-global-program-for-nda-success2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/eu-pharma-package-key-takeaways-for-clinical-evidence-jca-strategy2026-06-23https://www.veristat.com/instat-is-now-veristat/safety-tolerability-and-pharmacokinetics-of-a-single-orally-inhaled-dose-of-pur3100-a-dry-powder-formulation-of-dihydroergotamine-versus-intravenous-dihydroergotamine-a-phase-1-randomized-double-blind-study-in-healthy-adults2026-06-23https://www.veristat.com/services/on-demand-webinar-single-arm-studies-for-use-as-a-registrational-study-in-oncology2026-06-15https://www.veristat.com/services/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-presentation2026-06-15https://www.veristat.com/solutions/biostatisticians-ensuring-the-validity-reliability-and-interpretability-of-clinical-trial-data2025-06-12https://www.veristat.com/services/veristat-global-policy-insights-q1-20242026-06-15https://www.veristat.com/library-old/fda-meeting-types2024-06-27https://www.veristat.com/services/veristat-infographic2026-06-15https://www.veristat.com/services/improving-clinical-trial-efficiency-by-achieving-patient-recruitment-on-time2026-06-15https://www.veristat.com/library/elevating-cns-drug-development-veristats-agile-approach-in-medical-writing-and-project-management2024-07-03https://www.veristat.com/library/full-service-trial-delivery-fact-sheet2025-05-21https://www.veristat.com/rare-disease-cro/adaptive-design-fact-sheet2022-09-07https://www.veristat.com/library/understanding-and-operationalizing-a-complex-adaptive-design2025-10-29https://www.veristat.com/instat-is-now-veristat/mastering-a-global-approach-to-solving-the-complexities-of-successful-medical-writing2026-06-23https://www.veristat.com/library-old/different-approaches-for-preparing-a-marketing-application2024-06-27https://www.veristat.com/instat-is-now-veristat/protocol-specific-feasibility2026-06-23https://www.veristat.com/library-old/regulatory-submission-fact-sheet2024-06-27https://www.veristat.com/services/preparing-new-drug-application-ind2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/early-development-challenges-in-ind-applications2026-06-23https://www.veristat.com/solutions/the-power-of-publishing-for-an-efficient-nda-submission-process2025-06-12https://www.veristat.com/library/cross-functional-collaboration-a-cornerstone-of-successful-clinical-development2025-07-10https://www.veristat.com/instat-is-now-veristat/accelerating-patient-centric-clinical-trials-through-science-based-planning-delivery-and-support2026-06-23https://www.veristat.com/solutions/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/evaluating-adaptive-trials-do-they-align-with-your-studys-goals-and-requirements2026-06-23https://www.veristat.com/solutions/fda-cders-accelerating-rare-disease-cures-arc-program2025-06-12https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-july-20242024-10-10https://www.veristat.com/services/sfl_is_now_veristat/managing-e6r2-compliance-as-it-relates-to-risk-video2026-06-23https://www.veristat.com/solutions/preparing-new-drug-application-ind2025-06-12https://www.veristat.com/services/how-does-real-world-evidence-impact-medicinal-product-development-in-europe2026-06-15https://www.veristat.com/solutions/expertise-in-rna-therapies2025-06-12https://www.veristat.com/instat-is-now-veristat/future-trends-on-european-regulations-on-medicines2026-06-23https://www.veristat.com/solutions/understanding-fdas-project-optimus2025-06-12https://www.veristat.com/solutions/webinar-roadmap-to-market-cell-and-gene-therapies2025-06-12https://www.veristat.com/services/biometricshttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/images_sizedat600px/people_working_image3_new.jpgpeopleworkingimage3newpeopleworkingimage3newhttps://www.veristat.com/hubfs/images_sizedat600px/data_dataentryoniipad_600px_web.webpdatadataentryoniipad600pxwebdatadataentryoniipad600pxwebhttps://www.veristat.com/hubfs/images_sizedat600px/data%20image_programming_600px_web-1.webpdataimageprogramming600pxweb1dataimageprogramming600pxweb1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image16_virtualmeeting_600px.jpgpeopleworkingimage16virtualmeeting600pxpeopleworkingimage16virtualmeeting600pxhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Biometrics-2.pngBiometrics2Biometrics2https://www.veristat.com/hubfs/images_sizedat600px/data_handsenteringdata_darkblue_web.webpdatahandsenteringdatadarkbluewebdatahandsenteringdatadarkblueweb2026-07-09https://www.veristat.com/approachhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Our%20Approach.pngOurApproachOurApproachhttps://www.veristat.com/hubfs/Veristat_Partnership_Approach.webpVeristatPartnershipApproachVeristatPartnershipApproach2026-06-02https://www.veristat.com/services/sfl_is_now_veristat/selecting-endpoints-for-an-early-phase-cell-or-gene-study2026-06-23https://www.veristat.com/instat-is-now-veristat/reflections-from-asco-20252026-06-23https://www.veristat.com/library-old/replay-expanding-your-clinical-trial-into-the-us2024-06-27https://www.veristat.com/library/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2024-07-03https://www.veristat.com/library/a-roundup-of-perspectives-and-predictions-on-research-misconduct-inclusivity-ai-and-more2025-12-16https://www.veristat.com/solutions/selecting-the-right-oncology-cro-partner2025-06-12https://www.veristat.com/services/autologous-vs-allogeneic-cell-and-gene-therapies2026-06-15https://www.veristat.com/company/historyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2016-09-01https://www.veristat.com/solutions/regulatory-guidance-monthly-review-july-20232025-06-12https://www.veristat.com/library-old/news-you-can-use-for-rare-disease-trials2024-06-27https://www.veristat.com/solutions/presentation-expanding-your-clinical-trial-into-the-us2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/a-practical-guide-for-managing-multiple-global-regulatory-pathways2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-april-20242025-06-12https://www.veristat.com/services/marketaccess-reimbursementhttps://www.veristat.com/hubfs/CTA-BKGRD-02a.jpgCTABKGRD02aCTABKGRD02ahttps://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image13.jpgpeopleworkingimage13peopleworkingimage13https://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Market%20Access%20-Reimbursement.pngMarketAccessReimbursementMarketAccessReimbursementhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-07-03https://www.veristat.com/services/medical-writing-fact-sheet2026-06-15https://www.veristat.com/services/the-power-of-strategic-partnerships-how-veristat-and-ao-biome-redefined-cro-sponsor-collaboration2026-06-15https://www.veristat.com/library/different-approaches-for-preparing-marketing-applications2024-07-03https://www.veristat.com/instat-is-now-veristat/covid-19-success-guide2026-06-23https://www.veristat.com/instat-is-now-veristat/trends-in-oncology-regulation-fda-draft-guidance-on-os-and-radiopharmaceuticals2026-06-23https://www.veristat.com/library-old/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2024-06-27https://www.veristat.com/library-old/adaptive-design-recent-advancement-in-clinical-trials2024-06-27https://www.veristat.com/library/solutions-to-accelerate-cell-and-gene-therapies2024-07-03https://www.veristat.com/solutions/regulatory-guidance-monthly-review-march-20232025-06-12https://www.veristat.com/library/overcoming-nda-refusal-to-file2024-07-03https://www.veristat.com/library/regulatory-guidance-monthly-review-april-20232024-07-03https://www.veristat.com/library/regulatory-publishing-expertise2024-07-03https://www.veristat.com/services/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2026-06-15https://www.veristat.com/solutions/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2025-06-12https://www.veristat.com/services/veristat-global-policy-insights-q22026-06-15https://www.veristat.com/instat-is-now-veristat/regulatory-considerations-for-biosimilars-development-in-the-us2026-06-23https://www.veristat.com/homepage-2https://www.veristat.com/hubfs/images_sizedat600px/people_working_image10.jpgpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/Voyager_RareDisease_Feb2024.pngVoyagerRareDiseaseFeb2024VoyagerRareDiseaseFeb2024https://www.veristat.com/hubfs/Veristat_icon_oncology-216.pngVeristaticononcology216Veristaticononcology216https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_biologic.pngVeristaticonbiologicVeristaticonbiologichttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_enrollment.pngVeristaticonenrollmentVeristaticonenrollmenthttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_strategic-consulting-216.pngVeristaticonstrategicconsulting216Veristaticonstrategicconsulting216https://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH-2.pngSuccessStoriesPhaseIIIafterNH2SuccessStoriesPhaseIIIafterNH2https://www.veristat.com/hubfs/Home_ARMPR_Apr2024.pngHomeARMPRApr2024HomeARMPRApr2024https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_telemedicine-216.pngVeristaticontelemedicine216Veristaticontelemedicine216https://www.veristat.com/hubfs/image-png-3.pngimagepng3imagepng3https://www.veristat.com/hubfs/Veristat_CaseStudy_HomePage_Marketing.pngVeristatCaseStudyHomePageMarketingVeristatCaseStudyHomePageMarketinghttps://www.veristat.com/hubfs/Veristat_icon_diverse%20backgrounds-1.pngVeristaticondiversebackgrounds1Veristaticondiversebackgrounds1https://www.veristat.com/hubfs/homepage/homepage-2024/blue-lights-bkgd-w-diamonds-2024.jpgbluelightsbkgdwdiamonds2024bluelightsbkgdwdiamonds2024https://www.veristat.com/hubfs/image-png-2.pngimagepng2imagepng2https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_molecular%20entities-216.pngVeristaticonmolecularentities216Veristaticonmolecularentities216https://www.veristat.com/hubfs/veristat-phases-november-v2.svgveristatphasesnovemberv2veristatphasesnovemberv2https://www.veristat.com/hubfs/image-png-4.pngimagepng4imagepng4https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_regulatory-affairs-216.pngVeristaticonregulatoryaffairs216Veristaticonregulatoryaffairs216https://www.veristat.com/hubfs/SuccessStories_Phase%20I-II%20after%20NH.pngSuccessStoriesPhaseIIIafterNHSuccessStoriesPhaseIIIafterNHhttps://www.veristat.com/hubfs/homepage/homepage-2024/specialty-expertise-bkgd-2024.jpgspecialtyexpertisebkgd2024specialtyexpertisebkgd2024https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_rare-disease-216.pngVeristaticonraredisease216Veristaticonraredisease2162025-01-08https://www.veristat.com/services/comprehensive-planning-for-a-first-in-human-cancer-antibody-trial2026-06-15https://www.veristat.com/services/align-new-oncology-drug-development-with-fdas-project-frontrunner2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/considerations-for-natural-history-studies2026-06-23https://www.veristat.com/mark_chang_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-replay2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis-blog2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/unlock-the-secrets-of-effective-sd-file-preparation-for-fda-submissions2026-06-23https://www.veristat.com/custom-privacy/data-privacy-policyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2026-06-18https://www.veristat.com/solutions/trends-in-oncology-regulation-fda-draft-guidance-on-os-and-radiopharmaceuticals2025-08-28https://www.veristat.com/instat-is-now-veristat/rare-disease-fact-sheet2026-06-23https://www.veristat.com/services/webinar-gene-therapy-complex-clinical-development-pathways2026-06-15https://www.veristat.com/solutions/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development-blog2025-06-12https://www.veristat.com/services/marketing-application-key-planning-tips2026-06-15https://www.veristat.com/solutions/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer2025-06-12https://www.veristat.com/solutions/2026-cell-and-gene-therapy-predictions2026-02-13https://www.veristat.com/services/sfl_is_now_veristat/3-reasons-why-you-need-to-consider-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-23https://www.veristat.com/library/is-your-trial-stuck2024-07-03https://www.veristat.com/instat-is-now-veristat/regulatory-submission-fact-sheet2026-06-23https://www.veristat.com/solutions/early-data-strategy-building-todays-trial-for-tomorrows-scalable-success2026-01-28https://www.veristat.com/services/approvals-for-an-ultra-rare-hematologic-malignancy2026-06-15https://www.veristat.com/library/webinar-gene-therapy-complex-clinical-development-pathways2024-07-03https://www.veristat.com/instat-is-now-veristat/recist-oncology-guidelines2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/flexibility-drives-progress-during-a-rare-disease-gene-therapy-clinical-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/ind-planning-webinar-presentation2026-06-23https://www.veristat.com/library-old/protocol-specific-feasibility2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/pursuing-breakthrough-therapies-for-rare-metabolic-diseases-veristats-role-in-a-landmark-clinical-study2026-06-23https://www.veristat.com/library/cmc-pitfalls-from-benchtop-to-ind-blog2024-07-03https://www.veristat.com/instat-is-now-veristat/2026-cell-and-gene-therapy-predictions2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/biomarker-driven-adaptive-design-for-precision-medicine2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-april-20232026-06-23https://www.veristat.com/services/rescuing-site-monitoring-success2026-06-15https://www.veristat.com/library-old/lessons-learned-for-better-planning-of-decentralized-clinical-trials2024-06-27https://www.veristat.com/library/multi-regional-clinical-trials-key-recommendations-for-a-global-clinical-development-program2025-06-03https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-march-20252026-06-23https://www.veristat.com/services/managing-e6r2-compliance-as-it-relates-to-risk-video2026-06-15https://www.veristat.com/instat-is-now-veristat/data-driven-strategies-to-advance-development-and-approval-of-rareultra-rare-disease-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-replay2026-06-23https://www.veristat.com/instat-is-now-veristat/managing-e6r2-compliance-as-it-relates-to-risk-video2026-06-23https://www.veristat.com/library/expertise-in-rna-therapies2024-07-03https://www.veristat.com/solutions/marketing-application-publishing-best-practices2025-06-12https://www.veristat.com/library/ash-2025-interpreting-rapid-change-across-hematology2026-01-06https://www.veristat.com/services/regulatory-guidance-monthly-review-october-20232026-06-15https://www.veristat.com/library-old/presentation-the-role-of-natural-history-studies-in-ultra-rare-disease-trials2024-06-27https://www.veristat.com/instat-is-now-veristat/planning-for-a-successful-initial-ind-and-moving-beyond2026-06-23https://www.veristat.com/solutions/blog-nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2025-08-19https://www.veristat.com/library-old/data-collection-efficiency-for-a-novel-anti-infective-therapy2024-06-27https://www.veristat.com/solutions/the-logistics-of-a-clinical-study-scale-up2025-06-12https://www.veristat.com/instat-is-now-veristat/may-oncology-voyager-facing-global-oncology-clinical-development-hurdles2026-06-23https://www.veristat.com/instat-is-now-veristat/helping-a-sponsor-overcome-a-partial-clinical-hold-and-seamlessly-steer-multiple-products-through-development2026-06-23https://www.veristat.com/services/agile-solutions-to-maintain-trial-momentum2026-06-15https://www.veristat.com/services/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products-blog2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/a-scientific-approach-to-advance-your-novel-cancer-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/the-benefits-of-a-central-site-model2026-06-23https://www.veristat.com/library/exceeding-expectations-for-patient-enrollment-case-study2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-july-20252026-06-23https://www.veristat.com/library-old/solutions-to-accelerate-cell-and-gene-therapies2024-06-27https://www.veristat.com/solutions/exceeding-expectations-for-patient-enrollment-case-study2025-06-12https://www.veristat.com/why-veristathttps://info.veristat.com/hubfs/video-files/Veristat_2023_CorpVideo_BoldThinking_Cindy.mp4/medium.jpgVeristat2023CorpVideoBoldThinkingCindyVeristat2023CorpVideoBoldThinkingCindyhttps://www.veristat.com/hubfs/video-files/Veristat_2023_CorpVideo_BoldThinking_Cindy.mp453nonohttps://www.veristat.com/hubfs/images_sizedat600px/call_center_image5.jpgcallcenterimage5callcenterimage5https://www.veristat.com/hubfs/newspaper-4.jpegnewspaper4newspaper4https://www.veristat.com/hubfs/shutterstock_1065910013_Taipei.jpegshutterstock1065910013Taipeishutterstock1065910013Taipeihttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image3_new.jpgpeopleworkingimage3newpeopleworkingimage3newhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/people-high-five-careers-800.webppeoplehighfivecareers800peoplehighfivecareers800https://www.veristat.com/hubfs/images_sizedat600px/people_working_handshake.jpgpeopleworkinghandshakepeopleworkinghandshakehttps://www.veristat.com/hubfs/taipei-skyline-why-v-800.webptaipeiskylinewhyv800taipeiskylinewhyv800https://www.veristat.com/hubfs/women-having-coffee-success-800.webpwomenhavingcoffeesuccess800womenhavingcoffeesuccess800https://www.veristat.com/hubfs/images_sizedat600px/people_working_image6.jpgpeopleworkingimage6peopleworkingimage6https://www.veristat.com/hubfs/Web%20Page_Featured_why%20veristat.pngWebPageFeaturedwhyveristatWebPageFeaturedwhyveristat2026-06-23https://www.veristat.com/services/regulatory-guidance-monthly-review-november-20232026-06-15https://www.veristat.com/solutions/veristat-achieves-ecovadis-committed-badge-a-milestone-in-our-sustainability-journey2025-09-10https://www.veristat.com/library/advancing-oncology-innovation2025-11-07https://www.veristat.com/library/decentralized-trial-solutions-for-complex-clinical-trials2024-07-03https://www.veristat.com/library/on-demand-webinar-decentralized-trial-solutions-for-complex-clinical-trials2024-07-03https://www.veristat.com/solutions/cancer-research-trends-key-asco-2024-takeaways2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/navigating-the-ind-submission-labyrinth-a-veristat-success-story2026-06-23https://www.veristat.com/instat-is-now-veristat/adaptive-design-recent-advancement-in-clinical-trials2026-06-23https://www.veristat.com/solutions/endocrine-and-metabolic-fact-sheet2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/measuring-what-cant-be-seen-how-ptsd-clinical-trials-prove-a-drug-works2026-06-23https://www.veristat.com/instat-is-now-veristat/pursuing-breakthrough-therapies-for-rare-metabolic-diseases2026-06-23https://www.veristat.com/solutions/pharmacovigilance-customer-vignettes2025-06-12https://www.veristat.com/library/unlock-the-secrets-of-effective-sd-file-preparation-for-fda-submissions2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/migration-of-data-between-edcs-blog2026-06-23https://www.veristat.com/services/strategic-resourcinghttps://www.veristat.com/hubfs/Pharmacovigilance%20(2).pngPharmacovigilance2Pharmacovigilance2https://www.veristat.com/hubfs/image-png-May-06-2024-05-40-27-8608-PM.pngimagepngMay0620240540278608PMimagepngMay0620240540278608PMhttps://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB_Card%20Image_FS_FSP%20Model.pngHubDBCardImageFSFSPModelHubDBCardImageFSFSPModel2026-07-10https://www.veristat.com/library/on-track-and-in-sync-how-veristat-continues-to-support-efficient-fda-interactions2025-12-11https://www.veristat.com/library/the-next-leap-in-alzheimers-rd-is-coming2025-11-19https://www.veristat.com/services/sfl_is_now_veristat/mastering-a-global-approach-to-medical-writing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-october-20242026-06-23https://www.veristat.com/services/single-arm-studies-for-use-as-a-registrational-study-in-oncology-presentation2026-06-15https://www.veristat.com/instat-is-now-veristat/cell-and-gene-therapies-fact-sheet2026-06-23https://www.veristat.com/library/why-and-when-to-hold-a-pre-ind-meeting-with-fda2024-07-03https://www.veristat.com/library/webinar-slides-planning-for-a-successful-initial-ind-and-moving-beyond2024-07-03https://www.veristat.com/solutions/cmc-sd-files-for-regulatory-submissions2025-06-12https://www.veristat.com/veristat-eventshttps://www.veristat.com/hubfs/OCT%2025/OCT%20Logo.jpgOCTLogoOCTLogohttps://www.veristat.com/hubfs/events/default-events-logo-100-1.pngdefaulteventslogo1001defaulteventslogo1001https://www.veristat.com/hubfs/events/SwissBiotechDaySquare.pngSwissBiotechDaySquareSwissBiotechDaySquarehttps://www.veristat.com/hubfs/events/Orphan%20Europe%2021/Orphan%20300%20x%20300%20.pngOrphan300x300Orphan300x300https://www.veristat.com/hubfs/Pharmacovigilance%20US%202024/Square%20Pharmacovigilance%202024.pngSquarePharmacovigilance2024SquarePharmacovigilance2024https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/events/BiotechGate23/Logo%20Biotech%20Gate.pngLogoBiotechGateLogoBiotechGatehttps://www.veristat.com/hubfs/events/BIO%20EUROPE%202023/Bio%20Europe%20Munich%202023%20square%20image.pngBioEuropeMunich2023squareimageBioEuropeMunich2023squareimagehttps://www.veristat.com/hubfs/TOPRA%20logo%20(002).jpgTOPRAlogo002TOPRAlogo002https://www.veristat.com/hubfs/events/WODC%20US%2024/WODC%20US%2024%20%20image.pngWODCUS24imageWODCUS24imagehttps://www.veristat.com/hubfs/BIO%20Europe2024/Square%20picture%20Bio%20Europe.pngSquarepictureBioEuropeSquarepictureBioEuropehttps://www.veristat.com/hubfs/ASCO/ASCO%202025.pngASCO2025ASCO2025https://www.veristat.com/hubfs/v-stat-logo-only-sq.pngvstatlogoonlysqvstatlogoonlysqhttps://www.veristat.com/hubfs/SCOPE25/SCOPE%20LOGO%202025.pngSCOPELOGO2025SCOPELOGO2025https://www.veristat.com/hubfs/events/CPHI%202022%20square.jpgCPHI2022squareCPHI2022squarehttps://www.veristat.com/hubfs/endpoints-news-logo.jpgendpointsnewslogoendpointsnewslogohttps://www.veristat.com/hubfs/ASCGT%20Annual%20Meeting.pngASCGTAnnualMeetingASCGTAnnualMeetinghttps://www.veristat.com/hubfs/events/BioAsia_logo.jpgBioAsialogoBioAsialogohttps://www.veristat.com/hubfs/events/WODC%20EUROPE%2024/Image%20WODC%20%20Europe%20Square.pngImageWODCEuropeSquareImageWODCEuropeSquarehttps://www.veristat.com/hubfs/events/Life%20Science%20Dreamin%20image%20square.pngLifeScienceDreaminimagesquareLifeScienceDreaminimagesquarehttps://www.veristat.com/hubfs/German%20Days/German%20Days%20square%20image.pngGermanDayssquareimageGermanDayssquareimagehttps://www.veristat.com/hubfs/events/SwissBiotechDay/Swiss%20Biotech%20Day%20square%20image.pngSwissBiotechDaysquareimageSwissBiotechDaysquareimagehttps://www.veristat.com/hubfs/events/CROSummit.pngCROSummitCROSummithttps://www.veristat.com/hubfs/events/CITELINE%20WEBINAR%2023/Logo%20Citeline.pngLogoCitelineLogoCitelinehttps://www.veristat.com/hubfs/events/SFL%20Logo.jpgSFLLogoSFLLogohttps://www.veristat.com/hubfs/ASCO/ASCO%20image%20square.pngASCOimagesquareASCOimagesquarehttps://www.veristat.com/hubfs/Screenshot%202023-10-26%20at%204.39.05%20PM.pngScreenshot20231026at43905PMScreenshot20231026at43905PMhttps://www.veristat.com/hubfs/world%20vaccine%20congress%20logo.pngworldvaccinecongresslogoworldvaccinecongresslogohttps://www.veristat.com/hubfs/POST_Attendee-OCTNewEng-VZevallos_10.25-v02.jpgPOSTAttendeeOCTNewEngVZevallos1025v02POSTAttendeeOCTNewEngVZevallos1025v02https://www.veristat.com/hubfs/events/TOPRA%20SYMPOSIUM%2024/TOPRA%20SYMPOSIUM%20IMAGE-1.pngTOPRASYMPOSIUMIMAGE1TOPRASYMPOSIUMIMAGE1https://www.veristat.com/hubfs/SCOPE24/Square%20Logo%20SCOPE%20V2.pngSquareLogoSCOPEV2SquareLogoSCOPEV2https://www.veristat.com/hubfs/MEETIN%20ON%20THE%20MED/Meeting%20on%20the%20Med%20Logo%20square.pngMeetingontheMedLogosquareMeetingontheMedLogosquarehttps://www.veristat.com/hubfs/events/default-events-logo-100.pngdefaulteventslogo100defaulteventslogo100https://www.veristat.com/hubfs/events/BIOSPAIN23/BIO%20SPAIN%202023%20SQUARE.pngBIOSPAIN2023SQUAREBIOSPAIN2023SQUAREhttps://www.veristat.com/hubfs/xtalks_logo.webpxtalkslogoxtalkslogohttps://www.veristat.com/hubfs/events/ACDM%20Image%202023.pngACDMImage2023ACDMImage2023https://www.veristat.com/hubfs/events/Medtech2023/MedTech%20Pharma%202023%20Square%20Logo%20V2.pngMedTechPharma2023SquareLogoV2MedTechPharma2023SquareLogoV2https://www.veristat.com/hubfs/TOPRA%20Webinar%20On-Demand%20-%20Updated%20EU%20Regulations.pngTOPRAWebinarOnDemandUpdatedEURegulationsTOPRAWebinarOnDemandUpdatedEURegulationshttps://www.veristat.com/hubfs/clinical%20leader-rc.pngclinicalleaderrcclinicalleaderrchttps://www.veristat.com/hubfs/COG-CRO.pngCOGCROCOGCROhttps://www.veristat.com/hubfs/CMO%20Summit/CMO%20Summit%20image.pngCMOSummitimageCMOSummitimagehttps://www.veristat.com/hubfs/v-stat-logo-only-sq-1.pngvstatlogoonlysq1vstatlogoonlysq1https://www.veristat.com/hubfs/events/logo.jpglogologohttps://www.veristat.com/hubfs/events/Vaccine%20Congress%202023/World%20Vaccine%20Congress%20square%20image.pngWorldVaccineCongresssquareimageWorldVaccineCongresssquareimagehttps://www.veristat.com/hubfs/SCOPE%20Powering%20the%20Future%20of%20Clinical%20Research_Featured%20Image.pngSCOPEPoweringtheFutureofClinicalResearchFeaturedImageSCOPEPoweringtheFutureofClinicalResearchFeaturedImagehttps://www.veristat.com/hubfs/DTRA%20square%20(619%20%C3%97%20619%20px).pngDTRAsquare619619pxDTRAsquare619619pxhttps://www.veristat.com/hubfs/Marcus%20Evans%20Evolution%20logo.pngMarcusEvansEvolutionlogoMarcusEvansEvolutionlogohttps://www.veristat.com/hubfs/events/Logo%20Med%20Tech%20Forum%202023.pngLogoMedTechForum2023LogoMedTechForum2023https://www.veristat.com/hubfs/OCT%2025/oct%20image.jpgoctimageoctimagehttps://www.veristat.com/hubfs/TOPRA_Symposium_2025_400x400.pngTOPRASymposium2025400x400TOPRASymposium2025400x400https://www.veristat.com/hubfs/th-2.jpegth2th2https://www.veristat.com/hubfs/events/PHUSE%20US/phuse-logo.pngphuselogophuselogohttps://www.veristat.com/hubfs/regulatory_affairs_professionals_society_raps__logo.jpegregulatoryaffairsprofessionalssocietyrapslogoregulatoryaffairsprofessionalssocietyrapslogohttps://www.veristat.com/hubfs/events/ESMO%202023/ESMO%20Square%20image.pngESMOSquareimageESMOSquareimagehttps://www.veristat.com/hubfs/DIA%20EU%2025/DIA%20Europe%202025%20square%20image.png.jpgDIAEurope2025squareimagepngDIAEurope2025squareimagepnghttps://www.veristat.com/hubfs/social-channel_post-images/DIA.pngDIADIAhttps://www.veristat.com/hubfs/Veristat_ASH_FeaturedImage.pngVeristatASHFeaturedImageVeristatASHFeaturedImagehttps://www.veristat.com/hubfs/RAPS%20EURO%20CONVERGENCE.jpgRAPSEUROCONVERGENCERAPSEUROCONVERGENCEhttps://www.veristat.com/hubfs/events/TOPRA%20Webinar/TOPRA%20logo%20(002).jpgTOPRAlogo002TOPRAlogo002https://www.veristat.com/hubfs/GeneTherapy%2025/Gene%20Therapy%20and%20Rare%20US%202025%20Logo.jpgGeneTherapyandRareUS2025LogoGeneTherapyandRareUS2025Logohttps://www.veristat.com/hubfs/events/Life%20Science%20Webinar/Life%20Science%20Webinar.pngLifeScienceWebinarLifeScienceWebinarhttps://www.veristat.com/hubfs/events/SWAPP%2023/SWAPP%20Conf.%20Events.pngSWAPPConfEventsSWAPPConfEventshttps://www.veristat.com/hubfs/Conferences/BIO%20Europe%20Spring%20square%20image.pngBIOEuropeSpringsquareimageBIOEuropeSpringsquareimagehttps://www.veristat.com/hubfs/events/RAPS%20logo.jpgRAPSlogoRAPSlogohttps://www.veristat.com/hubfs/events/DIA.pngDIADIA2026-03-19https://www.veristat.com/instat-is-now-veristat/navigating-regulatory-challenges-in-biologics-a-case-study-in-overcoming-clinical-holds2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/dose-escalation-with-bayesian-strategies2026-06-23https://www.veristat.com/library/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-presentation2024-07-03https://www.veristat.com/library/planning-your-ind-when-and-why-to-engage-the-fda2025-06-19https://www.veristat.com/services/how-to-ensure-successful-fda-meeting-video-replay2026-06-15https://www.veristat.com/services/dose-escalation-with-bayesian-strategies2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/expertise-in-rna-therapies2026-06-23https://www.veristat.com/solutions/understanding-and-operationalizing-a-complex-adaptive-design2025-10-29https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-december-20242025-06-12https://www.veristat.com/services/sfl_is_now_veristat/development-of-a-covid-19-vaccine-challenges-for-data-managers2026-06-23https://www.veristat.com/library/marketing-application-fact-sheet2025-05-21https://www.veristat.com/solutions/presentation-how-to-better-plan-a-virtual-clinical-trial2025-06-12https://www.veristat.com/library/fda-guidance-on-dmcs-in-clinical-trials2024-09-05https://www.veristat.com/services/safety-tolerability-and-pharmacokinetics-of-a-single-orally-inhaled-dose-of-pur3100-a-dry-powder-formulation-of-dihydroergotamine-versus-intravenous-dihydroergotamine-a-phase-1-randomized-double-blind-study-in-healthy-adults2026-06-15https://www.veristat.com/sqn-is-veristathttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image1.jpgpeopleworkingimage1peopleworkingimage1https://www.veristat.com/hubfs/pv-experts-ICSR.jpgpvexpertsICSRpvexpertsICSRhttps://www.veristat.com/hubfs/email/asian_working%20team_300x200.jpgasianworkingteam300x200asianworkingteam300x200https://www.veristat.com/hubfs/people_working_image10.jpegpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/images_sizedat600px/people_working_image8.jpgpeopleworkingimage8peopleworkingimage8https://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapershttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/layout/page-images/people_working_woman_image3_opt1200px.jpgpeopleworkingwomanimage3opt1200pxpeopleworkingwomanimage3opt1200pxhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/clinical-care.jpgclinicalcareclinicalcare2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/replay-expanding-your-clinical-trial-into-the-us2026-06-23https://www.veristat.com/library/evaluating-adaptive-trials-do-they-align-with-your-studys-goals-and-requirements2025-03-18https://www.veristat.com/instat-is-now-veristat/fda-cders-accelerating-rare-disease-cures-arc-program2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/veristat-infographic2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/ind-planning-webinar-video-replay2026-06-23https://www.veristat.com/solutions/emergency-use-authorizations-blog2025-06-12https://www.veristat.com/solutions/similarities-and-differences-between-the-cta-and-ind2025-06-12https://www.veristat.com/services/clinical-operationshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Patient%20Retention.pngPatientRetentionPatientRetentionhttps://www.veristat.com/hubfs/images_sizedat600px/virtualtrials_homevisit1.jpgvirtualtrialshomevisit1virtualtrialshomevisit1https://www.veristat.com/hubfs/data_image_handipad_orginal-1.jpegdataimagehandipadorginal1dataimagehandipadorginal1https://www.veristat.com/hubfs/Project%20Management.pngProjectManagementProjectManagementhttps://www.veristat.com/hubfs/Clinical%20Operations.pngClinicalOperationsClinicalOperations2026-07-09https://www.veristat.com/solutions/covid-19-success-guide2025-06-12https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-march-20232026-06-23https://www.veristat.com/library-old/database-design-considerations-ig2024-06-27https://www.veristat.com/services/how-to-ensure-a-successful-fda-meeting-presentation-download2026-06-15https://www.veristat.com/library-old/why-and-when-to-hold-a-pre-ind-meeting-with-fda2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/biostatisticians-crucial-choreographers-behind-oncology-breakthroughs2026-06-23https://www.veristat.com/serviceshttps://www.veristat.com/hubfs/Web%20Page_Featured_Services%20Main.pngWebPageFeaturedServicesMainWebPageFeaturedServicesMainhttps://www.veristat.com/hubfs/layout/page-images/people_working_woman_image3_opt1200px.jpgpeopleworkingwomanimage3opt1200pxpeopleworkingwomanimage3opt1200pxhttps://www.veristat.com/hubfs/Risk%20Management_People%20Working_600x400.pngRiskManagementPeopleWorking600x400RiskManagementPeopleWorking600x400https://www.veristat.com/hubfs/pv-experts-ICSR.jpgpvexpertsICSRpvexpertsICSRhttps://www.veristat.com/hubfs/email/asian_working%20team_300x200.jpgasianworkingteam300x200asianworkingteam300x200https://www.veristat.com/hubfs/images_sizedat600px/people_working_image1.jpgpeopleworkingimage1peopleworkingimage1https://www.veristat.com/hubfs/images_sizedat600px/people_working_image8.jpgpeopleworkingimage8peopleworkingimage8https://www.veristat.com/hubfs/images_sizedat600px/people_working_image3_new.jpgpeopleworkingimage3newpeopleworkingimage3newhttps://www.veristat.com/hubfs/clinical-care.jpgclinicalcareclinicalcarehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/people_working_handsoverpapers.jpgpeopleworkinghandsoverpaperspeopleworkinghandsoverpapers2026-06-15https://www.veristat.com/library/understanding-the-impact-of-real-world-evidence-on-clinical-trials2025-03-27https://www.veristat.com/services/considerations-for-developing-rare-disease-treatments2026-06-15https://www.veristat.com/solutions/common-pitfalls-in-cell-therapy-studies2025-06-12https://www.veristat.com/services/biosimilar-fda-meeting-types2026-06-15https://www.veristat.com/solutions/orphan-drug-designations-and-orphan-subsets2025-06-12https://www.veristat.com/library/biosimilar-fda-meeting-types2024-07-03https://www.veristat.com/library/webinar-qa-how-to-advance-new-cancer-therapies-in-alignment-with-fda-project-frontrunner2024-07-03https://www.veristat.com/instat-is-now-veristat/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2026-06-23https://www.veristat.com/services/how-does-real-world-evidence-impact-medicinal-product-development-in-europe-blog2026-06-15https://www.veristat.com/library-old/is-your-trial-stuck2024-06-27https://www.veristat.com/ddr-is-now-veristathttps://www.veristat.com/hubfs/social-media-header.jpgsocialmediaheadersocialmediaheaderhttps://www.veristat.com/hubfs/Home%20Page_News%20Image_ART%202.pngHomePageNewsImageART2HomePageNewsImageART2https://www.veristat.com/hubfs/full-service-02.jpgfullservice02fullservice02https://www.veristat.com/hubfs/voyager-header-02.jpgvoyagerheader02voyagerheader02https://www.veristat.com/hubfs/full-service-01.jpgfullservice01fullservice01https://www.veristat.com/hubfs/clinical-care.jpgclinicalcareclinicalcarehttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/library/clinical-trials-meet-adaptive-design2025-10-22https://www.veristat.com/instat-is-now-veristat/marketing-application-publishing-best-practices2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/preparing-new-drug-application-ind2026-06-23https://www.veristat.com/contact-us-certuspvhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/different-approaches-for-preparing-marketing-applications2026-06-23https://www.veristat.com/instat-is-now-veristat/stem-cell-therapy-for-stroke-patients2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/early-data-strategy-building-todays-trial-for-tomorrows-scalable-success2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/rare-disease-fact-sheet2026-06-23https://www.veristat.com/solutions/multi-regional-clinical-trials-the-latest-guidance-from-fda2025-06-12https://www.veristat.com/solutions/future-trends-on-european-regulations-on-medicines2025-06-12https://www.veristat.com/library/real-world-considerations-when-administering-advanced-therapy-products2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/leveraging-fda-expedited-programs-webinar-replay2026-06-23https://www.veristat.com/solutions/understanding-the-impact-of-real-world-evidence-on-clinical-trials2025-06-12https://www.veristat.com/library/rapid-covid-19-phasei-vaccine-trial2024-07-03https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-october-20232026-06-23https://www.veristat.com/instat-is-now-veristat/fdas-project-frontrunner-explained2026-06-23https://www.veristat.com/library/veristats-most-downloaded-assets-of-20232024-07-03https://www.veristat.com/solutions/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis2025-08-01https://www.veristat.com/services/unlock-the-secrets-of-effective-sd-file-preparation-for-fda-submissions2026-06-15https://www.veristat.com/library-old/guiding-an-oncology-program-to-success2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/shortening-development-and-approval-timelines-for-novel-medicinal-products2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/overcoming-complexity-in-modern-clinical-trials2026-06-23https://www.veristat.com/services/fda-delays-push-biotech-companies-to-rethink-u.s.-drug-development-strategy2026-06-15https://www.veristat.com/instat-is-now-veristat/marketing-application-fact-sheet2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-february-20252026-06-23https://www.veristat.com/instat-is-now-veristat/meeting-the-challenges-of-the-moment2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-november-20242026-06-23https://www.veristat.com/instat-is-now-veristat/3-reasons-why-you-need-to-consider-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2026-06-23https://www.veristat.com/services/biostatisticians-crucial-choreographers-behind-oncology-breakthroughs2026-06-15https://www.veristat.com/solutions/veristats-most-downloaded-assets-of-20232025-06-12https://www.veristat.com/services/sfl_is_now_veristat/bridging-science-and-regulatory-success-with-medical-writing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/a-wearable-moment2026-06-23https://www.veristat.com/library/single-arm-registrational-studies-in-oncology-research2025-10-29https://www.veristat.com/library/bridging-science-and-regulatory-success-with-medical-writing2025-01-22https://www.veristat.com/solutions/staying-the-course-what-fda-staffing-reductions-mean-for-drug-development-today2025-06-12https://www.veristat.com/instat-is-now-veristat/veristat-works-well-with-growing-firms2026-06-23https://www.veristat.com/library/your-guide-to-mastering-cmc-regulatory-success-in-biotherapeutics-a-must-watch-webinar2024-07-03https://www.veristat.com/library/accelerating-oncology-breakthroughs2025-06-12https://www.veristat.com/instat-is-now-veristat/beyond-detection-how-ctdna-could-optimize-treatment-selection2026-06-23https://www.veristat.com/solutions/new-tumor-evaluation-modality2025-06-12https://www.veristat.com/services/data-driven-strategies-to-advance-development-and-approval-of-rareultra-rare-disease-therapies2026-06-15https://www.veristat.com/library-old/marketing-application-operational-timeline-complexities2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/veristat-achieves-ecovadis-committed-badge-a-milestone-in-our-sustainability-journey2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-fact-sheet2026-06-23https://www.veristat.com/library/veristat-fact-sheet2024-07-03https://www.veristat.com/library/common-pitfalls-to-avoid-when-planning-a-marketing-application-for-cell-and-gene-therapies2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/decentralized-trial-solutions-for-complex-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/weighing-the-suitability-of-a-functional-service-provider-fsp-model-for-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/accelerating-clinical-trial-design-and-operations2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/may-oncology-voyager-facing-global-oncology-clinical-development-hurdles2026-06-23https://www.veristat.com/services/neurology-psychiatry-fact-sheet2026-06-15https://www.veristat.com/instat-is-now-veristat/rescuing-site-monitoring-success2026-06-23https://www.veristat.com/instat-is-now-veristat/pharmacovigilance-customer-vignettes2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/early-detection-vs.-overdiagnosis-the-ctdna-screening-paradox2026-06-23https://www.veristat.com/library/how-to-ensure-a-successful-fda-meeting-presentation-download2024-07-03https://www.veristat.com/company/leadership-teamhttps://www.veristat.com/hubfs/John-P-Balser-2019.webpJohnPBalser2019JohnPBalser2019https://www.veristat.com/hubfs/CLint_Headshot_webiste.jpgCLintHeadshotwebisteCLintHeadshotwebistehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/ChatGPT%20Image%20Jun%2023%2c%202026%2c%2004_20_37%20PM.pngChatGPTImageJun232026042037PMChatGPTImageJun232026042037PMhttps://www.veristat.com/hubfs/Our%20Leadership.pngOurLeadershipOurLeadershiphttps://www.veristat.com/hubfs/large-KBoericke_768x512.pnglargeKBoericke768x512largeKBoericke768x512https://www.veristat.com/hubfs/Demetrius-Carter.jpgDemetriusCarterDemetriusCarterhttps://www.veristat.com/hubfs/Barbara-Balser-1.jpegBarbaraBalser1BarbaraBalser1https://www.veristat.com/hubfs/large-AJ-Mills-768x512-02.pnglargeAJMills768x51202largeAJMills768x51202https://www.veristat.com/hubfs/large-Josh-Korth_768x512.pnglargeJoshKorth768x512largeJoshKorth768x5122026-06-24https://www.veristat.com/library/the-compound-effect-of-specialized-knowledge2026-02-26https://www.veristat.com/services/guiding-an-emerging-biotechs-first-phase-i-oncology-trial2026-06-15https://www.veristat.com/services/regulatory-submission-fact-sheet2026-06-15https://www.veristat.com/services/exploring-future-trends-on-european-regulations-a-webinar-by-veristat-and-topra2026-06-15https://www.veristat.com/solutions/regulatory-submission-infographic2025-06-12https://www.veristat.com/library/pharmacovigilance-fact-sheet2024-07-03https://www.veristat.com/library/executing-patient-focused-drug-development-pfdd2024-07-03https://www.veristat.com/services/successful-swissmedic-marketing-authorization-application-for-an-oncology-therapy2026-06-15https://www.veristat.com/library/3-reasons-why-you-need-to-consider-a-cro-that-excels-in-oncology-regulatory-publishing2025-09-25https://www.veristat.com/services/migration-of-data-between-edcs-blog2026-06-15https://www.veristat.com/library/supporting-global-approval-of-a-first-in-classgene-therapy-for-a-rare-genetic-disorder2026-02-06https://www.veristat.com/library-old/rescue-patient-recruitment-for-lagging-trial2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/from-strategy-to-submission-end-to-end-clinical-biometrics-and-regulatory-support-in-neurology2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-may-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/exceeding-expectations-for-patient-enrollment-case-study2026-06-23https://www.veristat.com/library-old/veristat-fact-sheet2024-06-27https://www.veristat.com/solutions/natural-history-study-best-practices-for-engaging-regulatory-authorities2025-06-12https://www.veristat.com/services/may-oncology-voyager-facing-global-oncology-clinical-development-hurdles2026-06-15https://www.veristat.com/library/post-submission-ind-maintenance-veristat-as-u.s.-agent2025-08-05https://www.veristat.com/instat-is-now-veristat/medical-writing-fact-sheet2026-06-23https://www.veristat.com/solutions/regulatory-guidance-monthly-review-april-20232025-06-12https://www.veristat.com/services/sfl_is_now_veristat/pooled-analysis-of-the-phase-3-revive-trials2026-06-23https://www.veristat.com/library-old/biomarker-driven-adaptive-design-for-precision-medicine2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/single-arm-registrational-studies-in-oncology-research2026-06-23https://www.veristat.com/services/blog-nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-15https://www.veristat.com/library-old/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2024-06-27https://www.veristat.com/solutions/future-glances-more-change-more-tech-more-harmonisation2025-12-16https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-may-20252026-06-15https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-september-20242026-06-23https://www.veristat.com/services/sfl_is_now_veristat/lessons-learned-for-better-planning-of-decentralized-clinical-trials2026-06-23https://www.veristat.com/services/the-ctdna-clinical-trial-advantage-why-cro-work-puts-you-on-the-cutting-edge2026-06-15https://www.veristat.com/instat-is-now-veristat/marketing-applications-approval-record2026-06-23https://www.veristat.com/solutions/emergency-use-authorizations2025-06-12https://www.veristat.com/library/fspresourcing-meeting-the-moment-with-expert-resources2024-07-03https://www.veristat.com/library/how-does-real-world-evidence-impact-medicinal-product-development-in-europe2024-07-03https://www.veristat.com/rare-disease-cro/writing-multiple-marketing-applications-at-the-same-time2022-09-07https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-september-20242026-06-15https://www.veristat.com/instat-is-now-veristat/keeping-up-with-an-over-performing-site-case-study2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/solutions-to-accelerate-cell-and-gene-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-february-20242026-06-23https://www.veristat.com/solutions/supporting-a-sponsor-from-spa-rejection-to-bla-submission2025-06-12https://www.veristat.com/solutions/navigating-regulatory-challenges-in-biologics-a-case-study-in-overcoming-clinical-holds2025-06-12https://www.veristat.com/solutions/virtual-hybrid-clinical-trials2025-06-12https://www.veristat.com/instat-is-now-veristat/webinar-roadmap-to-market-cell-and-gene-therapies2026-06-23https://www.veristat.com/instat-is-now-veristat/blog-nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/different-approaches-for-preparing-a-marketing-application2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-december-20242026-06-15https://www.veristat.com/instat-is-now-veristat/european-medicines-and-medical-devices-future-trends2026-06-23https://www.veristat.com/solutions/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2025-06-12https://www.veristat.com/solutions/rapid-covid-19-phasei-vaccine-trial2025-06-12https://www.veristat.com/clinical-trial-planninghttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_protocol-216.pngVeristaticonprotocol216Veristaticonprotocol216https://www.veristat.com/hubfs/Clinical%20Trial%20Planning.pngClinicalTrialPlanningClinicalTrialPlanninghttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_medical%20writing-216.pngVeristaticonmedicalwriting216Veristaticonmedicalwriting216https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_experience-216.pngVeristaticonexperience216Veristaticonexperience216https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_timing-calendar-date-216.pngVeristaticontimingcalendardate216Veristaticontimingcalendardate2162026-07-10https://www.veristat.com/services/sfl_is_now_veristat/the-evolving-landscape-of-radiopharmaceuticals-in-oncology-research2026-06-23https://www.veristat.com/library/what-is-the-future-landscape-of-cell-gene-therapies-replay2024-07-03https://www.veristat.com/library/regulatory-considerations-for-biosimilars-development-in-the-us2024-07-03https://www.veristat.com/sqn-clinical-joins-veristat/purpose-of-ind-ig2024-07-03https://www.veristat.com/library/clinical-development-support-for-multiple-alzheimers-and-parkinsons-studies2025-10-23https://www.veristat.com/services/sfl_is_now_veristat/understanding-data-monitoring-committees2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/fdas-project-frontrunner-explained2026-06-23https://www.veristat.com/solutions/accelerating-clinical-trial-design-and-operations2025-06-12https://www.veristat.com/library/regulatory-guidance-monthly-review-may-20232024-07-03https://www.veristat.com/services/accelerating-patient-centric-clinical-trials-three-key-takeaways-for-smarter-design-and-execution2026-06-15https://www.veristat.com/library-old/collaborating-together-for-rare-disease2024-06-27https://www.veristat.com/instat-is-now-veristat/common-pitfalls-in-cell-therapy-studies2026-06-23https://www.veristat.com/instat-is-now-veristat/bayesian-study-designs-in-early-phase-oncology-trials2026-06-23https://www.veristat.com/services/conducting-clinical-trials-in-a-virtual-world2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-february-20232026-06-23https://www.veristat.com/services/exceeding-expectations-for-patient-enrollment-case-study2026-06-15https://www.veristat.com/instat-is-now-veristat/regulatory-considerations-for-biosimilars-development-in-the-us-blog2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/unleashing-flexibility-in-a-rare-disease-gene-therapy-clinical-trial2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/elevating-cns-drug-development-veristats-agile-approach-in-medical-writing-and-project-management2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/2026-cell-and-gene-therapy-predictions2026-06-23https://www.veristat.com/instat-is-now-veristat/cmc-sd-files-for-regulatory-submissions2026-06-23https://www.veristat.com/solutions/guiding-an-emerging-biotechs-first-phase-i-oncology-trial2025-10-08https://www.veristat.com/library/marketing-application-medical-writing-strategies2024-07-03https://www.veristat.com/library/regulatory-guidance-monthly-review-september-20232024-07-03https://www.veristat.com/instat-is-now-veristat/considerations-for-developing-rare-disease-treatments2026-06-23https://www.veristat.com/library/fda-expedited-programs-what-you-need-to-know2025-11-07https://www.veristat.com/solutions/natural-history-studieshttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_data%20manager.pngVeristaticondatamanagerVeristaticondatamanagerhttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_gene%20therapy.pngVeristaticongenetherapyVeristaticongenetherapyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons-2020/Veristat_icon_clinical%20operations.pngVeristaticonclinicaloperationsVeristaticonclinicaloperationshttps://www.veristat.com/hubfs/Icons-2020/Veristat_icon_enrollment.pngVeristaticonenrollmentVeristaticonenrollmenthttps://www.veristat.com/hubfs/Natural%20History%20Trials-2.pngNaturalHistoryTrials2NaturalHistoryTrials2https://www.veristat.com/hubfs/HubDB_HowDoesRWEImpactClinicalTrials.pngHubDBHowDoesRWEImpactClinicalTrialsHubDBHowDoesRWEImpactClinicalTrialshttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2025-09-24https://www.veristat.com/library/fda-introduces-new-term-nonclinical-tests-signaling-a-beginning-not-an-end2024-07-03https://www.veristat.com/library/global-pediatric-full-service-phase-iii-clinical-trial-begins-on-heels-of-successful-natural-history-study2024-07-03https://www.veristat.com/services/clinical-operations/project-managementhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Project%20Management-1.pngProjectManagement1ProjectManagement1https://www.veristat.com/hubfs/layout/cards/collaboration_image_handsoverpapers_opt1024px.jpgcollaborationimagehandsoverpapersopt1024pxcollaborationimagehandsoverpapersopt1024pxhttps://www.veristat.com/hubfs/Veristat_Clinical%20Development%20Support_HubDB%20Image.pngVeristatClinicalDevelopmentSupportHubDBImageVeristatClinicalDevelopmentSupportHubDBImage2026-07-10https://www.veristat.com/services/neurology-fact-sheet2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/advancing-dose-escalation-strategies-with-bayesian-modeling2026-06-23https://www.veristat.com/services/elevating-cns-drug-development-veristats-agile-approach-in-medical-writing-and-project-management2026-06-15https://www.veristat.com/solutions/rapid-response-to-ebola-outbreak2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/quick-feasibility-assessment-to-expand-trial-into-europe-case-study2026-06-23https://www.veristat.com/instat-is-now-veristat/advancing-to-your-next-milestone-global-regulatory-excellence-throughout-theentire-clinical-development-lifecycle2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/integrated-dct-solutions-for-complex-studies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/cross-functional-collaboration-a-cornerstone-of-successful-clinical-development2026-06-23https://www.veristat.com/library/data-driven-strategies-to-advance-development-and-approval-of-rareultra-rare-disease-therapies2026-02-26https://www.veristat.com/library/updated-future-trends-on-european-regulations-on-medicines2024-07-03https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-october-20242026-06-15https://www.veristat.com/services/sfl_is_now_veristat/navigating-clinical-trials-with-precision-enhancing-dmc-services-through-veristats-expert-biostatistics2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/mastering-a-global-approach-to-solving-the-complexities-of-successful-medical-writing2026-06-23https://www.veristat.com/library/leveraging-fda-expedited-programs-webinar-presentation2024-07-03https://www.veristat.com/solutions/resourcingfsp-model2025-06-12https://www.veristat.com/instat-is-now-veristat/single-arm-studies-for-use-as-a-registrational-study-in-oncology-replay2026-06-23https://www.veristat.com/services/updated-future-trends-on-european-regulations-on-medicines2026-06-15https://www.veristat.com/services/regulatory-affairs/regulatory-agency-meeting-supporthttps://www.veristat.com/hubfs/The%20Psychedelic%20Setback_%20What%20the%20MDMA%20Rejection%20Taught%20Drug%20Developers.jpgThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopersThePsychedelicSetbackWhattheMDMARejectionTaughtDrugDevelopershttps://www.veristat.com/hubfs/image-png-May-10-2023-05-17-53-7325-PM.pngimagepngMay1020230517537325PMimagepngMay1020230517537325PMhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat-December-2024-Global-Reach%20(1).webpVeristatDecember2024GlobalReach1VeristatDecember2024GlobalReach1https://www.veristat.com/hubfs/Agency%20Meetings.pngAgencyMeetingsAgencyMeetingshttps://www.veristat.com/hubfs/Infographic_FDAMeetingTypes.pngInfographicFDAMeetingTypesInfographicFDAMeetingTypes2025-06-12https://www.veristat.com/services/common-pitfalls-in-cell-therapy-studies2026-06-15https://www.veristat.com/library-old/marketing-application-key-planning-tips2024-06-27https://www.veristat.com/services/the-compound-effect-of-specialized-knowledge2026-06-15https://www.veristat.com/services/cmc-pitfalls-from-benchtop-to-ind-blog2026-06-15https://www.veristat.com/instat-is-now-veristat/are-autologous-therapies-here-to-stay-are-allogeneic-therapies-the-future2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/minimizing-complexity-in-oncology-clinical-trials2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-december-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/successful-swissmedic-marketing-authorization-application-for-an-oncology-therapy2026-06-23https://www.veristat.com/library/writing-multiple-marketing-applications-at-the-same-time2024-07-03https://www.veristat.com/solutions/the-benefits-of-a-central-site-model2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/veristats-most-downloaded-assets-of-20232026-06-23https://www.veristat.com/instat-is-now-veristathttps://www.veristat.com/hubfs/images_sizedat600px/people_working_woman_image3_opt1200px.webppeopleworkingwomanimage3opt1200pxpeopleworkingwomanimage3opt1200pxhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/FeaturedImages/Instat%20is%20Now%20Veristat%20-LP.pngInstatisNowVeristatLPInstatisNowVeristatLPhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image11.jpgpeopleworkingimage11peopleworkingimage11https://www.veristat.com/hubfs/images_sizedat600px/people_working_image3_new.jpgpeopleworkingimage3newpeopleworkingimage3newhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image16_virtualmeeting_600px.jpgpeopleworkingimage16virtualmeeting600pxpeopleworkingimage16virtualmeeting600pxhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_image8.jpgpeopleworkingimage8peopleworkingimage8https://www.veristat.com/hubfs/images_sizedat600px/data_handsenteringdata_darkblue.jpgdatahandsenteringdatadarkbluedatahandsenteringdatadarkbluehttps://www.veristat.com/hubfs/images_sizedat600px/asian_working%20team_300x200.webpasianworkingteam300x200asianworkingteam300x200https://www.veristat.com/hubfs/images_sizedat600px/people_working_image7.jpgpeopleworkingimage7peopleworkingimage72026-06-23https://www.veristat.com/instat-is-now-veristat/overcoming-challenges-in-orphan-drug-development2026-06-23https://www.veristat.com/library/ind-success-strategy-building-a-high-quality-ind-from-scratch-with-strategic-gap-analysis-blog2025-08-28https://www.veristat.com/solutions/indication-selection-using-adaptive-design2025-06-25https://www.veristat.com/chelsey_breau_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/fda-meeting-types2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-key-planning-tips2026-06-23https://www.veristat.com/instat-is-now-veristat/data-collection-efficiency-for-a-novel-anti-infective-therapy2026-06-23https://www.veristat.com/library/ensuring-regulatory-success-from-pre-ind-through-to-submission2024-07-03https://www.veristat.com/instat-is-now-veristat/supporting-global-approval-of-a-first-in-classgene-therapy-for-a-rare-genetic-disorder2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-june-20252026-06-23https://www.veristat.com/services/clinical-operations/monitoringhttps://www.veristat.com/hubfs/content-resource-thumbs-2020/regulatory-submission-expertise.jpgregulatorysubmissionexpertiseregulatorysubmissionexpertisehttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/review-of-successful-NDA-prep.jpgreviewofsuccessfulNDAprepreviewofsuccessfulNDAprephttps://www.veristat.com/hubfs/FactSheet_Veristat.pngFactSheetVeristatFactSheetVeristathttps://www.veristat.com/hubfs/layout/cards/data_image_handipad_opt_1024px.jpgdataimagehandipadopt1024pxdataimagehandipadopt1024pxhttps://www.veristat.com/hubfs/layout/cards/data_image_datareview_opt1024px.jpgdataimagedatareviewopt1024pxdataimagedatareviewopt1024px2026-07-10https://www.veristat.com/instat-is-now-veristat/expert-ind-publishing2026-06-23https://www.veristat.com/services/vaccines-fact-sheet2026-06-15https://www.veristat.com/solutions/single-arm-studies-for-use-as-a-registrational-study-in-oncology-article2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/roadmap-to-market-for-cell-and-gene-therapies2026-06-23https://www.veristat.com/solutions/regulatory-medical-device-ivd-fact-sheet2025-06-12https://www.veristat.com/services/a-wearable-moment2026-06-15https://www.veristat.com/instat-is-now-veristat/addressing-drug-developer-challenges-with-decentralized-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/accelerating-patient-centric-clinical-trials-three-key-takeaways-for-smarter-design-and-execution2026-06-23https://www.veristat.com/library/veristat-global-policy-insights-q1-20242024-07-03https://www.veristat.com/services/sfl_is_now_veristat/accelerate-neurologypsychiatry-trial-success-with-expert-guidance2026-06-23https://www.veristat.com/library/regulatory-guidance-monthly-review-november-20232024-07-03https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-november-20252026-01-06https://www.veristat.com/instat-is-now-veristat/vaccines-fact-sheet2026-06-23https://www.veristat.com/solutions/on-demand-webinar-decentralized-trial-solutions-for-complex-clinical-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development-blog2026-06-23https://www.veristat.com/services/migration-of-data-between-edcs2026-06-15https://www.veristat.com/solutions/a-roundup-of-perspectives-and-predictions-on-research-misconduct-inclusivity-ai-and-more2025-12-16https://www.veristat.com/instat-is-now-veristat/preparing-new-drug-application-ind2026-06-23https://www.veristat.com/instat-is-now-veristat/the-rise-of-decentralized-clinical-trials-transforming-research-through-technology-and-patient-centricity2026-06-23https://www.veristat.com/library/a-comprehensive-planning-approach-for-cancer-antibody2024-07-03https://www.veristat.com/library/efficient-regulatory-publishing-for-large-scale-fda-submission2026-02-06https://www.veristat.com/instat-is-now-veristat/what-is-the-future-cell-gene-presentation2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/the-importance-of-regulatory-project-management2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-july-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/marketing-application-best-practices-for-publishing2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/webinar-achieving-balance-in-database-design2026-06-23https://www.veristat.com/instat-is-now-veristat/demystifying-ectd-4.0-what-you-need-to-know2026-06-23https://www.veristat.com/library/orphan-medicinal-products-in-the-eu-integrated-available-tools-for-their-development2024-07-03https://www.veristat.com/instat-is-now-veristat/successful-preparation-strategies-for-nda-maa-marketing-applications2026-06-23https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-october-20252026-01-05https://www.veristat.com/instat-is-now-veristat/rapid-response-to-ebola-outbreak2026-06-23https://www.veristat.com/instat-is-now-veristat/wholistic-approach-to-strategic-consulting2026-06-23https://www.veristat.com/solutions/monthly-fda-guidance-and-regulatory-news-review-may-20252025-06-12https://www.veristat.com/services/biostats-programming-fact-sheet2026-06-15https://www.veristat.com/pharmacovigilancehttps://www.veristat.com/hubfs/call_center_image4.jpegcallcenterimage4callcenterimage4https://www.veristat.com/hubfs/Risk%20Management_People%20Working_600x400.pngRiskManagementPeopleWorking600x400RiskManagementPeopleWorking600x400https://www.veristat.com/hubfs/people_working_image10.jpegpeopleworkingimage10peopleworkingimage10https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Pharmacovigilance-1.pngPharmacovigilance1Pharmacovigilance1https://www.veristat.com/hubfs/images_sizedat600px/people_working_Hands%20on%20laptop%20with%20Coffee.jpgpeopleworkingHandsonlaptopwithCoffeepeopleworkingHandsonlaptopwithCoffeehttps://www.veristat.com/hubfs/Project%20Management.pngProjectManagementProjectManagementhttps://www.veristat.com/hubfs/images_sizedat600px/people_working_manwithbeard_movember.jpgpeopleworkingmanwithbeardmovemberpeopleworkingmanwithbeardmovemberhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-07-10https://www.veristat.com/library/a-creative-approach-to-achieving-an-aggressive-nda-timeline2025-10-08https://www.veristat.com/instat-is-now-veristat/the-next-leap-in-alzheimers-rd-is-coming2026-06-23https://www.veristat.com/services/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2026-06-15https://www.veristat.com/services/regulatory-guidance-monthly-review-march-20232026-06-15https://www.veristat.com/therapeutic-expertise/covid-19https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_vaccine_image11.jpgtherapeuticvaccineimage11therapeuticvaccineimage11https://www.veristat.com/hubfs/COVID19_TA%20page.pngCOVID19TApageCOVID19TApagehttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image15.jpgtherapeuticimage15therapeuticimage15https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/COVID19-1.pngCOVID191COVID191https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedPrograms2025-06-12https://www.veristat.com/solutions/data-driven-strategies-to-advance-development-and-approval-of-rareultra-rare-disease-therapies2026-02-26https://www.veristat.com/instat-is-now-veristat/global-pediatric-full-service-phase-iii-clinical-trial-begins-on-heels-of-successful-natural-history-study2026-06-23https://www.veristat.com/kathleen_boruchowski_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2019-11-14https://www.veristat.com/library/dose-escalation-with-bayesian-strategies2025-06-25https://www.veristat.com/library/running-successful-clinical-programs-external-biostatistics-team2024-07-03https://www.veristat.com/solutions/a-patient-centric-apprach-to-recruitment-and-retention22025-06-12https://www.veristat.com/services/sfl_is_now_veristat/webinar-roadmap-to-market-cell-and-gene-therapies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-medical-device-ivd-fact-sheet2026-06-23https://www.veristat.com/solutions/ensuring-patient-safety-and-data-integrity-with-veristats-dmc-expertise2025-06-12https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-june-20252026-06-15https://www.veristat.com/services/timeline-mastery-the-strategic-backbone-of-marketing-application-success2026-06-15https://www.veristat.com/library/7-habits-of-highly-successful-medical-writers2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2026-06-23https://www.veristat.com/services/marketing-applications-approval-record2026-06-15https://www.veristat.com/services/biostatisticians-ensuring-the-validity-reliability-and-interpretability-of-clinical-trial-data2026-06-15https://www.veristat.com/library/database-design-considerations-ig2024-07-03https://www.veristat.com/solutions/randomized-phase-2-study-of-cbp501-cisplatin-and-nivolumab-as-3rd-line-treatment-for-exocrine-pancreatic-cancer-patients-with-white-blood-cell-count-wbc-10000mm32025-06-12https://www.veristat.com/instat-is-now-veristat/draft-mhpd-guidance-reporting-adverse-events-marketed-products-presentation2026-06-23https://www.veristat.com/services/bayesian-study-designs-in-early-phase-oncology-trials2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/meeting-the-challenges-of-the-moment2026-06-23https://www.veristat.com/library/presentation-expanding-your-clinical-trial-into-the-us2024-07-03https://www.veristat.com/patient-retention-and-site-engagementhttps://www.veristat.com/hubfs/layout/page-images/Clinical%20Trial%20Study%20Branding_Digital%20and%20Web%20Media.jpgClinicalTrialStudyBrandingDigitalandWebMediaClinicalTrialStudyBrandingDigitalandWebMediahttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/layout/page-images/Clinical%20Trial%20Study%20Material%20Branding.jpgClinicalTrialStudyMaterialBrandingClinicalTrialStudyMaterialBrandinghttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Patient%20Retention-1.pngPatientRetention1PatientRetention1https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/HubDB_Card%20Image_Podcast_Big4Bio%20DCT.pngHubDBCardImagePodcastBig4BioDCTHubDBCardImagePodcastBig4BioDCT2025-06-12https://www.veristat.com/solutions/regulatory-guidance-monthly-review-may-20232025-06-12https://www.veristat.com/services/sfl_is_now_veristat/post-submission-ind-maintenance-veristat-as-u.s.-agent2026-06-23https://www.veristat.com/solutions/regulatory-guidance-monthly-review-december-20232025-06-12https://www.veristat.com/solutions/preserving-what-matters-how-institutional-knowledge-protects-value-through-ma2026-01-09https://www.veristat.com/solutions/weighing-the-suitability-of-a-functional-service-provider-fsp-model-for-clinical-trials2025-06-12https://www.veristat.com/library/data-management-fact-sheet2025-05-21https://www.veristat.com/library/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2024-07-03https://www.veristat.com/services/cancer-research-trends-key-asco-2024-takeaways2026-06-15https://www.veristat.com/instat-is-now-veristat/similarities-and-differences-between-the-cta-and-ind2026-06-23https://www.veristat.com/solutions/single-arm-studies-for-use-as-a-registrational-study-in-oncology-replay2025-06-12https://www.veristat.com/resources/articles-whitepapershttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2018-09-20https://www.veristat.com/library/monthly-fda-guidance-and-regulatory-news-review-november-20242025-03-13https://www.veristat.com/instat-is-now-veristat/ensuring-patient-safety-and-data-integrity-with-veristats-dmc-expertise2026-06-23https://www.veristat.com/instat-is-now-veristat/regulatory-guidance-monthly-review-january-20232026-06-23https://www.veristat.com/instat-is-now-veristat/different-approaches-for-preparing-a-marketing-application2026-06-23https://www.veristat.com/instat-is-now-veristat/biostatisticians-ensuring-the-validity-reliability-and-interpretability-of-clinical-trial-data2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-january-20262026-06-23https://www.veristat.com/services/an-introduction-to-natural-history-studies2026-06-15https://www.veristat.com/solutions/mastering-a-global-approach-to-solving-the-complexities-of-successful-medical-writing2025-06-12https://www.veristat.com/library/overcoming-challenges-in-orphan-drug-development2024-07-03https://www.veristat.com/solutions/strategic-clinical-development-consulting2025-06-12https://www.veristat.com/solutions/clinical-development-support-for-multiple-alzheimers-and-parkinsons-studies2025-10-23https://www.veristat.com/library/reflections-from-asco-20252025-06-18https://www.veristat.com/services/advancing-dose-escalation-strategies-with-bayesian-modeling2026-06-15https://www.veristat.com/instat-is-now-veristat/unleashing-flexibility-in-a-rare-disease-gene-therapy-clinical-trial2026-06-23https://www.veristat.com/library-old/successful-preparation-strategies-for-nda-maa-marketing-applications2024-06-27https://www.veristat.com/services/sfl_is_now_veristat/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-presentation2026-06-23https://www.veristat.com/library/meeting-the-challenges-of-the-moment2024-07-03https://www.veristat.com/library-old/7-habits-of-highly-successful-medical-writers2024-06-27https://www.veristat.com/solutions/decentralized-solutions-for-complex-clinical-trails2025-06-12https://www.veristat.com/library/regulatory-guidance-monthly-review-january-20232024-07-03https://www.veristat.com/library/a-scientific-approach-to-advance-your-novel-cancer-therapies2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2026-06-23https://www.veristat.com/solutions/addressing-drug-developer-challenges-with-decentralized-clinical-trials2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/a-roundup-of-perspectives-and-predictions-on-research-misconduct-inclusivity-ai-and-more2026-06-23https://www.veristat.com/services/planning-for-a-successful-initial-ind-and-moving-beyond2026-06-15https://www.veristat.com/solutions/advancing-oncology-innovation-with-adaptive-trial-designs2026-01-13https://www.veristat.com/instat-is-now-veristat/study-collaboration-for-successful-covid-19-vaccine-program2026-06-23https://www.veristat.com/library/delivering-data-that-matters-an-integrated-approach-to-biostatistics-data-management-statistical-programming-in-clinical-trials2025-09-03https://www.veristat.com/instat-is-now-veristat/vaccine-clinical-trial-showcase-phase-2b-hipra-study-against-covid-19-presented-by-veristat2026-06-23https://www.veristat.com/instat-is-now-veristat/evaluating-adaptive-trials-do-they-align-with-your-studys-goals-and-requirements2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/regulatory-guidance-monthly-review-january-20242026-06-23https://www.veristat.com/library-old/replay-how-to-better-plan-a-virtual-clinical-trial2024-06-27https://www.veristat.com/solutions/evaluating-adaptive-trials-do-they-align-with-your-studys-goals-and-requirements2025-06-12https://www.veristat.com/instat-is-now-veristat/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2026-06-23https://www.veristat.com/solutions/what-is-the-future-landscape-of-cell-gene-therapies-replay2025-06-12https://www.veristat.com/services/regulatory-guidance-monthly-review-june-20232026-06-15https://www.veristat.com/services/draft-mhpd-guidance-reporting-adverse-events-marketed-products-webinar-on-demand2026-06-15https://www.veristat.com/library/trends-in-oncology-regulation-fda-draft-guidance-on-os-and-radiopharmaceuticals2025-08-28https://www.veristat.com/solutions/3-reasons-why-you-need-to-consider-a-cro-that-excels-in-oncology-regulatory-publishing2025-09-25https://www.veristat.com/solutions/cross-functional-collaboration-a-cornerstone-of-successful-clinical-development2025-07-10https://www.veristat.com/library/safety-tolerability-and-pharmacokinetics-of-a-single-orally-inhaled-dose-of-pur3100-a-dry-powder-formulation-of-dihydroergotamine-versus-intravenous-dihydroergotamine-a-phase-1-randomized-double-blind-study-in-healthy-adults2024-07-03https://www.veristat.com/services/shortening-development-and-approval-timelines-for-novel-medicinal-products2026-06-15https://www.veristat.com/library/use-of-pro-in-cell-and-gene-therapy-studies2024-07-03https://www.veristat.com/instat-is-now-veristat/considerations-for-natural-history-studies2026-06-23https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-november-20252026-06-15https://www.veristat.com/solutions/7-habits-of-highly-successful-medical-writers2025-06-12https://www.veristat.com/library-old/an-introduction-to-natural-history-studies2024-06-27https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-march-20252026-06-23https://www.veristat.com/services/sfl_is_now_veristat/delivering-data-that-matters-an-integrated-approach-to-biostatistics-data-management-statistical-programming-in-clinical-trials2026-06-23https://www.veristat.com/services/driving-multiple-global-gene-therapy-studies2026-06-15https://www.veristat.com/instat-is-now-veristat/veristat-expands-global-regulatory-expertise2026-06-23https://www.veristat.com/instat-is-now-veristat/minimizing-complexity-in-oncology-clinical-trials2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/presentation-how-to-better-plan-a-virtual-clinical-trial2026-06-23https://www.veristat.com/solutions/expert-ind-publishing2025-06-12https://www.veristat.com/regulatory-submissionhttps://www.veristat.com/hubfs/images_sizedat600px/call_center_image2.jpgcallcenterimage2callcenterimage2https://www.veristat.com/hubfs/Regulatory%20Submission.pngRegulatorySubmissionRegulatorySubmissionhttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_telemedicine-216.pngVeristaticontelemedicine216Veristaticontelemedicine216https://www.veristat.com/hubfs/Veristat_Marketing%20Applications.pngVeristatMarketingApplicationsVeristatMarketingApplicationshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_medical%20writing-216.pngVeristaticonmedicalwriting216Veristaticonmedicalwriting216https://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_protocol-216.pngVeristaticonprotocol216Veristaticonprotocol2162026-07-09https://www.veristat.com/services/sfl_is_now_veristat/successful-ind-submission-paves-the-way-for-a-global-full-service-phase-i-clinical-trial-targeting-cancers2026-06-23https://www.veristat.com/services/medical-affairs/safety-pharmacovigilancehttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/images_sizedat600px/people_working_manwithbeard_movember.jpgpeopleworkingmanwithbeardmovemberpeopleworkingmanwithbeardmovemberhttps://www.veristat.com/hubfs/Icons_2021_sized%20216x216px/Veristat_icon_medical%20affairs-216.pngVeristaticonmedicalaffairs216Veristaticonmedicalaffairs216https://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Clinical%20Trial%20Safety.pngClinicalTrialSafetyClinicalTrialSafetyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412026-07-10https://www.veristat.com/library/navigating-the-ind-submission-labyrinth-a-veristat-success-story2024-07-03https://www.veristat.com/instat-is-now-veristat/marketing-application-best-practices-for-publishing2026-06-23https://www.veristat.com/solutions/regulatory-guidance-monthly-review-november-20232025-06-12https://www.veristat.com/solutions/real-world-considerations-when-administering-advanced-therapy-products2025-06-12https://www.veristat.com/hematology-and-blood-cancer-clinical-trial-and-regulatory-submission-experience/achieving-an-aggressive-nda-timeline2024-07-03https://www.veristat.com/instat-is-now-veristat/your-guide-to-mastering-cmc-regulatory-success-in-biotherapeutics-a-must-watch-webinar2026-06-23https://www.veristat.com/services/selecting-the-right-oncology-cro-partner2026-06-15https://www.veristat.com/services/measuring-what-cant-be-seen-how-ptsd-clinical-trials-prove-a-drug-works2026-06-15https://www.veristat.com/services/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-replay2026-06-15https://www.veristat.com/solutions/decentralized-trial-solutions-for-complex-clinical-trials-slides2025-06-12https://www.veristat.com/sqn-bloghttps://www.veristat.com/hubfs/approach-nda-blog-2.jpgapproachndablog2approachndablog2https://www.veristat.com/hubfs/tony-s-tribe.pngtonystribetonystribehttps://www.veristat.com/hubfs/SQN-Veristat-logo-lockup-white-2.pngSQNVeristatlogolockupwhite2SQNVeristatlogolockupwhite2https://www.veristat.com/hubfs/paper-trials-blog.jpgpapertrialsblogpapertrialsbloghttps://www.veristat.com/hubfs/adopting-electronic-blog.jpgadoptingelectronicblogadoptingelectronicbloghttps://www.veristat.com/hubfs/SQN-Veristat-logo-lockup-white.pngSQNVeristatlogolockupwhiteSQNVeristatlogolockupwhitehttps://www.veristat.com/hubfs/EF-interview-blog.jpgEFinterviewblogEFinterviewbloghttps://www.veristat.com/hubfs/PW-interview-blog.jpgPWinterviewblogPWinterviewbloghttps://www.veristat.com/hubfs/specialty-expertise-bkgd-31e-1.jpgspecialtyexpertisebkgd31e1specialtyexpertisebkgd31e1https://www.veristat.com/hubfs/stop-annotating-blog.jpgstopannotatingblogstopannotatingblog2021-08-31https://www.veristat.com/solutions/from-clinical-strategy-to-patient-impact-5-lessons-from-cindy-henderson2025-07-31https://www.veristat.com/solutionshttps://www.veristat.com/hubfs/images_sizedat600px/happy_people_image19.jpghappypeopleimage19happypeopleimage19https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Web%20Page_Featured_Services%20Main.pngWebPageFeaturedServicesMainWebPageFeaturedServicesMainhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image7.jpgtherapeuticimage7therapeuticimage7https://www.veristat.com/hubfs/images_sizedat600px/virtualtrials_telemedicine.jpgvirtualtrialstelemedicinevirtualtrialstelemedicinehttps://www.veristat.com/hubfs/Risk%20Management_People%20Working_600x400.pngRiskManagementPeopleWorking600x400RiskManagementPeopleWorking600x400https://www.veristat.com/hubfs/Solutions_CellandGene_600x400.pngSolutionsCellandGene600x400SolutionsCellandGene600x400https://www.veristat.com/hubfs/email/asian_working%20team_300x200.jpgasianworkingteam300x200asianworkingteam300x200https://www.veristat.com/hubfs/biologics_ivInfusion.jpgbiologicsivInfusionbiologicsivInfusionhttps://www.veristat.com/hubfs/images_sizedat600px/therapeutic_image14.jpgtherapeuticimage14therapeuticimage14https://www.veristat.com/hubfs/images_sizedat600px/data_dataentryoniipad_600px-1.jpgdatadataentryoniipad600px1datadataentryoniipad600px12025-06-12https://www.veristat.com/library/how-to-ensure-successful-fda-meeting-video-replay2024-07-03https://www.veristat.com/solutions/understanding-data-monitoring-committees2025-06-12https://www.veristat.com/services/the-influence-of-mdrs-article-117-in-the-marketing-of-combination-products2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/successful-dmc-services-for-complex-hematologic-cancer-trial2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/a-playbook-for-effective-sponsorcro-partnership2026-06-23https://www.veristat.com/library/vaccine-clinical-trial-showcase-phase-2b-hipra-study-against-covid-19-presented-by-veristat2024-07-03https://www.veristat.com/services/executing-patient-focused-drug-development-pfdd2026-06-15https://www.veristat.com/services/successful-full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-15https://www.veristat.com/services/are-autologous-therapies-here-to-stay-are-allogeneic-therapies-the-future2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-july-20242026-06-23https://www.veristat.com/services/decentralized-trial-solutions-for-complex-clinical-trials-slides2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/wholistic-approach-to-strategic-consulting2026-06-23https://www.veristat.com/solutions/delivering-data-that-matters-an-integrated-approach-to-biostatistics-data-management-statistical-programming-in-clinical-trials2025-09-03https://www.veristat.com/instat-is-now-veristat/accelerate-neurologypsychiatry-trial-success-with-expert-guidance2026-06-23https://www.veristat.com/library/covid-19-success-guide2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/planning-your-ind-when-and-why-to-engage-the-fda2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/laying-the-groundwork-to-measure-the-impact-of-decentralized-clinical-trials-dcts2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/advancing-to-your-next-milestone-global-regulatory-excellence-throughout-theentire-clinical-development-lifecycle2026-06-23https://www.veristat.com/solutions/agile-solutions-to-maintain-trial-momentum2025-06-12https://www.veristat.com/library/future-trends-on-european-regulations-on-medicines-replay2024-07-03https://www.veristat.com/instat-is-now-veristat/decentralized-clinical-trials-infographic2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/successful-preparation-strategies-for-nda-maa-marketing-applications2026-06-23https://www.veristat.com/services/nda-success-strategy-using-non-us-clinical-data-in-an-nda-submission2026-06-15https://www.veristat.com/instat-is-now-veristat/preserving-what-matters-how-institutional-knowledge-protects-value-through-ma2026-06-23https://www.veristat.com/services/successful-dmc-services-for-complex-hematologic-cancer-trial2026-06-15https://www.veristat.com/solutions/programmed-narratives-working-smarter-not-harder2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/trends-in-oncology-regulation-fda-draft-guidance-on-os-and-radiopharmaceuticals2026-06-23https://www.veristat.com/instat-is-now-veristat/monthly-fda-guidance-and-regulatory-news-review-august-20242026-06-23https://www.veristat.com/solutions/preparing-data-for-maa-marketing-authorization-appliation2025-06-12https://www.veristat.com/instat-is-now-veristat/single-arm-studies-a-strategic-path-to-oncology-drug-approval2026-06-23https://www.veristat.com/library/apples-to-apples-playing-the-comparability-game-in-biotherapeutics-development2024-07-03https://www.veristat.com/rare-disease-cro/cardiology-fact-sheet2022-09-07https://www.veristat.com/services/european-medicines-and-medical-devices-future-trends2026-06-15https://www.veristat.com/library-old/understanding-and-operationalizing-a-complex-adaptive-design2024-06-27https://www.veristat.com/services/regulatory-guidance-monthly-review-september-20232026-06-15https://www.veristat.com/rare-disease-cro/achieving-an-aggressive-nda-timeline2022-09-07https://www.veristat.com/services/inside-2026-the-industrys-ai-turning-point2026-06-15https://www.veristat.com/services/marketing-application-publishing-best-practices2026-06-15https://www.veristat.com/careers/open-positionshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_Inc5000_Inc%202-2.pngVeristatInc5000Inc22VeristatInc5000Inc22https://www.veristat.com/hubfs/Web%20Page_Featured_open%20positions.pngWebPageFeaturedopenpositionsWebPageFeaturedopenpositionshttps://www.veristat.com/hubfs/Veristat_Careers_Header.pngVeristatCareersHeaderVeristatCareersHeader2025-12-15https://www.veristat.com/services/on-demand-webinar-decentralized-trial-solutions-for-complex-clinical-trials2026-06-15https://www.veristat.com/library/orphan-drug-designations-and-orphan-subsets2024-07-03https://www.veristat.com/services/accelerating-oncology-breakthroughs2026-06-15https://www.veristat.com/library/supporting-multiple-global-gene-therapy-studies-for-rare-diseases2024-11-21https://www.veristat.com/library-old/presentation-expanding-your-clinical-trial-into-the-us2024-06-27https://www.veristat.com/services/3-reasons-why-you-need-to-consider-a-cro-that-excels-in-oncology-regulatory-publishing2026-06-15https://www.veristat.com/library-old/achieving-balance-in-clinical-trial-database-design2024-06-27https://www.veristat.com/library/regulatory-medical-device-ivd-fact-sheet2024-07-03https://www.veristat.com/solutions/marketing-application-fact-sheet2025-06-12https://www.veristat.com/services/multi-regional-clinical-trials-key-recommendations-for-a-global-clinical-development-program2026-06-15https://www.veristat.com/library-old/competing-risk-analysis-in-a-large-cardiovascular-clinical-trial-an-apex-substudy2024-06-27https://www.veristat.com/instat-is-now-veristat/the-ctdna-clinical-trial-advantage-why-cro-work-puts-you-on-the-cutting-edge2026-06-23https://www.veristat.com/services/meeting-the-challenges-of-the-moment2026-06-15https://www.veristat.com/instat-is-now-veristat/rare-disease-development-navigating-small-populations-and-complex-protocols2026-06-23https://www.veristat.com/scinopsis-is-now-veristathttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapieshttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card%20Image_Successful%20IND%20Submission.pngVeristatHubDBCardImageSuccessfulINDSubmissionVeristatHubDBCardImageSuccessfulINDSubmissionhttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurology2024-11-20https://www.veristat.com/services/recognize-rare-disease-month-with-veristat2026-06-15https://www.veristat.com/solutions/executing-patient-focused-drug-development-pfdd2025-06-12https://www.veristat.com/library-old/implementation-of-mastercontrol-etmf-in-a-gcp-compliant-cro2024-06-27https://www.veristat.com/solutions/marketing-application-medical-writing-strategies2025-06-12https://www.veristat.com/services/monthly-fda-guidance-and-regulatory-news-review-august-20252026-06-15https://www.veristat.com/services/sfl_is_now_veristat/supporting-multiple-global-gene-therapy-studies-for-rare-diseases2026-06-23https://www.veristat.com/library/the-rise-of-decentralized-clinical-trials-transforming-research-through-technology-and-patient-centricity2024-07-03https://www.veristat.com/solutions/regulatory-guidance-monthly-review-october-20232025-06-12https://www.veristat.com/instat-is-now-veristat/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-presentation2026-06-23https://www.veristat.com/solutions/expediting-access-to-novelmedicinal-products-in-the-us-and-eu-replay2025-06-12https://www.veristat.com/covid-response-0https://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos0412024-07-03https://www.veristat.com/library/timeline-mastery-the-strategic-backbone-of-marketing-application-success2025-02-24https://www.veristat.com/solutions/mastering-a-global-approach-to-medical-writing2025-06-26https://www.veristat.com/services/marketing-application-best-practices-for-publishing2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/the-rapid-pace-of-regulatory-change2026-06-23https://www.veristat.com/instat-is-now-veristat/accelerating-clinical-trial-design-and-operations2026-06-23https://www.veristat.com/services/randomized-phase-2-study-of-cbp501-cisplatin-and-nivolumab-as-3rd-line-treatment-for-exocrine-pancreatic-cancer-patients-with-white-blood-cell-count-wbc-10000mm32026-06-15https://www.veristat.com/services/sfl_is_now_veristat/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-presentation2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/monthly-fda-guidance-and-regulatory-news-review-august-20252026-06-23https://www.veristat.com/solutions/supporting-global-approval-of-a-first-in-classgene-therapy-for-a-rare-genetic-disorder2026-02-06https://www.veristat.com/amanda_truesdale_biographyhttps://www.veristat.com/hubfs/Veristat_logo_tm.pngVeristatlogotmVeristatlogotm2024-07-03https://www.veristat.com/services/sfl_is_now_veristat/building-confidence-in-rwe-delivering-smarter-regulatory-strategies2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/rare-disease-development-navigating-small-populations-and-complex-protocols2026-06-23https://www.veristat.com/services/presentation-how-to-better-plan-a-virtual-clinical-trial2026-06-15https://www.veristat.com/instat-is-now-veristat/timeline-mastery-the-strategic-backbone-of-marketing-application-success2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/data-analysis-excellence-the-backbone-of-successful-marketing-applications2026-06-23https://www.veristat.com/library/essential-considerations-foradaptive-design-in-clinical-trials2024-07-03https://www.veristat.com/instat-is-now-veristat/supporting-multiple-global-gene-therapy-studies-for-rare-diseases2026-06-23https://www.veristat.com/instat-is-now-veristat/infectious-disease-fact-sheet2026-06-23https://www.veristat.com/services/multiple-arms-design-incorporating-efficacy-and-safety2026-06-15https://www.veristat.com/instat-is-now-veristat/weighing-the-suitability-of-a-functional-service-provider-fsp-model-for-clinical-trials2026-06-23https://www.veristat.com/library/why-you-need-a-cro-that-excels-in-oncology-regulatory-publishing2026-02-06https://www.veristat.com/solutions/supporting-multiple-global-gene-therapy-studies-for-rare-diseases2025-06-12https://www.veristat.com/instat-is-now-veristat/successful-full-service-randomized-pancreatic-cancer-phase-ii-trial2026-06-23https://www.veristat.com/services/introduction-statistical-powerhttps://www.veristat.com/hubfs/HubDB-Infographic-Four%20Pillars%20of%20Success%20in%20Neurology.pngHubDBInfographicFourPillarsofSuccessinNeurologyHubDBInfographicFourPillarsofSuccessinNeurologyhttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/Veristat_StatisticalPower_Fig4.webpVeristatStatisticalPowerFig4VeristatStatisticalPowerFig4https://www.veristat.com/hubfs/Veristat_StatisticalPower_Fig2.webpVeristatStatisticalPowerFig2VeristatStatisticalPowerFig2https://www.veristat.com/hubfs/Veristat%20HubDB%20Advancing%20Oncology%20Innovation.pngVeristatHubDBAdvancingOncologyInnovationVeristatHubDBAdvancingOncologyInnovationhttps://www.veristat.com/hubfs/Statistical%20Power_Figure1.pngStatisticalPowerFigure1StatisticalPowerFigure1https://www.veristat.com/hubfs/Statistical%20Power.pngStatisticalPowerStatisticalPowerhttps://www.veristat.com/hubfs/StatisticalPower_Figure7_Full.pngStatisticalPowerFigure7FullStatisticalPowerFigure7Fullhttps://www.veristat.com/hubfs/StatisticalPower_Figure6_Full.pngStatisticalPowerFigure6FullStatisticalPowerFigure6Fullhttps://www.veristat.com/hubfs/Statistical%20Power_Figure3.pngStatisticalPowerFigure3StatisticalPowerFigure3https://www.veristat.com/hubfs/StatisticalPower_Figure5c_Full.pngStatisticalPowerFigure5cFullStatisticalPowerFigure5cFullhttps://www.veristat.com/hubfs/StatisticalPower_Figure5a_Full.pngStatisticalPowerFigure5aFullStatisticalPowerFigure5aFullhttps://www.veristat.com/hubfs/StatisticalPower_Figure5b_Full.pngStatisticalPowerFigure5bFullStatisticalPowerFigure5bFullhttps://www.veristat.com/hubfs/HubDB%20Fact%20Sheet%20Rare%20Disease%20Therapies.pngHubDBFactSheetRareDiseaseTherapiesHubDBFactSheetRareDiseaseTherapies2025-06-12https://www.veristat.com/endocrine-metabolic-diseasehttps://www.veristat.com/hubfs/HubDB_Card%20Image_Flexibility%20Drives%20Progress.pngHubDBCardImageFlexibilityDrivesProgressHubDBCardImageFlexibilityDrivesProgresshttps://www.veristat.com/hubfs/Veristat_logos-04%201.pngVeristatlogos041Veristatlogos041https://www.veristat.com/hubfs/images_sizedat600px/patient-doctor_image4.jpgpatientdoctorimage4patientdoctorimage4https://www.veristat.com/hubfs/A%20practical%20guide%20for%20managing%20multiple%20regulatory%20%20pathways.pngApracticalguideformanagingmultipleregulatorypathwaysApracticalguideformanagingmultipleregulatorypathwayshttps://www.veristat.com/hubfs/images_sizedat600px/People_therapeutic_Consent_image10.jpgPeopletherapeuticConsentimage10PeopletherapeuticConsentimage10https://www.veristat.com/hubfs/images_sizedat600px/therapeutic_Pediatric_image8.jpgtherapeuticPediatricimage8therapeuticPediatricimage8https://www.veristat.com/hubfs/Endocrine_Metabolic-1.pngEndocrineMetabolic1EndocrineMetabolic1https://www.veristat.com/hubfs/Veristat_Clinical%20Trials%20Meet%20Adaptive%20Design_HubDB%20Image.pngVeristatClinicalTrialsMeetAdaptiveDesignHubDBImageVeristatClinicalTrialsMeetAdaptiveDesignHubDBImagehttps://www.veristat.com/hubfs/Veristat%20HubDB%20Card_Expedited%20Programs.pngVeristatHubDBCardExpeditedProgramsVeristatHubDBCardExpeditedPrograms2026-07-10https://www.veristat.com/services/navigating-regulatory-challenges-in-biologics-a-case-study-in-overcoming-clinical-holds2026-06-15https://www.veristat.com/solutions/why-and-when-to-hold-a-pre-ind-meeting-with-fda2025-06-12https://www.veristat.com/services/sfl_is_now_veristat/future-trends-on-european-regulations-on-medicines-replay2026-06-23https://www.veristat.com/services/sfl_is_now_veristat/your-guide-to-mastering-cmc-regulatory-success-in-biotherapeutics-a-must-watch-webinar2026-06-23https://www.veristat.com/library/the-evolving-landscape-of-radiopharmaceuticals-in-oncology-research2025-04-22https://www.veristat.com/services/sfl_is_now_veristat/understanding-the-impact-of-real-world-evidence-on-clinical-trials2026-06-23https://www.veristat.com/services/impact-of-new-medical-device-eu-regulation-mdr-on-the-development-of-drug-device-combination-products-replay2026-06-15https://www.veristat.com/instat-is-now-veristat/rapid-covid-19-phasei-vaccine-trial2026-06-23https://www.veristat.com/instat-is-now-veristat/orphan-drug-designation-the-considerations-the-rewards-and-how-they-differ-between-the-us-and-europe-presentation2026-06-23https://www.veristat.com/services/vaccine-clinical-trial-showcase-phase-2b-hipra-study-against-covid-19-presented-by-veristat2026-06-15https://www.veristat.com/services/biomarker-driven-adaptive-design-for-precision-medicine2026-06-15https://www.veristat.com/services/sfl_is_now_veristat/rapid-response-to-ebola-outbreak2026-06-23https://www.veristat.com/library/virtual-hybrid-clinical-trials2024-07-03